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Abstract 
Background: There is an interaction between HIV, antiretroviral treatment (ART) and endothelial 
dysfunction; furthermore, HIV-infected individuals (± ART) show an increased incidence of 
cardiovascular risk factors. However, the evidence stems mainly from studies in developed countries 
with a paucity of data on these interactions in the South African context.  
Aims: To investigate the effects of first line and second line ART on HIV exposed vascular 
endothelial function, in a clinical and in vitro setting.  
Methods: In the clinical study, participants were recruited in Worcester and allocated to one of four 
study groups: HIV-negative, HIV-positive ART naïve, HIV-positive first line ART and HIV-positive 
second line ART. Data were collected via health questionnaires, anthropometric assessments, blood 
pressure measurements, brachial artery flow mediated dilatation (FMD) and blood chemistry analyses 
(C-reactive protein (CRP), fasting glucose, HbA1c, total cholesterol, LDL-cholesterol, HDL-
cholesterol, triglycerides, as well as CD4 count and viral load in HIV-infected individuals). For the 
in vitro sub-study, a conditioned growth medium was developed containing HIV-related proteins in 
which aortic endothelial cells (AECs) were incubated. Additionally, AECs were treated with first and 
second ART drugs. End-points were nitric oxide (NO) production, cell viability and ROS production 
measured by flow cytometric analysis.  
Results: There were no inter-group differences with regard to FMD. The median BMI and waist 
circumference measurements were lower in the HIV-positive groups versus HIV-negative (p < 0.05). 
Median total cholesterol levels were lower (p < 0.05) in the HIV-positive ART groups versus HIV-
negative, and higher in the HIV-positive first line ART group versus the ART naïve group (p< 0.05). 
Furthermore, mean LDL-cholesterol levels were lower in all HIV-positive groups versus HIV-
negative (p< 0.05). Median HBA1C% values were lower in the HIV-positive second line ART versus 
ART-naïve group (p < 0.05). Regression analyses showed that smoking in first line ART, and CRP 
and CD4 levels in second line ART were negatively associated with FMD%. In the in vitro sub-study, 
the HIV-1 gp160 protein was identified in the HIV-conditioned medium. No effects were observed 
in HIV-conditioned medium treated AECs. In the first and second line ART dose-response 
investigations, it was found that double first line drug concentration and normal second line drug 
concentration exerted no harmful effects on AECs. 
Discussion and Conclusion: Clinical data suggested that the cardiovascular risk profile appeared to 
be more favourable in HIV-positive groups versus HIV-negative. There were no inter-group 
differences in terms of endothelial function (FMD). CD4 and CRP, as well as female gender were 
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independent predictors of vascular endothelial function in the HIV-positive second line ART group. 
Furthermore, smoking was found to be a negative independent predictor of endothelial function in 
the HIV-positive first line ART group. The in vitro findings showed that the HIV-conditioned 
medium protocol successfully resulted in the expression of the HIV-1 gp160 protein; however, the 
conditioned medium failed to induce injury. In the ART dose-response investigations, the double 
drug concentration for first line ART and normal drug concentration for second line ART, could be 
considered a safe concentration to use in future investigations. 
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Abstrak 
Agtergrond: Daar bestaan ‘n interaksie tussen MIV, antiretrovirale terapie (ART) en 
endoteeldisfunksie; verder toon MIV-geïnfekteerde persone (±ART) ‘n hoër insidensie van 
kardiovaskulêre risikofaktore. Hierdie verwantskappe is hoofsaaklik bepaal in populasies van 
ontwikkelde lande en daar is ‘n tekort aan data in die Suid-Afrikaanse konteks. 
Doelwitte: Om die effekte van eerste en tweede linie ART op MIV-blootgestelde vaskulêre 
endoteelfunksie in ‘n kliniese en in vitro omgewing te ondersoek. 
Metodes: In die kliniese studie was deelnemers in Worcester gewerf en in een van vier studiegroepe 
ingedeel: MIV-negatief, MIV-positief sonder ART, MIV-positief eerste linie ART en MIV-positief 
tweede linie ART. Data is ingesamel via vraelyste, antropometriese metings, bloeddruk bepalings, 
bragiale arterie vloei-gemedieerde dilatasie (FMD) en bloed biochemiese analises (C-reaktiewe 
proteïen (CRP), vastende glukose, HbA1C, totale cholesterol, LDL-cholesterol, HDL-cholesterol, 
trigliseriede, asook CD4 telling en virale lading in MIV-geïnfekteerde individue). Vir die in vitro sub-
studie was ‘n gekondisioneerde groeimedium ontwikkel wat MIV-verwante proteïene bevat waarin 
aorta endoteelselle (AECs) geïnkubeer was. Verder was AECs met eerste en tweede linie ART 
middels behandel. Eindpunte was stikstofoksied (NO) produksie, sellewensvatbaarheid en ROS 
produksie soos gemeet met vloeisitometriese analise. 
Resultate: Daar was geen inter-groep verskille t.o.v. FMD nie. Die mediaan BMI en middellyf 
omtrek metings was laer in die MIV-positiewe groepe versus MIV-negatief (p<0.05). Mediaan totale 
cholesterol vlakke was laer (p<0.05) in die MIV-positiewe ART groepe versus MIV-negatief, en hoër 
in die MIV-positief eerste linie ART groep versus geen ART (p<0.05). Verder was die gemiddelde 
LDL-cholesterol vlakke laer in alle MIV-positiewe groepe versus die MIV-negatiewe groep (p<0.05). 
Mediaan HbA1c% waardes was laer in die MIV-positiewe tweede linie ART groep versus MIV-
positief sonder ART (p<0.05). Regressie analises het getoon dat rook in eerste linie ART, en CRP en 
CD4 vlakke in tweede linie ART negatief met FMD% geassosieer het. In die in vitro sub-studie was 
die MIV-1 gp160 proteïen geïdentifiseer in die MIV-gekondisioneerde medium. Geen effekte was in 
AECs wat aan MIV-gekondisioneerde medium blootgestel was, waargeneem nie. In die eerste en 
tweede linie ART dosis-respons eksperimente, het die dubbel dosis eerste linie ART en normale dosis 
tweede linie ART geen nadelige effekte op die AECs uitgeoefen nie. 
Bespreking en Slotsom: Die kliniese data toon ‘n meer gunstige kardiovaskulêre risiko profiel in die 
MIV-positiewe groepe versus MIV-negatiewe groep. Daar was geen inter-groep verskille t.o.v. 
endoteelfunksie (FMD) nie. CD4 en CRP, sowel as vroulike geslag was onafhanklike voorspellers 
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van vaskulêre endoteelfunksie in die MIV-positiewe tweede linie ART groep. Verder was rook ‘n 
negatiewe onafhanklike voorspeller van endoteelfunksie in die MIV-positiewe eerste linie ART 
groep. Die in vitro data het getoon dat die MIV-gekondisioneerde protokol op suksesvolle wyse tot 
die uitdrukking van die MIV-1 gp160 proteïen gelei het, hoewel die gekondisioneerde medium nie 
daarin kon slaag om skade te veroorsaak nie. In die ART dosis-respons eksperimente is aangetoon 
dat die dubbel dosis eerste linie ART en normale dosis tweede linie ART ‘n veilige konsentrasie is 
wat in toekomstige studies gebruik kan word. 
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Chapter 1 : Literature Review 
1.1 Cardiovascular Disease 
1.1.1 Introduction and Epidemiology 
Cardiovascular disease (CVD) represents diseases of the heart, blood vessels, and vascular diseases 
of the brain (Mendis, Puska et al. 2011). There are several underlying mechanisms of CVDs. For the 
purpose of the current study, the focus will be on CVDs due to atherosclerosis.  
Currently, CVD is the most common and the leading cause of death worldwide (Lin, Zhang et al. 
2013, Townsend, Nichols et al. 2015). According to the world health organization (WHO), CVD 
mortality will continue to increase in the decades ahead. In 2012, an estimated 17.5 million people 
died from CVDs, which represents 31% of all deaths globally. Furthermore, of these deaths, an 
estimated 7.4 million were as a result of coronary artery disease and 6.5 million were due to stroke 
(WHO 2010, WHO 2015). However, interestingly, for the past two decades, there has been a decline 
in deaths from CVD in high income countries contrasted by a rapid increase in low- and middle 
income countries (Mendis, Puska et al. 2011, Cappuccio & Miller 2016, Mendis 2014). In fact, 80% 
of CVD-related deaths occur in low-and middle income countries (Cappuccio & Miller 2016).  
As with other low- and middle income regions, sub-Saharan Africa (SSA) also has a rising epidemic 
of non-communicable diseases, including CVD. CVD has evolved into a major health concern due to 
its rising mortality and morbidity rates in SSA (Dalal, Beunza et al. 2011). In South Africa (SA), 
particularly, the WHO estimates the burden of NCD to be two to three times higher than in developed 
countries, with the poor in the urban settings being increasingly affected disproportionately (Mayosi, 
Flisher et al. 2009). It has been further projected that there will be a 41% increase in cardiovascular 
related deaths between the year 2000 to 2030 (Mpe 2010).  
 
1.1.2 Atherosclerosis pathophysiology 
The underlying process in the blood vessels that results in ischaemic heart disease (IHD) and 
cerebrovascular disease (stroke) is known as atherosclerosis. It accounts for a large proportion of 
CVDs. In fact, IHD has the largest contribution to CVD mortality worldwide. The pathological 
process of atherosclerosis is complex and involves the development of an arterial plaque due to the 
cholesterol rich fraction of the blood, low density lipoproteins (LDL) (Naseem 2005). Plaque 
development is a long-term process over several years in the walls of the arteries. The process 
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involves all the structural elements of the arterial wall, including circulating cells such as platelets, 
leukocytes and inflammatory cells such as monocytes and macrophages. Briefly, in atherosclerosis, 
cholesterol rich fractions are continuously deposited inside the lumen of the arteries which 
progressively lead to narrowing of the lumen diameter and eventually restricting arterial blood flow 
(Mendis, Puska et al. 2011, Naseem 2005, Sakakura, Nakano et al. 2013). Furthermore, there are 
many factors that promote the process of atherosclerosis and CVDs which are described in the section 
below. 
More precisely, the initiation of atherosclerosis, is when LDL passively diffuses into the arterial wall 
where it is trapped as a result of its interaction with apolipoprotein B100 (protein moiety of LDL) and 
matrix proteoglycans. Through prolonged exposure to reactive oxygen species (ROS) and reactive 
nitrogen species (which are present in an attempt to repair localized damage), LDL is oxidatively 
modified. This oxidised LDL leads to a proinflammatory response in the surrounding cells and 
stimulates the production of chemokines such as chemotactic protein- 1 and growth factors (which 
attract monocytes to the area). (Barbaro 2003, Naseem 2005). In addition, the oxidised LDL leads to 
the expression of adhesion molecules such as P-selectin, vascular adhesion molecule-1 and 
intercellular adhesion molecule-1 on the endothelium’s surface (Naseem 2005, Barbaro 2003). This 
enables the entry of recruited monocytes into the arterial wall (Naseem 2005). Eventually, this process 
leads to the formation of lipid-laden foam cells and a necrotic core of oxidized lipids, which is highly 
thrombotic in nature (Naseem 2005). Ultimately, the highly thrombotic core of the plaque ruptures to 
form platelet-rich thrombi (Naseem 2005). 
Atherosclerosis is triggered by hypercholesterolaemia (refer to figure 1.1 for the process 
atherosclerotic changes in the arterial wall). Expression of vascular cell-adhesion molecule-1 
(VCAM-1), and selectins facilitates the monocyte rolling and attachment to endothelium. The 
secretion of macrophage-chemotactic protein 1 (MCP-1) is elicited by alterations and oxidation of 
LDL. Monocytes present in the arterial intima mature into macrophages which express scavenger 
receptors such as Scavenger Receptor A (SRA) and CD36. These receptors enable the uptake of the 
altered and oxidised LDL and convert them into foamy macrophages which are rich in cholesterol 
esters and free fatty acids. Macrophages increase due to the present MCP-1 and macrophage colony 
stimulating factor (MCSF). T cells undergo antigen specific activation, after which they enter the 
intima and amplify the inflammatory response and sustain it by secreting interferon-γ which send 
signals to aid in the process. The presence of reactive oxygen species allows an enhanced release of  
matrix metalloproteinases (MMPs) by the macrophages. This facilitates the breakdown of collagen 
to allow migration of cells within the plaque. Foamy macrophages (foam cells) infiltrate the 
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pathological intimal thickening (PIT) lesion and the lipid pool areas that are formed by smooth muscle 
cell apoptosis, and proteoglycan aggregation. Accumulation of oxidised LDL and macrophage 
infiltration elicits the conversion of the lipid pool to a necrotic core. Once in the necrotic core, 
oxidised LDL and macrophage infiltration further elicits macrophage death and defective 
efferocytosis (removal of apoptotic and necrotic cells by phagocytic cells). (Sakakura, Nakano et al. 
2013). 
 
 
Figure 1.1: Sequence of events that lead to pro-atherosclerotic changes in the arterial wall (Sakakura, 
Nakano et al. 2013). 
 
Stellenbosch University  https://scholar.sun.ac.za
4 
 
1.1.3 Cardiovascular Risk factors 
A risk factor is defined as a variable that increases the likelihood of developing a disease or infection 
(Fedele, Bruno et al. 2011). The Framingham Heart Study introduced the concept of risk factors for 
future cardiovascular diseases (Kannel, Dawber et al. 1961, Mensah 2013). These factors are 
predominantly the same in SSA in comparison to the rest of the world. The risk factors include high 
blood pressure (BP), tobacco use, including exposure to second hand smoke, harmful use of alcohol, 
high total blood cholesterol, high fasting plasma glucose, high body mass index (BMI), high intake 
of dietary sodium, low dietary intake of fruits and vegetables, low physical activity, and household 
and ambient air pollution (Mensah 2013). These mentioned risk factors explain the majority of the 
population burden of CVD in SSA (Mensah 2013). Furthermore, the risk factors can be divided into 
modifiable and non-modifiable risk factors. Refer to table 1.1. 
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Table 1.1: Modifiable and non-modifiable risk factors (Adapted from Fedele, Bruno et al. 2011, 
Mensah 2013). 
Modifiable Risk factors Non-modifiable Risk factors 
 Lack of exercise Age 
Visceral obesity Sex 
Left ventricular hypertrophy Ethnic origin 
Tobacco use, smoking, second hand smoke Family history of CVD 
High blood pressure  
High LDL cholesterol  
Low HDL cholesterol  
Diabetes and glucose intolerance.  
Harmful use of alcohol  
High intake of dietary salt  
BMI  
Low dietary intake of fruit and vegetables  
Abbreviations: LDL: Low-Density Lipoprotein; HDL: High-Density Lipoproteins; BMI: Body 
mass index; CVD: Cardiovascular disease. 
 
1.2 The Vascular Endothelium and its function 
The endothelium represents the inner most layer of all blood vessels. It consists of a continuous 
monolayer of endothelial cells (ECs). The ECs are known to represent a total surface area of 
approximately 4000 to 7000m2 (Flammer & Luscher , 2011). The endothelium forms an interface 
between the circulating blood in the lumen and the rest of the vessel wall, thereby playing a critical 
role in vascular homeostasis (Van den Oever, Raterman et al. 2010). It actively controls the vascular 
tone and permeability, and regulates the exchange of molecules in response to environmental and 
molecular signals (Flammer & Luscher , 2011). It essentially maintains the balance between 
coagulation and fibrinolysis, inflammatory activity, and cell proliferation. A healthy endothelium not 
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only is crucial in preventing thrombotic events but further exerts anticoagulant, antiplatelet, and 
fibrinolytic properties (Davignon, Ganz 2004, Flammer & Luscher , 2011) Refer to table 1.2 for an 
overview of the effects of healthy endothelium. 
 
Table 1.2: List of favourable and atheroprotective effects of healthy endothelium (Adapted from 
Bonetti, Lerman et al. 2003) 
Favourable and atheroprotective effects of the healthy endothelium 
Promotion of vasodilation 
Antioxidant effects 
Anti-inflammatory effects 
Inhibition of leukocyte adhesion and migration 
Inhibition of smooth muscle cell proliferation and migration 
Inhibition of platelet aggregation and adhesion 
Anticoagulant effects 
Profibrinolytic effects 
 
 
The highly complex endothelium has mechanosensors in its cells which give them the ability to sense 
mechanical stimuli such as pressure and shear stress, as well as receptors for hormonal and other 
vasoactive substances; to which the endothelium responds to by releasing agents that regulate 
vasomotor function, trigger inflammatory processes, and affect homeostasis (Endemann & Schiffrin 
2004, Limaye & Vadas 2007). The endothelium releases endothelium-derived relaxing factors 
(EDRF) such as nitric oxide (NO), bradykinin, prostacyclin (PGI2) and endothelial-derived 
hyperpolarisation factor (EDHF), mostly in response to an increase in intracellular calcium. The 
endothelium also produces many endothelial-derived constricting factors (EDCF) such as endothelin-
1 (ET-1), thromboxane A (TXA2) and angiotensin 11 (Mudau, Genis et al. 2012, Flammer & Luscher 
2011). 
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1.2.1 The endothelium-derived factors and their role in endothelial 
function 
As discussed above, the metabolically active endothelium plays a vital role in maintaining vascular 
homeostasis by releasing a range of vasoactive factors that can either dilate or constrict the blood 
vessels in response to a stimulus (Mudau, Genis et al. 2012).  
 
1.2.1.1 Endothelium-derived relaxing factors (EDRFs) 
The vasodilatory state of the endothelium is maintained by EDRFs such as nitric oxide (NO), 
bradykinin, prostacyclin (PGI2) and endothelial-derived hyperpolarisation factors (EDHF).  
 
1.2.1.1.1   Nitric oxide (NO) 
The most prevalent and important of the endothelium derived relaxing factors is NO (Hall & Gyton 
2015). NO, initially loosely termed EDRF, was discovered and characterised in 1987 (Ignarro, Buga 
et al. 1987). This molecule was shown to relax vascular smooth muscle cells (Flammer & Luscher 
2011). NO is a simple diatomic gas and a free radical which makes it highly reactive in signalling 
pathways and easily transportable between tissues and cells (Strijdom, Chamane et al. 2009).  It is 
produced in endothelial cells by a family of enzymes called NO synthases (NOS) (Fitridge 
&Thompson 2011). NOS can be found in many tissues throughout the body, especially in the nervous 
and cardiovascular system. (Strijdom, Chamane et al. 2009) The NOS family has 3 isoforms, namely 
neuronal NOS (nNOS, NOS-1), inducible NOS (iNOS, NOS-2) and endothelial NOS (eNOS, NOS-
3) (Mudau, Genis et al. 2012). Physiologically, eNOS and nNOS are known to be calcium-dependent. 
However, eNOS can also be calcium independent and is known to be the primary enzyme responsible 
for the generation of NO in ECs under physiological conditions (Mudau, Genis et al. 2012). eNOS 
specifically, is the endothelial isoform that catalyses NO biosynthesis via a two-step oxidation of L 
arginine to L-citrulline (Andrew & Mayer 1999) (refer to figure 1.1). 
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Figure 1.2: NO synthesis via the NOS enzyme (Andrew, Mayer 1999). 
The release of NO is mainly in response to shear stress, the primary activator of eNOS. Furthermore, 
circulating hormones (catecholamines, vasopressin, aldosterone), plasma constituents (thrombin, 
sphingosine-1-phosphate), platelet products (serotonin, adenosine diphosphate [ADP]), and autacoids 
(histamine, bradykinin, prostaglandin) can also elicit the release of NO (Lüscher & Vanhoutte, 1990; 
Vanhoutte et al., 2009; Michel & Vanhoutte 2010). Once NO is synthesized, it diffuses towards the 
luminal surface of the endothelium and the underlying vascular smooth muscle cells and activates 
guanylate cyclase which produces the second messenger, cyclic guanosine monophosphate (cGMP). 
cGMP activates two specific cGMP-dependent protein kinases (PKGI and PKG II) (Gewaltig & 
Kojda 2002). Of the two, PKGI is the primary kinase that mediates vasodilation and inhibition of 
platelet aggregation  (Flammer & Luscher 2011, Gewaltig & Kojda 2002, Deanfield, Halcox et al. 
2007).  
The most important role of NO is that it promotes a vasodilatory effect on the vasculature (Endemann 
2004, Strijdom, Chamane et al., 2009). It also inhibits smooth muscle cell proliferation and prevents 
platelet adhesion and aggregation as well as leukocyte adhesion and migration into the arterial wall 
(Flammer & Luscher 2011). Therefore, NO not only acts as a vasodilator but also has anti-
inflammatory and anti-thrombotic effects on the vasculature and thus is a key role player in 
maintaining vascular homeostasis and endothelial function. (Endemann 2004,  Strijdom, Chamane et 
al., 2009). Refer to figure 1.3. 
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Figure 1.3: Synthesis and properties of NO as an important factor in endothelial function (Van den 
Oever, Raterman et al. 2010). 
 
Furthermore, NO has several other effects in the cardiovascular system. In the myocardium it is 
known to be anti-hypertrophic, anti-apoptotic, and cardioprotective against ischaemic injury. In 
addition, NO is found to play a role in cardiac cell contractility, generation and proliferation. In 
contrast, excessive amounts of NO in cardiomyocytes are found to be harmful, pro-apoptotic and pro-
necrotic (Strijdom, Chamane et al., 2009). 
 
1.2.1.1.2 Prostacyclin (PGI2) 
Prostacyclin (PGI2) is an eicosanoid which is synthesised by cyclooxygenase-1 (COX-1) from 
arachidonic acid and increases cAMP in smooth muscle cells as well as in platelets (Flammer & 
Luscher 2011). Unlike NO, which is continuously released by agonists, PGI2 is released only in a 
transient manner. It is partly released in response to shear stress but rather produced when there are 
disturbances in the endothelial function. Upon release it binds to a specific receptor on platelets and 
vascular smooth muscle cells to limit vasoconstriction (Fitridge & Thompson 2011). PGI2 aids in the 
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release of NO by endothelial cells and vice versa, the action of PGI2 in the vascular smooth muscle 
is also potentiated by NO, which prolongs its half-life (Flammer & Luscher 2011). 
 
1.2.1.1.3 Endothelium-derived hyperpolarisation factors (EDHF) 
Non- NO and non- prostaglandin meditated endothelium dependent vasodilation has been partly 
attributed to EDHF (Ozkor & Quyyumi 2011). These factors are mostly site and species specific and 
are ultimately responsible for vascular smooth muscle hyperpolarisation and eventually vasodilation 
(Ozkor & Quyyumi 2011, Taddei, Ghiadoni et al. 1999). Studies suggest that the EDRFs response 
persists and increases when the vessel size decreases, and in presence of combined inhibition of NO 
and PG12 (Ozkor & Quyyumi 2011, Flammer & Luscher , 2011, Taddei, Ghiadoni et al. 1999). These 
factors are also thought to play a compensatory role in endothelium dependent vasodilation during 
reduced NO availability (Ozkor & Quyyumi 2011, Flammer & Luscher , 2011, Taddei, Ghiadoni et 
al. 1999).  
EDHFs mainly act by increasing potassium (K+) conductance which subsequently results in the 
propagation of depolarization of vascular smooth muscle cells and relaxation. Acetylcholine is known 
to be responsible for hyperpolarization of vascular smooth muscle cells of healthy blood vessels. The 
action of hyperpolarization is simulated by certain K+ agonists which are unaffected by inhibitors of 
nitric oxide synthase or cyclooxygenase (Ozkor & Quyyumi 2011). EDHFs allow smooth muscle cell 
K+ channels to open, permitting K+ efflux along its chemical gradient, resulting in membrane 
hyperpolarization (Ozkor & Quyyumi 2011). There are many identified EDHFs. In 2011, hydrogen 
sulphide was recognized as a major EDHF that acts by activating ATP-sensitive, intermediate 
conductance and small conductance potassium channels through cysteine S-sulfhydration (Mustafa, 
Sikka et al. 2011). Other EDHFs include K+, cytochrome P450 metabolites (epoxyeicosatrienoic 
acids- arachidonic acids) and hydrogen peroxide (also activates calcium dependent potassium 
channels) (Ozkor & Quyyumi 2011). Furthermore, lipoxygenase products, NO, cyclic adenosine 
monophosphate, C type natriuretic peptide, and electrical coupling through myoendothelial gap 
junctions are also identified as EDHF. (Flammer & Luscher 2011, Mustafa, Sikka et al. 2011, Ozkor 
& Quyyumi 2011). 
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1.2.1.1.4 Interactions between NO, PG12 and EDHF 
NO, PGI2 and EDHFs are the three main mediators of endothelium-dependent vasodilation. They do 
not appear to be mutually exclusive, in fact, they act in a synergistically complex way to maintain a 
healthy vasculature (Ozkor & Quyyumi 2011) (Refer to figure 1.4). NO dominates in the conduit 
arteries, whereas EDHFs appear to contribute more in the resistance vessels of the microcirculations 
(Shimokawa, Yasutake et al. 1996). Studies have shown that NO could inhibit EDHF while further 
research demonstrates that EDHF responds once NO and PGI2 production is inhibited (Ozkor & 
Quyyumi 2011). 
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Figure 1.4: Mechanisms for endothelial cell mediated relaxation. Agonist (bradykinin/acetylcholine/substance P) or shear stress increases the activity of 
endothelial NO synthase (eNOS) and cyclooxygenase (COX), providing nitric oxide (NO) and prostacyclin(PGI2) (Ozkor & Quyyumi 2011) 
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1.2.1.2 Endothelium-derived constricting factors (EDCFs) 
The vasoconstrictory state is maintained by EDCFs such as endothelin-1 (ET-1), thromboxane A 
(TXA2) and angiotensin 11.  
 
1.2.1.2.1 Endothelin 1 (ET-1) 
ET-1 is a potent vasoconstrictor which was discovered a few years after NO. The ETs belong to a 
family of 21 amino acid peptides, of which there are three isoforms (ET-1, ET-2, and ET-3) (Fitridge 
& Thompson 2011). These isoforms are basically converted by the endothelin converting enzyme 
(ECE) from their precursors known as ‘big endothelin’ originating from pre-proendothelin peptides 
cleaved by endopeptidases (Flammer & Luscher , 2011). ET-1 is more dominant in the cardiovascular 
system and is mostly synthesized by vascular endothelial cells; however, ET-1 can also be synthesized 
in vascular smooth muscle cells, extravascular tissues and glomerular and endothelial cells in the 
kidney (Bourque, Davidge et al. 2011). ET-1 can exert opposite effects to NO, and there are many 
factors playing a role in its production and release (Luscher, Yang et al. 1990). These factors include, 
hypoxia, shear stress, angiotensin II, thrombin, adrenaline, inflammatory cytokines and oxidized low 
density lipoproteins (Fitridge & Thompson 2011, Flammer & Luscher , 2011). 
There are known receptors for ET-1 such as ETA and ETB, and ET-1 acts predominantly by binding 
to these G-protein coupled receptors. Both the receptor isoforms are found in vascular smooth muscle 
cells, however, ETB is additionally located in the endothelium (Bourque, Davidge et al. 2011).  ETA 
receptors are mainly responsible for vasoconstriction, whereas ETB receptors promote NO and 
prostacyclin production which ultimately results in reduced ET-1 production (Bourque, Davidge et 
al. 2011). 
 
1.2.1.2.2 Thromboxane A 
Similar to the prostaglandin family, thromboxane A2 (TXA2) is a product of the cyclooxygenase 
(COX) pathway (Smith, Tan et al. 2010). However, in contrast to PGI2, TXA2 is a proatherogenic 
prostanoid that can induce vasoconstriction, platelet activation and adhesion (Smith, Tan et al. 2010). 
TXA2 mediated platelet activation is a key event in thrombus formation (Ellinsworth, Shukla et al. 
2014). Therefore, the relative concentrations of TXA2, PGI2 and NO in the circulation and 
microenvironment are critical for normal cardiovascular and endothelial function (Smith, Tan et al. 
2010). 
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TXA2 is produced following the metabolism of prostaglandin H2 (PGH2) by a TXA2 synthase, a 
member of the cytochrome P450 epoxygenase (CYP 5) family, and is the preferred ligand for TXA2 
receptors known as thromboxane prostanoid (TP) receptors (Ellinsworth, Shukla et al. 2014).  TXA2 
essentially acts as an agonist after it is converted by COX and TXA2 synthase (Capra, Bäck et al. 
2014) (Refer to figure 1.5). Activation of the platelet TP receptor triggers platelet activation, 
secretion, and aggregation, which play important roles in the formation of both hemostatic plugs and 
pathological thrombi, particularly at high arterial wall shear rates (Roald, Barstad et al. 1994). A 
normal response to TP receptor activation supports normal hemostasis (Capra, Bäck et al. 2014).  
Furthermore, other prostanoids such as PGI2 and hydroxyeicosatetraenoic acids (HETEs), can also 
activate TP receptors. The receptors are expressed in both vascular smooth muscle cells (VSMCs) 
and ECs, indicating both paracrine and autocrine actions of TXA2. (Refer to figure 1.5) Once TXA2 
occupies the VSMC TP receptors, contraction is initiated through coupling of either Gq/11 or, to a 
greater extent, G12/13 (Ellinsworth, Shukla et al. 2014). Coupling with the latter evokes the 
biosynthesis of inositol 1,4,5-trisphophate (IP3) and activation of specific RhoA guanine nucleotide 
exchange factors that in turn activates Rho kinase. This is achieved by G12/13 coupling to 
phospholipase C (PLC). Ultimately, Rho kinase alters the phosphorylation status of threonine 
residues within the MYPT1 subunit of myosin light chain phosphatase (MLCP) and the MLCP 
inhibitory protein CPI-17, thus eliciting contraction (Ellinsworth, Shukla et al. 2014). 
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Figure 1.5: Mechanisms of endothelial cell (EC)-derived thromboxaneA2 (TxA2) biosynthesis and 
direct TxA2-induced vascular smooth muscle cell (VSMC) contraction. AA, arachidonic acid; 
COX, cyclooxygenase; cPLA2, constitutive phospholipase A2; CYP, cytochromeP450; IP3, inositol 
1,4,5-trisphosphate; ER, endoplasmic reticulum; PGH2, prostaglandin H2; PLC, phospholipase C; 
SR, sarcoplasmic reticulum; TP, thromboxane/prostaglandin receptor; TRPV4, transient receptor 
potential vanilloid type 4 channel (Ellinsworth, Shukla et al. 2014). 
 
1.2.1.2.3 Angiotensin II 
Angiotensin II (Ang II) is a pleiotropic hormone that influences the function of many cell types and 
regulates many organ systems. In the cardiovascular system it promotes vascular inflammation and 
atherogenesis (Doughan, Harrison et al. 2008).  It is a potent vasoconstrictor that increases peripheral 
vascular resistance and elevates arterial blood pressure. It is known for its pathophysiological role in 
CVDs such as hypertension, heart failure and atherosclerosis. Studies have additionally shown that 
Ang II promotes endothelial oxidative stress by redox activation of xanthine oxidase synthase 
(Landmesser, Spiekermann et al. 2007).  
Ang II essentially is a bioactive peptide of the renin-angiotensin system (RAS). The diverse actions 
of Ang II are mediated via AT1 and AT2 receptors, which couple to many signalling molecules, 
including small G proteins, phospholipases, mitogen-activated protein (MAP) kinases, phosphatases, 
tyrosine kinases, NADPH oxidase, and transcription factors (Cat & Touyz 2011). In general, acute 
Ang II stimulation induces vasoconstriction through changes in the intracellular free calcium 
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concentration [Ca2+] whereas long-term stimulation leads to cell proliferation and proinflammatory 
responses (Cat & Touyz 2011).  
 
1.3 Endothelial dysfunction  
1.3.1 Introduction 
Endothelial dysfunction (ED) is a term generally used to describe any abnormality in the endothelium, 
especially that of impaired endothelium-dependent vasorelaxation, as well as altered anticoagulant 
and anti-inflammatory properties (Cai & Harrison 2000).  ED is essentially characterized by an 
imbalance in endothelium-derived factors that can negatively affect vascular function (Flammer & 
Luscher 2011). ED is associated with many CVDs such as atherosclerosis, hypertension, coronary 
artery disease, diabetes and severe viral infections such as HIV. 
 
1.3.2 Pathophysiology of ED 
The pathophysiology of ED is complex and involves many mechanisms, however the hallmark of ED 
is impaired NO bioavailability largely due to increased oxidative stress and inflammation. The 
reduced NO availability is either due to decreased NO production or through loss of NO biological 
activity (Van den Oever, Raterman et al. 2010). The production of NO is halted in cells that are 
exposed to oxidative stress, which is caused by either an increase in oxidant production, or a reduction 
in antioxidant protection or a failure in repairing oxidative damage (Van den Oever, Raterman et al. 
2010). Several cardiovascular risk factors such as hyperglycaemia, insulin resistance, dyslipidaemia, 
inflammation and cigarette smoking may induce oxidative stress (Van den Oever, Raterman et al. 
2010). Cell damage is induced by ROS, which under normal conditions are scavenged by intra and 
extra cellular mechanisms but due to increased oxidative stress, these mechanisms are unable to cope 
with ROS (Van den Oever, Raterman et al. 2010). These free radicals can disrupt the balance of NO 
and leave the endothelium overtly permeable, permitting toxins to pass through as well as allowing 
cells that should remain in the blood to pass through blood vessels and into adjacent tissues (Rubanyi 
& Vanhoutte 1986, Rajendran, Rengarajan et al. 2013). Some of these include proteins such as C 
reactive protein (CRP), which is produced by the liver and is responsible for inflammation 
(Rajendran, Rengarajan et al. 2013). Inflammation is also known to decrease NO bioavailability and 
CRP is shown to lower eNOS activity (Verma, Wang et al. 2002, Endemann 2004) 
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In some cases, NO can react with some superoxide to form peroxynitrite (a highly reactive and 
harmful species), that leads to the degradation of the eNOS cofactor tetrahydrobioptrerin (BH4), 
followed by oxidative stress permitting uncoupling of eNOS (refer to figure 1.6). The reductase 
function of eNOS is activated and thus more ROS is produced instead of NO (Endemann 2004, Van 
den Oever, Raterman et al. 2010). Oxidative stress is linked to the proinflammatory state of the vessel 
wall. (Verma, Wang et al. 2002, Endemann 2004). Furthermore, oxidative stress can also lead to cell 
death, specifically programmed cell death or apoptosis (Van den Oever, Raterman et al. 2010). 
 
 
Figure 1.6: Schematic representation of the tetrahydrobiopterin (BH4) recycling pathway and eNOS 
coupling. BH4 is synthesized de novo from GTP via a series of reactions involving GTP cyclo 
hydrolase (GTPCH), 6- pyruvoyltetrahydropterin synthase, and sepiapterin reductase. Dygyrdofolate 
reductase (DHFR) can be inhibited by methotrexate (MTX) and can regenerate BH4 from BH2 as 
part of the recycling pathway. Both BH4 and BH2 bind eNOS with equal affinity, however, BH4-
bound eNOS produces NO, whereas BH2- bound eNOS promotes uncoupling and eNOS-derived 
superoxide rather than NO (Crabtree, Hale et al. 2011) 
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1.4 Assessment of Endothelial Function 
In 1986, ED was demonstrated for the first time by intracoronary infusion of acetylcholine and 
quantitative coronary angiography in atherosclerotic coronary arteries (Ludmer, Selwyn et al. 1986). 
Since then, several less invasive and even non-invasive techniques have been developed to measure 
endothelial function. Refer to table 1.3 for some of the techniques available to assess endothelial 
function. The principle behind all of these techniques relates to large conduit arteries such as the 
brachial or radial artery dilating in response to reactive hyperaemia or as a result of intra-arterial 
infusion of pro-vasodilatory agents such as acetylcholine (Ach), bradykinin or serotonin in presence 
of an endothelium that is functionally capable of releasing NO and other vasodilatory factors 
(Flammer, Anderson et al. 2012, Flammer & Luscher , 2011, Flammer & Lüscher 2010).  
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Table 1.3:Various techniques for the measurement of endothelial function (Adapted from Mudau, 
Genis et al. 2012) 
Method Brief description 
Flow-dependent dilation of the 
brachial artery 
This method employs a high-resolution ultrasound to 
quantify flow-mediated dilation of the brachial artery. The 
technique relies on endothelium-dependent release of NO 
and other EDRF’s in response to reactive hyperaemia. 
Forearm plethysmography Involves intra-brachial infusion of endothelial-dependent 
vasodilators such as acetylcholine, metacholine, substance P 
and bradykinin, with subsequent measurement of changes in 
endothelial function of forearm arterioles. The response to 
acetylcholine is significantly reduced by intra-arterial 
infusion of NG-monomethyl-L-arginine (but not by 
acetylsalicylic acid), thus demonstrating a key role of NO in 
this technique. 
Finger-pulse plethysmography 
(ENDO-PAT) hyperaemia. 
A non-invasive technique that measures changes of the 
pulse-wave amplitude during reactive hyperaemia. Low 
pulse-wave amplitudes are associated with compromised 
endothelial function and are therefore good predictors of 
cardiovascular disease. This technique reflects changes in 
flow and in digital microvessel dilatation and is only partly 
dependent on NO. 
Pulse curve analysis A non-invasive technique that relies on the measure of 
arterial stiffness to quantify endothelial function. This 
technique relies on accurate recording of the radial pressure 
wave, its calibration against brachial pressure, then 
generation of the ascending aortic pressure waveform 
through use of a generalized transfer function in a 
computerized process.  
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Quantitative coronary 
angiography following 
intracoronary infusion of 
acetylcholine 
 
An invasive approach of quantifying endothelial function, 
which involves intracoronary infusion of the endothelium-
dependent vasodilator, acetylcholine, and subsequent 
measurement of the vasomotor response due to relaxing 
factors. 
 
 
1.4.1 Flow mediated dilatation (FMD) of the brachial artery 
FMD of the brachial artery has become the gold standard non-invasive technique for the measurement 
of endothelial function in clinical research. This technique was developed in 1992 to evaluate early 
changes in vascular function of systemic arteries. The technique relies on endothelium-dependent 
release of NO and other EDRF’s in response to reactive hyperaemia (Green, Dawson et al. 2014, 
Flammer & Lüscher 2010, Flammer & Luscher , 2011). The reactive hyperaemia is induced by a 
rapid deflation of a pneumatic blood pressure cuff, wrapped around the forearm that has been hyper-
inflated to a suprasystolic pressure of 200 mm Hg for five minutes (Deanfield, Halcox et al. 2007). 
Deflation of the cuff after 5 minutes’ occlusion of the brachial artery results in a surge of blood flow 
(hyperaemia) and a concomitant increase in shear stress along the vessel which activates the 
mechanoreceptors in ECs to release NO. FMD is then expressed as a percentage change in the brachial 
artery diameter in response to the increased shear stress induced by the reactive hyperaemia, and this 
is measured by a high resolution ultra sound technique (refer to figure1.7). (Jarrete, Zanesco et al. 
2016, Flammer, Anderson et al. 2012). The technique is relatively complicated and requires intensive 
training of the operators as well as standardization of the protocols (Flammer & Lüscher 2010, 
Flammer & Luscher , 2011, Flammer, Anderson et al. 2012). 
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Figure 1.7: The FMD procedure consists of three phases. 
A. Baseline arterial diameter is measured. B. Occlusion phase. The blood pressure cuff is hyper-
inflated to approximately 50 mm Hg above systolic blood pressure value, or 200 mm Hg, for five 
minutes. C. The reactive hyperaemia phase (post-occlusion). Measurement of the maximum arterial 
diameter after the cuff release (peak of the response occurs between 45 to 60 seconds), characterizing 
the hyperaemic period (Jarrete, Zanesco et al. 2016). Abbreviation: NO: nitric oxide. 
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1.5 ED, risk factors and cardiovascular disease 
Long term exposure of the vascular endothelium to cardiovascular risk factors leads to the loss of its 
defence mechanisms. This can result in endothelial activation and dysfunction. Current literature 
refers to ED as one of the major links between exposure to cardiovascular risk factors and the 
development of atherosclerotic disease (Sampson, Engelgau et al. 2015, Bonetti, Lerman et al. 2003, 
Mudau, Genis et al. 2012). Refer to figure 1.8 below. 
 
 
Figure 1.8: The link between endothelial dysfunction, cardiovascular risk-factors and 
atherosclerosis. Traditional and non-traditional risk factors, local factors (e.g. shear stress), and 
genetic factors determine the status of endothelial function.  Sustained exposure to harmful factors 
can lead to pathophysiological changes in the endothelium, i.e. endothelial activation and 
dysfunction which can progress to atherosclerosis, the underlying mechanism of many CVDs such 
as IHD (Sampson, Engelgau et al. 2015). 
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1.6 Human immunodeficiency virus and acquired 
immunodeficiency syndrome (HIV/AIDS) 
1.6.1 Introduction and Epidemiology of HIV /AIDS 
HIV/AIDS was first described in 1981, and two years later, the HI virus was confirmed to be the 
aetiological agent for AIDS. Initially it was believed to be on a slow rise, today, HIV is one of the 
most devastating and widespread infectious agents known to mankind (Delpech 2013). The response 
to the HIV pandemic for the first two decades was poor and only began to improve once successful 
antiretroviral therapy (ART) was introduced (Delpech 2013, Deeks, Lewin et al. 2013). Since its 
introduction in 1996, ART has become a major milestone in revolutionising the clinical management 
of HIV/AIDS (De Cock, Jaffe et al. 2012). Even though HIV is a disease without cure, today it is 
managed as a chronic rather than acute disease with over 30 different approved ART drugs (Ruelas 
& Greene 2013). 
Since the beginning of the HIV epidemic, more than 70 million people have been infected with HIV 
and approximately 35 million people have died of HIV/AIDS worldwide (WHO 2016). Globally, by 
the end of 2015, approximately 36.7 million people were living with HIV. The burden of HIV varies 
significantly between different countries and regions; however, HIV is largely concentrated in SSA, 
with nearly 1 in every 25 adults (4.4%) living with HIV which accounts for nearly 70% of the people 
living with HIV worldwide. It is noteworthy, however, that the number of newly infected people with 
HIV is declining worldwide, with sharp declines in the Caribbean and the SSA region (O’Cofaigh & 
Lewthwaite 2013). Declining transmission can be attributed to a combination of testing, prevention 
counselling and treatment (O’Cofaigh & Lewthwaite 2013). However, the global prevalence of HIV 
is still on the rise as people on anti-retroviral therapy are living longer (Maartens, Connie, et al., 
2014). 
 
1.6.2 Pathophysiology of HIV 
Currently, HIV isolates are grouped into two types, HIV- type 1 (HIV-1) and HIV-type 2 (HIV-2). 
Globally, HIV-1 is mainly responsible of AIDS, whereas HIV-2 is largely restricted to parts of 
western and central Africa. Genetically, HIV is a member of the Lentivirus genus of the Retroviridae 
family. Infections with lentiviruses, generally prescribe to a chronic course in the disease progression, 
with a long period of clinical latency and persistent viral replication (Luciw 1996, Fanales-Belasio, 
Raimondo et al. 2010). HIV, a retrovirus, comprises of two identical copies of RNA molecules. The 
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virus is characterized by the presence of structural genes such as gag, pol, env as well as other 
regulatory and accessory genes. The gag gene encodes for the structural proteins of the core such as 
(p24, p7, p6) and matrix (p17). The env gene encodes glycoprotein gp160 which forms a homodimer 
and is cleaved into the viral envelope glycoproteins gp120 and gp41, responsible for the recognition 
of the cell surface receptors and the pol gene encodes for enzymes crucial for viral replication, which 
are the reverse transcriptase (known to convert viral RNA into DNA),  the integrase that incorporates 
the viral DNA into host chromosomal DNA (the provirus), and the protease that cleaves large Gag 
and Pol protein precursors into their components. Refer to figure 1.9 for the structure of HIV-1 
particle. 
 
 
Figure 1.9: Structure of HIV-1 particle (Fanales-Belasio, Raimondo et al. 2010). 
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1.6.3 HIV life cycle 
Refer to figure 1.10 for a schematic representation of the HIV replication cycle. The main target of 
HIV is activated CD4- T lymphocytes (Maartens, Celum, et al., 2014). Entry of the virus is via its 
interaction with CD4 and Chemokine Co-Receptors (CCR) and is divided into three major events: 
virus binding, activation and fusion (Fanales-Belasio, Raimondo et al. 2010). The viral envelope is a 
trimeric complex, comprising of the heterodimer proteins gp120 and gp41, which are vital for virus 
recognition and entry into target cells. The HIV gp120 binds a 58 kDa monomeric glycoprotein 
(considered as CD4) which is found on 60% of circulating T lymphocytes cell surfaces. Gp120 
binding with the CD4 protein leads to a structural change in the virus envelope complex, exposing a 
specific domain in the gp120 permitting binding with the chemokine receptors on the cell membrane 
(Weiss 1993, Fanales-Belasio, Raimondo et al. 2010). The double binding of gp120 to both the CD4 
and chemokine receptor permits a stable attachment of the virus which allows the N terminal fusion 
protein gp41 to penetrate the cell membrane and cause a collapse of the extracellular portion into a 
hairpin bringing the virus and cell membrane close together leading to fusion and subsequent entrance 
in the viral capsid (Fanales-Belasio, Raimondo et al. 2010, Kirchhoff 2013). 
 
Figure 1.10: HIV replication cycle. RT: reverse transcriptase; dsDNA: double strand DNA 
(Kirchhoff 2013, Fanales-Belasio, Raimondo et al. 2010) 
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After the membrane fusion, the virus core uncoats into the cytoplasm of the target cell, freeing its 
viral RNA. The action of reverse transcriptase and integrase enzymes converts viral RNA to proviral 
DNA. The integration of proviral DNA and the expression of the provirus require that the target cell 
is in an activated state. Upon cell activation, transcription of proviral DNA into a messenger RNA 
occurs (Figure1.10). The transcription process initially results in the early synthesis of regulatory 
HIV-1 proteins such as Tat and Rev (Fanales-Belasio, Raimondo et al. 2010, Kirchhoff 2013). Viral 
messenger RNA coding for long fragments migrates into the cytoplasm, where structural proteins of 
the new virus are synthesized (Figure 1.10). Large gp160 precursor molecules are cleaved by the 
HIV-1 protease into gp120 and gp41. The Gag and Pol proteins are also derived from a large 160 kD 
precursor molecule, from which the HIV protease cleaves the p24, p17, p9 and p7 Gag final products 
and the Pol proteins (Miceli & Parnes 1993, Fanales-Belasio, Raimondo et al. 2010). The cleavage 
of the precursor molecules by the HIV-1 protease is necessary for the generation of infectious viral 
particles. The formation of new viral particles is a stepwise process: two viral RNA strands associate 
together with replication enzymes, while core proteins assemble over them forming the virus capsid. 
This immature particle migrates towards the cell surface (Fanales-Belasio, Raimondo et al. 2010). 
The large precursor molecules are then cleaved by the HIV-1 protease, resulting in new infectious 
viral particles. Finally, the newly formed HIV particle buds off through the host cell membrane 
(Figure 1.10), thus acquiring a new envelope. The surface of the newly formed HIV particle becomes 
studded with HIV glycoproteins (protein/sugar combinations) that are used to bind to CD4 cell co-
receptors to infect other cells (Kirchhoff 2013, Fanales-Belasio, Raimondo et al. 2010). 
 
1.6.4 Antiretroviral therapy (ART) 
The management of HIV/ AIDS was significantly revolutionized with the development of ART in 
the 1990s  (Ruelas, Greene 2013). Soon after the initial development of ART, approved for 
monotherapy, combination ART (cART), also known as highly active ART (HAART), was approved 
which transformed HIV from a progressive fatal illness to a chronic manageable disease (Maartens, 
Celum, et al., 2014, O’Cofaigh & Lewthwaite 2013). The use of HAART is known to dramatically 
suppress the overall burden of HIV, maintaining adequate immune function as well as preventing 
fatal opportunistic infections (Moore, Chaisson 1999, Maartens, Gary, Celum, Connie, Lewin,Sharon 
R, 2014). Today, successful use of HAART has decreased the progression of HIV to AIDS in many 
parts of the world (Fauci & Folkers 2012). 
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Antiretroviral agents predominantly act on various stages of the HIV life cycle to inhibit key steps in 
viral replication. At the moment, there are six classes of antiretroviral agents classified according to 
their molecular mechanism and their target viral enzymes. (Arts & Hazuda 2012, Soriano, Mendoza 
2002, O’Cofaigh & Lewthwaite 2013). Refer to figure 1.11 for a schematic representation. Refer to 
table 1.4 for examples of drugs available in each class. Nucleoside/ nucleotide reverse transcriptase 
inhibitors (NRTIs) were the first class of agents approved by the Food and Drug Administration 
(FDA) (Arts & Hazuda 2012). NRTIs play an integral role in the HIV treatment and remain part of 
the current standard care, even though they are known to be less potent than the other classes of drugs 
(Shen, Peterson et al. 2008, Cox, Aperia et al. 1994). They are often administered as prodrugs, which 
can elicit antiviral effects upon cell entry and phosphorylation by cellular kinases. NRTI’s 
competitively inhibit reverse transcriptase (RT) and cause a termination of the DNA chain (Weller, 
Williams 2001, Arts & Hazuda 2012). The structural similarity of NRTIs to the DNA nucleoside 
bases, permits integration into the proviral DNA chain, preventing other nucleoside incorporation and 
thus terminating the proviral DNA formation. As with all ARTs, treatment with NRTIs can result in 
resistance, often mediated by one of the two mechanisms: 1) impaired incorporation into the proviral 
DNA chain or 2) removal of the NRTIs from the proviral DNA chain (Arts & Hazuda 2012, Clavel 
& Hance 2004, Soriano, Mendoza 2002) 
A few years later, non-nucleoside/ nucleotide reverse transcriptase inhibitors (NNRTIs) were 
introduced in 1996 which act by non-competitively inhibiting reverse transcriptases by binding to 
their allosteric site. NNRTIs have an impact in the handling of substrate (nucleotides) by reverse 
transcriptase via binding near the active site (Arts & Hazuda 2012). The agents are further classified 
in 1st generation and 2nd generation NNRTIs. Resistance in this class generally results from mutations 
in the RT that alter the ability of NNRTIs to bind to the binding site (Clavel, Hance 2004). 
Interestingly HIV-2 is naturally resistant to the agents in this class (Arts & Hazuda 2012, Soriano & 
Mendoza 2002). Another important class of ARTs are the protease inhibitors (PIs). They act by 
blocking the viral protease enzymes which are responsible for the production of mature virions after 
budding from the membrane. Agents from this class specifically inhibit the cleavage of gag and 
gag/pol precursor proteins (Kim & Baxter 2008, Arts & Hazuda 2012). Surviving viral particles that 
are formed in the presence of the PIs are flawed and mostly non-infectious (Flexner 1998). Cross 
resistance in this class is mostly observed with primary resistance mutations occurring near the active 
site of the enzyme, located at the inhibitor binding site (Arts & Hazuda 2012, Clavel & Hance 2004, 
Flexner 1998). 
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Furthermore, some of the relatively recent classes of ART include fusion inhibitors and integrase 
inhibitors. Integrase inhibitors target the viral enzyme integrase responsible for integration of viral 
DNA into the DNA of the infected cell. All agents in this class competitively inhibit the strand transfer 
reaction and thus can also be referred to as integrase strand transfer inhibitors (InSTIs) (Arts & 
Hazuda 2012). Fusion inhibitors are also known as entry inhibitors, and they target the HIV cycle 
extracellularly by inhibiting the fusion of HIV with the CD4 of the target cell. Lastly, similar to fusion 
inhibitors, there is one novel drug available today that acts particularly on CCR5, a chemokine 
receptor antagonist, which inhibits fusion between the cell membranes (Arts & Hazuda 2012, Bai, 
Xue et al. 2013). 
 
 
Figure 1.11: Schematic representation of the HIV life cycle and the sites of action of the various 
classes of ART (Reyskens, Essop 2014).  
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Table 1.4: ARV drugs available in each of the ART classes. 
NRTIs NNRTIs PIs Integrase 
Inhibitors 
Fusion 
Inhibitors 
CCR5 
antagonists 
Abacavir (ABC) 
Didanosine (ddI) 
Emtricitabine (FTC) 
Lamivudine (3TC) 
Stavudine (d4T) 
Tenofovir  DF (TDF) 
Zalcitabine (ddC) 
Zidovudine (AZT) 
Delavirdine 
(DLV) 
Efavirenz 
(EFV) 
Nevirapine 
(NVP)  
Etravirine 
(ETR)  
Rilpivirin 
(RPV) 
Atazanavir (ATV) 
Darunavir (DRV) 
Fosamprenavir 
(FPV) 
Indinavir (IDV) 
Lopinavir/ritonavir 
(LPV/r)  
Nelfinavir (NFV) 
Saquinavir (SQV) 
Tipranavir (TPV) 
Elvitegravir 
(EVG) 
Raltegravir  
(RAL) 
Dolutagravil 
(DTG) 
Enfuvirtide 
(ENF) 
Maraviroc 
(MVC) 
 
 
1.7 HIV and ART- A South African perspective 
1.7.1 Introduction 
In South Africa (SA), the HIV/AIDS epidemic began in the 1980s. At present, South Africa has the 
highest prevalence of people living with HIV/AIDS in the world. In 2015, approximately 7 million 
people were living with HIV and about 380, 000 were newly infected with HIV. Furthermore, in the 
same year, 180 000 South Africans died from AIDS related illnesses. ART for the treatment of HIV 
was introduced in 1996 in SA, however the national HIV ART treatment programme only officially 
began in 2003. Interestingly, globally, SA today has the largest government sponsored ART rollout 
programme (Refer to table 1.5 for a detailed overview of some of the ART drugs available in SA). 
SA has followed the WHO recommendations on initiating treatment based on the individuals CD4 
count. Furthermore, South Africa changed the CD4 level at which people could start ART from 200 
to 350 in 2013 and then later to 500 by the end of 2014, making more people eligible for treatment. 
Recently in 2015, WHO released guidelines recommending ART treatment should now be initiated 
immediately after HIV diagnosis and SA has begun this implementation in 2016. 
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1.7.2 Fixed dose combination (FDC) drug regimens 
In April 2013, a fixed dose combination (FDC) tablet (trade name: Atripla®, or Odimune®) was 
introduced in SA, which contains 300mg of Tenofovir, 200 mg of Emtricitbine and, 600mg of 
Efavirenz (Davies 2013). Refer to table 1.5 for a summary and classification of the drugs. In adults, 
the tablet is taken once daily on an empty stomach. Dosing at bedtime is recommended to improve 
tolerability of nervous system symptoms. The tablet is not recommended for patients under 18 years 
of age. 
This initiation of a triple FDC tablet was a significant advancement in the SA’s national ART 
programme. This substantially simplified the prescription of ART drugs, dispensing and stock 
management due to a reduction from three separate drugs to one combined tablet (Davies 2013). This 
further improved treatment adherence and the burden of patients subjected to multiple drug regimens 
(Meintjes, Conradie et al. 2014) The efficacy of the FDC ART has previously been proven in 
randomized control trials (Davies 2013, Gallant, Staszewski et al. 2004, Gallant, DeJesus et al. 2006). 
 
1.7.3 First line ART in SA  
First line treatment for HIV infected individuals over the age of 15, includes a combination of 
Tenofovir, Emtricitabine or Lamividune and Efavirenz (Davies, 2013). These drugs are provided as 
FDC. Alternative first line treatment for individuals in whom any of the abovementioned drugs are 
contraindicated, comprises of replacing the contraindicated drug with another recommended drug, 
for instance Efavirenz can be replaced with Nevarapine and Tenofovir can be replaced with Abacavir. 
If the contraindication is to both Efavirenz and Nevarapine then those drugs can be replaced with 
Lopinavir together with Ritonavir (Davies 2013).  
 
1.7.4 Second line ART in SA 
For patients failing first line treatment, the WHO recommends switching from NRTI/NNRTI 
regimens to PI based regimens (Ramadhani, Bartlett et al. 2014). According to the South African 
antiretroviral guidelines (Adult) 2015, second line regimens for HIV individuals include a 
combination of Zidovudine, Lamivudine and, Lopinavir with Ritonavir. For an alternative treatment, 
Tenofovir can be replaced with Zidovudine if the above mentioned combination fails. 
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. 
Table 1.5: Detailed overview of ART drugs approved in SA. 
Drug  Recommended 
dose and 
Molecular mass 
Class Mechanism of Action Adverse events 
Emtricitabine 
(FTC) 
300mg/ day;  
247.2g/ mol 
NRTI Cellular enzymes phosphorylate FTC to FTC-5’- 
triphosphate which in turn competes with the 
natural substrate, deoxycytidine 5’- triphosphate 
and is subsequently incorporated into the nascent 
viral DNA and leads to chain termination It 
lowers the patient’s viral load and increases 
CD4 count. 
Common side effects include headache, 
diarrhoea, nausea, fatigue, dizziness, 
depression, insomnia, abnormal 
dreams, rash, abdominal pain, asthenia, 
increased cough, and rhinitis. Skin 
hyperpigmentation is very common in 
paediatric patients. 
Tenofovir 
Disoproxial 
Fumarate 
(TDF) 
300 mg/ day; 
287.2g/mol 
NRTI TDF diphosphate inhibits HIV reverse 
transcriptase through competition with the natural 
substance deoxyadenosine 5’- triphosphate and 
leads to DNA chain termination after 
incorporation into the viral-DNA. 
The most common side effects include 
nausea, vomiting, diarrhoea, 
and asthenia. Less frequent side effects 
include hepatotoxicity, abdominal pain, 
and flatulence. TDF has also been 
implicated in causing kidney toxicity, 
particularly at elevated concentrations.  
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Table 1.5 continued 
 
 
Efavirenz 
(EFV) 
300 mg/ day; 
315.7g/mol 
NNRTI EFV is selective for HIV-1 and diffuses into the 
host cell and binds next to the active site of the 
reverse transcriptase enzyme which leads to a 
conformation change and inhibits the enzyme’s 
function. It is further a non-competitive inhibitor 
of HIV-1 reverse transcriptase with respect to 
template, primer or nucleoside triphosphates  
Common side effects include diarrhoea, 
dizziness, drowsiness, headache, 
increased sweating, poor concentration, 
trouble sleeping, depression and skin 
rash. 
 
Lamivudine 
(3TC) 
300 mg/ day; 
229.26 g/mol 
NRTI 3 TC is an analogue of cytidine. It can inhibit 
both types (1 and 2) of HIV reverse 
transcriptase and also the reverse transcriptase 
of hepatitis B virus. It is phosphorylated to 
active metabolites that compete for 
incorporation into viral DNA. It has a 
synergistic effect when given with AZT 
Common side effects included 
headache, nausea, malaise, fatigue, 
nasal signs and symptoms, respiratory 
tract infections, throat and tonsil 
discomfort, abdominal discomfort and 
pain, vomiting, diarrhoea, and cough. 
Zidovudine 
(AZT) 
300 mg twice daily;  
267.2 g/mol 
NRTI AZT is a thymidine analogue. AZT works by 
selectively inhibiting HIV's reverse 
transcriptase, the enzyme that the virus uses to 
make a DNA copy of its RNA. 
Serious side effects include lactic 
acidosis, liver problems, muscle 
weakness and blood disorders such as 
severe anaemia or neutropenia. 
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Table 1.5 continued 
Lopinavir 
(LPV) 
400 mg twice daily; 
628.8 g/mol 
PI Lopinavir inhibits the HIV viral protease 
enzyme. This prevents cleavage of the gag-
pol polyprotein and results in an inadequate 
viral assembly. This subsequently results in 
non-infectious, immature viral particles. 
Common side effects include an increase in 
serum cholesterol and triglycerides.  
Ritonavir 
(RPV) 
100 mg twice daily;  PI Ritonavir was originally developed as an 
inhibitor of HIV protease; however, it is 
rarely used for its own anti-viral activity. It 
remains widely used as a booster of other 
protease inhibitors. More specifically, 
ritonavir is used to inhibit a particular liver 
enzyme that normally metabolizes protease 
inhibitors, cytochrome P450-3A4 
(CYP3A4). This drug is mostly given in 
combination with lopinavir. 
Common side effects include asthenia, 
malaise, diarrhoea, nausea and vomiting, 
abdominal pain, dizziness, insomnia, 
sweating, taste abnormality, metabolic 
hypercholesterolemia, 
hypertriglyceridemia, elevated 
transaminases and elevated creatine 
phosphokinase(CPK) 
An interesting side effects of this drug is 
hyperglycaemia. It appears that ritonavir 
directly inhibits the GLUT4 insulin-
regulated transporter, keeping glucose from 
entering fat and muscle cells. This can lead 
to insulin resistance and cause problems for 
people with type Ⅱ diabetes.  
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1.8 Cardiovascular disease and risk factors in HIV infected 
individuals 
1.8.1 Introduction 
Successful management of HIV-infection and HIV/AIDS with ART has resulted in CVD to become 
one of the top causes of death in the HIV infected population, partially due to increased lifespan of 
these individuals as well as due to direct effects of ART drugs. Understanding the risk of CVD in 
HIV infected individuals is complex (de Gaetano Donati, Cauda et al. 2010). The prevalence of 
cardiovascular risk factors in HIV infected individuals is known to be high and may precede HIV 
infection (Fedele, Bruno et al. 2011). Several studies have also shown a high prevalence of smoking 
and saturated fat rich diets in HIV infected individuals when compared to the general population 
(Fedele, Bruno et al. 2011). In addition, some studies have shown low physical activity and a greater 
incidence of overweight / obesity present in HIV infected individuals (Mashinya, Alberts et al. 2015, 
Paik & Kotler 2011). All factors such as the host’s genetics, traditional risk factors, adverse effects 
of ART as well as the inflammatory state of HIV may be considered as potential risk factors for CVD 
(de Gaetano Donati, Cauda et al. 2010, Aberg 2009) (Refer to figure 1.12).  
 
Figure 1.12: Risk factors of CVD in HIV. Cardiovascular risk in HIV-infected individuals can be 
attributed to the host’s genetics, traditional risk factors, adverse effects from antiretroviral therapy 
or the inflammatory state associated with HIV itself (De Gaetano Donati, Cauda et al. 2010). 
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1.8.2 Effects of HIV infection on cardiovascular disease and risk 
It has been found that HIV infected individuals are at greater risk of developing CVD both in the 
presence and absence of ART (Wang, Yi et al. 2015). Furthermore, studies have demonstrated a 
higher rate of acute myocardial infarction (AMI) and cardiovascular risk factors in HIV infected 
individuals compared to the controls (Wang, Yi et al. 2015). Several studies have investigated the 
mechanisms and nature of atherosclerosis in HIV infected populations. For example, a study found 
an increased presence of plaque and non-calcified plaque in HIV infected participants compared to 
the control population. This study ultimately demonstrated that HIV-infected individuals without 
significant metabolic abnormalities may still develop non-calcified plaque and thus have an increased 
risk of IHD (Fitch, Lo et al. 2010, Wang, Yi et al. 2015) 
An increased risk of CVD in HIV-infected individuals remains incompletely understood. One theory 
relates to HIV induced hyperlipidaemia and hypercholesterolemia which promote the pathogenesis 
of atherosclerosis. It has been found that HIV-infection and some ART drug classes, especially agents 
from the PI class can cause dyslipidaemia in the HIV infected population, thus contributing to an 
increased risk of CVD (Wang, Yi et al. 2015, Stein, Currier et al. 2014, Brown & Glesby 2012). In 
fact, unmanaged HIV replication has been found to be an independent risk factor for changes in the 
individual’s lipid profile (Fedele, Bruno et al. 2011). Two studies in particular have shown that HIV 
infected individuals have a higher total LDL and HDL cholesterol as well as serum triglyceride levels 
compared to the control groups entailing that these infected individuals are at a much higher risk of 
developing CVD (Kaplan, Kingsley et al. 2007, Fedele, Bruno et al. 2011). The effect of these risk 
factors is found to be similar in both HIV infected and non-infected individuals, suggesting that these 
factors contribute to the risk in a comparable way regardless of the HIV status (Joy, Keogh et al. 
2007, Fedele, Bruno et al. 2011). Furthermore, current literature suggests that the events progressing 
to CVD overlap and intertwine, and do not necessarily occur in a distinct manner in HIV infected 
individuals (Fedele, Bruno et al. 2011). 
It is debatable as to whether HIV or ART has a greater contribution to cardiovascular risk. However, 
untreated HIV has been associated with an increased level of systemic inflammatory markers, such 
as IL-6, proinflammatory cytokines and CRP. Increased IL-6 levels are found to be a strong predictor 
of future cardiovascular events and overall mortality in ART naïve and ART treated HIV infected 
patients (Kuller, Tracy et al. 2008, Wang, Yi et al. 2015).  Several studies have demonstrated that the 
continuing HIV replication and immune depletion significantly contributes to an increased prevalence 
of elevated biomarkers of inflammation, altered coagulation, and monocyte activation, and this 
contribution is independent of the substantial contribution from comorbid conditions (Sandler, Wand 
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et al. 2011, Wang, Yi et al. 2015). A study found that HIV infection correlates with premature 
atherosclerosis even in absence of detectable viremia and ART, thus appearing to be an independent 
risk factor (Hsue, Hunt et al. 2009). High rates of cardiovascular events when ART is halted further 
suggests that HIV infection in itself may elevate cardiovascular risk (Fedele, Bruno et al. 2011, Wang, 
Yi et al. 2015).  
 
1.8.3 Effects of ART on cardiovascular disease and risk 
The relationship between ART and cardiovascular risk is not well understood. However, as 
mentioned, the literature suggests that HIV individuals regardless of ART generally do present with 
underlying traditional cardiovascular risk factors, which complicates the demonstration of the risk 
associated with the type of ART or specific ART drugs. In fact, recently, data have emerged 
suggesting that ART may improve factors associated with increased CVD risk (Fedele, Bruno et al. 
2011).   
Although there are many benefits of ART, upon its introduction, several reports of MI and premature 
atherosclerosis emerged in individuals receiving ART (Maggi, Lillo et al. 2004, Fedele, Bruno et al. 
2011). ART induced hyperlipidaemia and hypercholesterolemia is also found to promote the 
pathogenesis of atherosclerosis. It has been further found that a few ART drugs, especially agents 
from the PI class can cause dyslipidaemia in HIV infected population, thus contributing to an 
increased risk of CVD (Wang, Yi et al. 2015, Stein, Currier et al. 2014, Brown & Glesby 2012). Other 
studies have specifically found NRTIs and PIs to increase the risk of developing IHD (Steyn, Sliwa 
et al. 2005, Skowyra, Zdziechowicz et al. 2012). Many studies have found a strong association 
between the type, duration, and current use or non-use of ART and the severity of metabolic disorders 
such as hyperlipidaemia, insulin resistance, and lipodystrophy. In the ongoing Data Collection on 
Adverse Events of Anti-HIV Drugs (D:A:D) study, it was found that the relative risk of CVD 
increased as the duration of ART increased, however the absolute risk of cardiovascular disease 
remained low for most patients, except those with multiple other cardiovascular risk factors (Caron, 
Auclair et al. 2001, Fedele, Bruno et al. 2011). However as soon as it was established that uncontrolled 
HIV viremia and the presence of risk factors similar to the general population may cause CVD 
amongst HIV infected individuals, it was suggested that discontinuation or interruption in ART may 
be of little benefit in lowering cardiovascular risk (Wang, Yi et al. 2015). Data from a study 
demonstrated that patients in the CD4-guided intermittent ART group were at increased risk of 
myocardial damage in comparison to individuals who received ART (Fedele, Bruno et al. 2011, 
Ananworanich, Gayet-Ageron et al. 2006). Furthermore, the study found that, IL-6 and D-dimer 
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levels increased after discontinuation of ART, and this increase was associated with increases in HIV 
RNA levels (Phillips, Carr et al. 2008, Fedele, Bruno et al. 2011). 
 
1.9 Endothelial dysfunction in HIV-infected individuals 
1.9.1 Introduction 
HIV is capable of infecting endothelial cells which may directly lead to endothelial dysfunction 
(Skowyra, Zdziechowicz et al. 2012). The exact underlying mechanism by which the virus induces 
ED is not fully understood. However, several possible mechanisms which have been proposed (refer 
to table 1.6) and are currently the focus of research (Subbarao, Lowe et al. 2011, Monsuez, Charniot 
et al. 2009).  
Table 1.6: Proposed mechanisms of HIV induced ED (Adapted from Monsuez, Charniot et al. 
2009). 
Proposed pathogenesis of HIV induced ED 
Direct endothelial injury from the HIV-1 virus and the component proteins of HIV-1 
 HIV-induced chronic inflammation 
 HIV-induced dyslipidaemia and metabolic syndrome 
 Direct endothelial injury from antiretroviral therapy 
ART-induced dyslipidaemia and metabolic syndrome 
 
1.9.2 HIV infection and ED 
The untreated state of HIV is associated with ED. HIV is able to enter ECs via several ways such as 
through the CCR-3 and CCR-4, cluster of differentiation 4 (CD4) or galactosyl-ceramide receptors 
(Wang, Yi et al. 2015, Skowyra, Zdziechowicz et al. 2012). Entry of the virus also occurs though 
GP120 and tat protein as well as participation of cytokines secreted by HIV infected mononuclear 
and adventitial cells. The HI virus can injure the endothelium in a few ways. It can cause direct cell 
death through apoptosis or necrosis (Wang, Yi et al. 2015). In addition, the virus can infect and 
decrease endothelial progenitor cells (the circulating colony forming unit endothelial cells) which are 
essential for the endothelial damage repair (Teofili, Iachininoto et al. 2010). Furthermore, HIV 
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proteins, such as Gp120, are responsible for apoptosis of the endothelial cells and stimulation of 
macrophages to produce excessive amounts of NO, which can progress to direct endothelial damage 
(Wang, Yi et al. 2015). Interestingly it has been found that exposure to cigarette smoke and HIV 
gp120 causes a synergistic increase in endothelial cell death (Green, Yi et al. 2014, Wang, Yi et al. 
2015). Moreover, the HIV TAT protein can activate inflammatory pathways via mononuclear cells 
that are known to produce tumour necrosis factor-α (TNF-α) and the pro-inflammatory transcription 
factor, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). Tat protein also elicits 
the expression of adhesion molecules E-selectin, vascular cell adhesion protein 1 (VCAM-1) and 
intercellular adhesion molecule 1 (ICAM-1), which alter endothelial permeability (Willerson & 
Ridker 2004, Wang, Yi et al. 2015). 
It has been found that HIV infected individuals have an increased levels of endothelial micro-particles 
(released particularly during apoptosis), which may be seen as a marker of EC injury. Furthermore, 
it has been established that HIV infected individuals have higher levels of cellular adhesion molecules 
in comparison to the control individuals (Francisci, Giannini et al. 2009, Wang, Melancon et al. 2013). 
The individuals also appear to have increased levels of plasma proinflammatory cytokines such as 
TNF- α, interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-8 (IL-8), monocyte chemotactic protein 
1 (MCP-1), and VCAM-1, ICAM-1, P-selectin, and von Willebrand factor (vWF). All of the above 
mentioned inflammatory biomarkers appeared to be elevated irrespective of the antiretroviral therapy. 
In addition, a study has shown that ED is more pronounced when HIV infection is severe and more 
advanced (Wang, Yi et al. 2015, Subbarao, Lowe et al. 2011). Furthermore, impaired endothelial 
function was demonstrated by means of FMD in HIV infected individuals compared to the control 
(Skowyra, Zdziechowicz et al. 2012, Solages, Vita et al. 2006). 
 
1.9.3 ART and ED 
Several studies have suggested that ART may result in the development of ED. Particularly NRTIs 
and PIs seem to play a major role in ED (Skowyra, Zdziechowicz et al. 2012, Subbarao, Lowe et al. 
2011). HAART can play a role in the aetiology of ED in several ways. Firstly, it has been found to 
cause a significant increase in total cholesterol (TC) and triglyceride (TG) levels. Secondly, HAART 
in some individuals has led to insulin resistance or lipodystrophy (Mooser 2003, Skowyra, 
Zdziechowicz et al. 2012). Most notably ART drugs from the PI class are known to cause adverse 
effects on lipid profile. Studies have also found an increased level of P-selectin, tissue plasminogen 
activator and plasminogen activator inhibitor in treated HIV individuals when compared to the ART 
naive group. In addition, higher levels of cholesterol co-exists with a high concentration of P-selectin, 
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t-PA and ICAM-1 (whereas triglycerides correlate with plasminogen activator inhibitor 1) (De 
Gaetano Donati, Rabagliati et al. 2003, Skowyra, Zdziechowicz et al. 2012). Furthermore, HAART 
has been shown to result in decreased NO levels while increasing ROS and cholesterol, which could 
accelerate foam cell formation (as seen in atherosclerosis) (Chan, Sviridov et al. 2009, Skowyra, 
Zdziechowicz et al. 2012). 
While analysing the literature, most studies investigating the effects of HAART on ED were found 
to be performed on two groups of drugs: PIs and NRTIs. The PIs are found to directly induce ED. 
They are thought to be responsible for mitochondrial DNA damage in ECs which can lead to total 
destruction of the endothelium independent of the individual’s lipid profile (Zhong, Lu et al. 2002a, 
Skowyra, Zdziechowicz et al. 2012). It has been found that HIV infected individuals on PIs have a 
significantly lower FMD values and higher carotid intima media thickness (CIMT), a method to detect 
early atherosclerotic vascular disease. However, during analysis of specific drugs, there are some 
contradicting results. For instance, dramatic endothelial impairment is found with the drug indinavir, 
whereas the newer PI drugs such as lopinavir and ritonavir have not been shown to induce ED in HIV 
infected individuals (Dube, Shen et al. 2008, Grubb, Dejam et al. 2006, Skowyra, Zdziechowicz et 
al. 2012).  
Interestingly, NRTIs are also found to increase total cholesterol, LDL-cholesterol and TG. Individuals 
on drugs from this class are found to be more prone to develop vascular complications as these drugs 
are associated with endothelial damage. In addition, NRTIs lead to an increased level of the 
vasoconstrictor endothelin-1, cell proliferation and cause the appearance of intracellular gaps in 
endothelial surface (Hebert, Crenshaw et al. 2004a, Skowyra, Zdziechowicz et al. 2012) . Moreover, 
a significant negative influence on the aortic endothelium-dependent relaxation is observed 
(Skowyra, Zdziechowicz et al. 2012). Furthermore, drugs from this class are suspected to increase 
the production of ROS. The drug abacavir (ABC) is particularly known to play a role in ED. It has 
been found that individuals treated with ABC present with a more severe form of ED in comparison 
to other drugs in this class. In general, NRTI intake was also associated with higher levels of 
proinflammatory cytokines and CRP (DAD Study Group 2007, Skowyra, Zdziechowicz et al. 2012). 
 
1.9.4 HIV infection in vitro studies 
In vitro infection of human umbilical vein endothelial cells (HUVECs) with HIV-1 has previously 
been demonstrated (Kline & Sutliff 2008). The method used in the study involved inoculation of the 
cells with the different isolates of HIV-1 infection (Corbeil, Evans et al. 1995). It was found that HIV 
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infection in HUVECs significantly enhanced viral protein synthesis and up regulates the production 
of interleukin-6 (IL-6), and granulocyte colony-stimulating factor, which are cytokines that stimulate 
HIV-1 synthesis (Conaldi, Serra et al. 1995, Kline & Sutliff 2008).  
There are various other in vitro HIV infection models that can be used for experiments. One such 
method is the use of HL2/ 3 cells. These cells have been used by many studies to demonstrate the 
HIV infection in in vitro models. The cells are derived from the Hela cell line and are transfected with 
a clone of the HXB2 strain that lack the reverse transcriptase coding sequence. This results in a high 
level production of the HIV-1 gag, Env (particularly gp120), Tat, Rev and Nef proteins without shedding 
of infectious viral particles (Ciminale & Felber et al. 1990, Klug, Ashkenazi et al. 2014, Africa 2014). For 
this very reason the HL2/3 cell line can be used as an ideal research tool for the investigation of the 
inflammatory viral proteins or as a HIV cell model to test the effects of the various ARV drugs on cells 
exposed to HIV related proteins in vitro. 
 
1.9.5 ART and ED in in vitro studies 
In comparison to studies investigating the role of ART in ED in humans, in vitro studies are scarce. 
Studies focus mostly on cell toxicity. However, it has been found that ART can lead to direct 
microvascular changes. It has been found that drugs from the class of NRTIs have a role in ED 
(Sutliff, Dikalov et al. 2002). Notably, Zidovudine (AZT), seems to be a major role player in inducing 
cytotoxicity in cultured endothelial cells without the induction of apoptosis. Zidovudine has also been 
found to promote the release of vasoconstrictor and mitogen endothelin 1 and enhance proliferation 
of vascular smooth muscle cells and HUVECs (Hebert, Crenshaw et al. 2004). In addition, cytotoxic 
effects of AZT have been found, where intercellular gaps between adjacent human coronary artery 
endothelial cells are damaged and hence promoting a platform for the inflammatory cascade (Jiang, 
Hebert et al. 2007, Fiala, Murphy et al. 2004). Furthermore, cell culture experiments show an 
enhanced endothelial ROS production, in response to AZT (Kline & Sutliff 2008). 
The drugs from the class of PI, have been of great interest in in vitro experiments. Many studies have 
demonstrated PI-induced endothelial dysfunction (Wang, Chai et al. 2007). PI treatment in in vitro 
experiments have demonstrated serious mitochondrial disturbances by reduced cellular respiration 
and ATP production. The drugs in this class are further implicated to increase production of ROS in 
experiments (Kline & Sutliff 2008). They have been found to also increase endothelial cell 
permeability and leukocyte adhesion in cell culture models (Mondal, Pradhan et al. 2004, Kline & 
Sutliff 2008). Notably, the drug ritonavir has been found to directly cause endothelial mitochondrial 
DNA damage and cell death, especially via the necrosis pathway (Zhong, Lu et al. 2002, Subbarao, 
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Lowe et al. 2011). Furthermore, ritonavir has been found to decrease eNOS mRNA and protein levels 
in cultured human coronary endothelial cells (Fu, Chai et al. 2005, Subbarao, Lowe et al. 2011). 
 
1.10 Concluding Remarks 
The introduction of ART has substantially decreased HIV/AIDS related mortality. HIV infected 
people are living longer with a better quality of life, however infected people are riddled with earlier 
unrecognized complications such as endothelial dysfunction and cardiovascular diseases (Skowyra, 
Zdziechowicz et al. 2012, Gresele, Falcinelli et al. 2012). The underlying mechanisms of these 
complications are unclear. As discussed, there are many reports indicating that HIV infected 
individuals on ART are at a greater risk of developing CVD. ED is an initiating event in atherogenesis 
and may contribute to HIV associated atherosclerosis. We are now aware, that the virus interacts with 
the cardiovascular system (CVS), especially the endothelium and platelets (Subbarao, Lowe et al. 
2011). In fact, the virus itself may lead to ED. However, it is not well understood whether HIV or the 
ART is more responsible for ED. Furthermore, it is unclear as to which ARV drugs or regimens are 
more associated with cardiovascular risk and ED. Therefore, further exploration in the matter is 
warranted. 
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1.11 Problem Identification & Aims of the Study 
1.11.1 Problem identification 
Very few studies have assessed cardiovascular risk factors in HIV infected individuals in low income 
countries (Mashinya, Alberts et al. 2015). Most studies on cardiovascular risk factors in HIV 
individuals are performed in Western countries (Mashinya, Alberts et al. 2015). Furthermore, there 
is a paucity of studies on cardiovascular risk factors in the HIV population in South Africa (Fourie, 
Van Rooyen et al. 2010, Malaza, Mossong et al. 2012, Mashinya, Alberts et al. 2015). A recent study 
described the association of ART and CVD risk in the rural individuals in the Mpumalanga Province 
of SA. However, the use of ART was self-reported in the study and according to the authors, the CVD 
risk may have been underestimated due to the stigma associated with HIV (Clark, Gómez-Olivé et al. 
2015, Mashinya, Alberts et al. 2015).  
Moreover, very few studies have investigated the association between HIV/ ART and ED in SA. A 
recent study in the Northwest confirmed the link between endothelial activation and HIV (Fourie, 
Schutte et al. 2015), however, very little has been investigated on the SA approved first (combination 
of efavirenz, emtricitibine and tenofivir) and second (lopinavir and ritonavir) line treatment on ED in 
adult South Africans and to the best of our knowledge nothing has been reported in Western Cape 
populations. In addition, very little is known about which type of treatment regimen is more prone to 
be associated with ED. Furthermore, in vitro studies investigating the effects of these particular drugs 
on ECs are scarce. 
Therefore, the overall aim of the study was to investigate the association between HIV and the South 
African approved first line and second line ART drugs, endothelial function and cardiovascular risk. 
The epidemiological (main) study was underpinned by an in vitro sub-study. 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
43 
 
1.11.2 Main aim of the study 
To investigate the effects of first line and second line antiretroviral drugs on HIV exposed vascular 
endothelial function and cardiovascular risk. 
 
1.11.2.1 Specific aims of the Epidemiological (main) Study 
 
i. To investigate endothelial function in a cohort of HIV positive, ART naïve; HIV positive on 
first line ART treatment; HIV positive on second line treatment, and HIV negative participants. 
Endothelial function was assessed using non-invasive flow-mediated dilation (FMD) of the 
brachial artery, by Doppler technology.  
 
ii. To investigate the possible association between the type of ART treatment (i.e. first line and 
second line), and changes in endothelial function in the participants. 
 
iii. To investigate the possible association between the cardiovascular risk profile (dyslipidaemia, 
hypertension, obesity, diabetes mellitus and smoking) and endothelial function (as assessed by 
FMD) in the cohort, using data from comprehensive health questionnaires, anthropometric 
measurements, and clinical screening and serum analyses. 
 
  
1.11.2.2 Specific aims of the in vitro sub-study 
 
i. To develop an in vitro model of HIV-infection by exposing aortic endothelial cells (AECs) 
to growth medium containing HIV-related proteins. 
 
ii. To investigate the effects of first line and second line ART drugs administered to AECs 
exposed to HIV-related proteins in culture on cell viability, NO production and oxidative 
stress status. 
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Chapter 2 : Methods (clinical study) 
This chapter describes the experimental design and methods used for the epidemiological studies. All 
data was collected in partnership with an assigned post-doctoral fellow at the Worcester Community 
Health Care Centre. 
 
2.1  Ethics approval 
Ethics approval was received from the Health Research Ethics Committee (HREC) of the University 
of Stellenbosch (ethics reference: N12/12/086). Good Clinical practice (GCP) was maintained 
throughout the study and adhered to the South African GCP guidelines. Furthermore, research was 
conducted in line with the standard operating procedures and guidelines of the HREC of the 
University of Stellenbosch. 
 
2.2  Study design and participants  
This was a sub-study embedded in a larger, international study called ‘EndoAfrica’. The study was 
of a cross sectional nature and data were collected from May 2015 to July 2016. The study was in 
collaboration with the Winelands HAART to HEART study lead by Prof Faadiel Essop from the 
Department of Physiological Sciences of Stellenbosch University. The participants were recruited 
from Worcester and surrounding areas of the Western Cape Province by a Health Professions Council 
of South Africa (HPCSA) registered nurse. Refer to table 2.1 for the inclusion and exclusion criteria 
for the participants of this study.  
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Table 2.1: Inclusion and exclusion criteria used for the participants of the study 
Inclusion criteria Exclusion Criteria 
Participants ≥18 years of age  Participants < 18 years of age 
Not pregnant Pregnant 
≥ 3 months’ post-partum < 3 months’ post-partum 
HIV-positive participants’ not on treatment Terminally ill 
HIV-positive participants on first line ART Active TB 
HIV-positive participants on second line ART   
Abbreviations: ART, antiretroviral therapy 
 
The recruitment commenced a few days before the assessments, where the participants were informed 
about the study and requested to fast for at least 10 hours prior to the assessments. Assessments 
commenced at 08h00 in the morning. This also ensured that the participants had some time to make 
an informed and a well thought decision before volunteering to be part of the study. The research 
nurse had access to the clinic patient files and was able to recruit participants based on their HIV 
status. Furthermore, HIV testing for participants with unknown status was performed with the Quality 
advance HIV virus, rapid confirmation test by Abon, China. The participants were also pre and post 
counselled by the registered nurse who had training in HIV counselling. The study consisted of four 
groups of participants, stratified according to their HIV status and ART (refer to figure 2.1). 
Informed consent was obtained from the participants prior to any assessments (refer to appendix A 
for the informed consent document)  
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Figure 2.1: A schematic representation of the four study groups and their respective sample sizes. 
 
The HIV negative participants were recruited in the same manner as those with HIV. They 
predominantly belonged to the same socio economic status and ethnicity as the HIV positive 
participants. They were individuals from the community who attended the clinic as out-patients, or 
worked at the clinic, and were recruited by the research nurse based on the study’s inclusion criteria. 
This recruitment process enabled the study to consider the HIV negative group as a relevant control 
group for the HIV positive groups. 
 
2.3  Qualitative assessments (Medical History and Lifestyle 
questionnaires) 
Qualitative data was collected by means of an interview and questionnaire. Medical history and 
lifestyle parameters including smoking and drinking (alcohol consumption) status were assessed. 
Refer to appendix B for the questionnaire used in the study. The participants were asked the 
questions objectively in either English, Afrikaans or Xhosa language based on their language 
preference. In addition, the patient clinic file was used to retrieve and confirm medical and treatment 
history data of all the participants. 
 
Total sample 
n= 152
HIV positive ART 
naive
n= 33
HIV positive 1st 
line ART
n= 50
HIV positive 2nd 
line ART
n= 33
HIV negative
n= 36
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2.4  Clinical investigations 
2.4.1 Biochemical assessments 
Fasting whole blood samples were collected by the research nurse and prepared according to 
standardized methods.   Serum C-reactive protein (CRP), whole blood fasting glucose and glycated 
haemoglobin (HbA1c), as well as serum triglycerides, high density lipoprotein (HDL), low density 
lipoproteins (LDL), and total cholesterol were analysed by the National Health Laboratory Services 
(NHLS), Worcester, Western Cape which was located at the Worcester Hospital, next to the clinic 
(field site). In addition, CD4 and viral load levels were determined by the NHLS, Green Point, 
Western Cape, for the HIV-infected participants. These samples were transported to the NHLS by the 
research nurse or the clinic porters, immediately after collection of blood from all the participants on 
the day. 
 
2.4.2 Anthropometric measurements 
The anthropometric measurements included: body mass index (BMI), waist and hip circumference, 
and waist-hip ratio (WHR). Before the body mass was recorded, a digital Electric Platform scale 
(Adult, 200kg, 0.02 increments) was set to zero, after which the participant was instructed to stand 
on the centre of the scale without any support. The measurement was recorded to the nearest 0.1 kg. 
Height was measured using a stadiometer to the nearest 0.1cm. The participant was requested to stand 
on the centre of the base with their back to the stadiometer. They were requested to keep their feet 
together and move back until their heels, buttocks and upper part of the back has touched the 
stadiometer. BMI was calculated by dividing the body mass by height squared. Waist circumference 
(WC) and hip circumference (HC) were measured using a measuring tape. A cross hand technique 
was used and participants were requested to stand in upright position with their abdomen relaxed, 
arms at sides and feet together. For WC, the measuring tape was placed around the participant’s waist 
between the 10th lower costal rib and the superior iliac crest at the narrowest plane of the abdomen. 
For HC, the measuring tape was placed around the largest area of the buttocks around the gluteal 
muscles of the participant with their feet together. Both WC and HC measurements were taken to the 
nearest 0.1cm. Waist to hip ratio was calculated by dividing WC by HC.  
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2.4.3 Blood pressure measurements 
Blood pressure and heart rate measurements were recorded using a digital OMRON® 
sphygmomanometer. The participants were requested to sit in a relaxed position before the 
measurement was taken. All blood pressure and heart rate measurements were taken in triplicate to 
ensure accuracy and minimise white coat hypertension and possible anxiety. There was a 15 to 20 
min period of rest between each of the three measurements. 
 
2.4.4 Measurement of endothelial function- Flow mediated dilatation 
(FMD) 
As described earlier in chapter 1, section 1.5.1, FMD is a non-invasive technique for the assessment 
of endothelial function. For this study, FMD was measured on fasted participants in a supine position 
in a quiet room. A blood pressure cuff was wrapped below the antecubital fossa on the right arm of 
the participant. The brachial artery of the right arm was located in B mode with an Esaote 
MyLabTMFive ultrasound, (Maastricht, Netherlands) and 12 MHz linear probe, after application of 
CLINICA ultrasound gel. The probe was securely fixed on a single axis probe holder from SMT 
Medical, (Graz, Austria) (refer to figure 2.2 and 2.3), ensuring a stable image of the located artery. 
Doppler mode was used to visualise and locate the brachial artery, with pulse repetition frequency 
(PRF) set at 6.7 kHz.  Once the artery was clearly visualised, depth was increased to 3 cm before 
switching to pulse wave mode.  In pulse wave mode, the angle of insonation was set to 600 (refer to 
figure 2.4). Following this, the brachial artery diameter and shear rate were automatically recorded 
throughout the assessment (with FMD studio and Cardiovascular Suite version 2.8.1. edge detection, 
QUIPU software, Pisa, Italy) on an Apple MacBook Pro laptop (2010 edition). Baseline brachial 
artery diameter was recorded for 60 seconds (refer to figure 2.3. A). After the baseline recording 
phase, occlusion of the brachial artery was achieved via inflation of the blood pressure cuff to a supra- 
systolic pressure of 200 mmHg (or 50 mmHg above the prior systolic pressure measurement) for 5 
min (refer to figure 2.3. B). Finally, the cuff was deflated and the post-occlusion artery diameter was 
recorded for a further 120s (refer to figure 2.3. C). FMD was then automatically calculated by the 
FMD studio and Cardiovascular Suite QUIPU software as the ratio of brachial artery diameter after 
reactive hyperaemia to the baseline diameter and was expressed as a percentage change. In summary, 
the basic formula that the softer used to calculate FMD % was:   
𝐌𝐚𝐱𝐢𝐦𝐮𝐦 𝐝𝐢𝐚𝐦𝐞𝐭𝐞𝐫 −  𝐌𝐞𝐚𝐧 𝐁𝐚𝐬𝐞𝐥𝐢𝐧𝐞 𝐃𝐢𝐚𝐦𝐞𝐭𝐞𝐫
 𝐌𝐞𝐚𝐧 𝐁𝐚𝐬𝐞𝐥𝐢𝐧𝐞 𝐝𝐢𝐚𝐦𝐞𝐭𝐞𝐫
 𝐗 𝟏𝟎𝟎 
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Figure 2.2: A photograph representing a typical FMD assessment with the MyLabTMFive ultrasound 
and 12 MHz linear probe. On the left, is an Apple Macbook pro laptop with FMD studio and 
Cardiovascular Suite version 2.8.1. edge detection QUIPU software that records the artery diameter 
and shear rate throughout the assessment. The study participant is in the supine position with the right 
arm resting on the probe-holder platform. (This photograph features individuals from the study 
research team, and consent was given by both individuals to include it in the thesis). 
 
 
 
Figure 2.3: A photograph depicting the blood pressure cuff wrapped around the right arm of the study 
participant and the probe securely fixed in the SMT medical probe holder. 
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Figure 2.4: An image of the brachial artery on an Esaote MyLabTMFive ultrasound with the correct 
settings in Doppler mode. The yellow arrows indicate the location of the brachial artery on the image. 
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A. 
 
 
B. 
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C.   
 
Figure 2.5: An example of Flow mediated dilation (FMD) technique in 3 phases using FMD studio 
and Cardiovascular Suite version 2.8.1, edge detection software images. The yellow arrows indicate 
the phase of interest in each image A. Baseline artery diameter is measured for a duration of 60 
seconds. The recording is relatively stable indicating no or minimal changes in the artery diameter. 
B.  Inflation of the blood pressure cuff (occlusion) for a total duration of 300 seconds which leads to 
ischaemia C. Deflation of blood pressure cuff leading to hyperaemia and subsequent shear stress-
induced arterial dilation with maximum diameter recording followed by recovery diameter recording 
(total duration 120 seconds). FMD is then calculated as a percentage change in the arterial diameter 
from the baseline to maximum diameter. The FMD % is circled in yellow on the image for this 
particular assessment. 
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2.5  Experimental protocol 
In summary, the assessments were performed in a stepwise manner (refer to figure 2.6). Step one 
included recruitment, scheduling of an appointment obtaining informed consent, performing 
anthropometric measurements and collection of blood samples from the left arm. Step two comprised 
of blood pressure measurements and collection of qualitative data via an interview and filling in of a 
health questionnaire. The final step comprised of the FMD measurement of the participant’s brachial 
artery. Upon completion, participants were offered a small snack as they had arrived fasted for the 
assessments.  
 
 
Figure 2.6: A schematic representation of a stepwise experimental protocol. 
 
 
 
 
 
Step 1: Recruitment, appointment for 
assessment made, infomed consent obtained on 
day of assessment, anthropometric 
measurements and collection of blood samples
Step 2: Medical history, life style questionaires 
and blood pressure measurements
Step 3: Measurement of endothelial function 
(FMD). Participants offered a snack upon 
departure.
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2.6 Statistical analysis 
All collected data was captured in Microsoft Office Excel 2016. Stata® version 14 was used to 
analyse the data and the level of significance was set at p <0.05.  
Descriptive statistics: For normally distributed data, one-way ANOVA was performed with 
Bonferroni post hoc test to determine significant differences between the four groups. Pearson’s Chi 
square analysis was performed for categorical data. In addition, for non-parametric data, a pairwise 
comparisons of group was done using a one way Kruskal-Wallis ANOVA.   
Independent predictors and associations: Multiple linear regression models were used, with entry and 
exit criteria set at 0.05 and 0.1 respectively, and data were stratified on group for all models. The 
remaining predictor variables were entered in a stepwise forward fashion. The regression analysis 
were performed to determine independent predictors and associations in each of the 4 study groups 
as well as in total HIV positive and the total HIV negative group. In addition, regression analysis was 
performed on the total population. Baseline artery diameter, maximum artery diameter and FMD% 
were used as dependent variables in the regression models. Independent variables included HIV status 
(for total population), gender, age, use of cardiovascular medication, smoking history, waist 
circumference, mean systolic blood pressure, LDL cholesterol, HDL cholesterol, CRP, and fasting 
glucose.  The confounding variables gender, age, use of cardiovascular medicine, smoking and waist 
circumference were forced to remain in all regression models. Additionally, CD4 was included as an 
independent variable in the HIV positive groups. The candidate performed all statistical analyses 
using Statistica Software version 13 (StatSoft, Inc., USA) the level of significance was set at p <0.05, 
which were subsequently independently validated by a professional biostatistician from the 
Biostatistics Unit, Faculty of Medicine and Health Sciences of Stellenbosch University. The results 
from the biostatistician is included in this thesis. 
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Chapter 3 : Methods (in vitro sub-study) 
This chapter describes the materials and methods used for the in vitro sub-study.  
 
3.1 General materials 
 Lonza Ltd (Clonetics, Cambrex Bio Science, Walkersville, USA) (supplied by Whitehead 
Scientific locally): Endothelial cell growth medium (EGM-2) and Dulbecco’s modified 
Eagle’s Medium (DMEM) with 4.5g/L glucose and L Glutamine. 
 Life Technologies (Carlsbad, California, USA): Attachment factor and trypsin (500 
BAEE units’ trypsin / 180 μg EDTA•4Naper ml in Dulbecco’s PBS)  
 Biochom-Biotech: Foetal bovine serum (FBS).  
 Calbiochem (San Diego, CA, USA) (supplied by Merck locally): 4,5-diaminofluorescein-
2/diacetate (DAF-2/DA). 
 Sigma-Aldrich (St Louis, Mo, USA): Dimethyl sulfoxide (DMSO); 2′, 7′-Dichlorofluorescein 
(DCF); 2,3-Dimethoxy-1,4-naphthoquinone(DMNQ); Diethylamine NONOate 
diethylammonium salt (DEA/NO) and Penstrep. 
 Bio-Legend (San Diego, CA, USA) (supplied by Biocom-Biotech locally): Propidium iodide 
solution and cell staining buffer. 
 VEC Technologies (University at Albany Foundation, 1 University Pl, Rensselaer, NY 12144, 
USA): Aortic endothelial cells (rat) (AECs). 
 
3.2 Introduction to cell culture technique 
Cell culture is a process whereby cells are grown in a condition outside of their natural environment. 
All cells were cultured and incubated in a standard CO2 incubator (Forma Series II, Thermo Electron 
Corporation, Waltham, MA, USA) at 370 C, 40 – 60% humidified and 5% CO2  atmosphere. The cells 
were cultured in a sterile environment and passaged (division and growth of cells) from one 
generation to the next. 
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3.2.1 The trypsinzing and passaging procedure of AECs 
Cells received in a single 75mm2 flask (VEC Technologies), were passaged as shown in figure 3.1 
and stored in liquid nitrogen for later use. Pellets from these passages were stored in 1ml of “freezing 
medium” containing 900µl FBS, 50µl AEC medium and 50µl DMSO. For experimental purposes, 
cells were removed from storage in liquid nitrogen, cultured in 35mm petri dishes and 2ml specialized 
aortic endothelial growth medium (supplemented with 10% FBS, vascular endothelial growth factor 
- VEGF, human epidermal growth factor – hEGF, human fibroblastic growth factor hFGF, long chain 
human insulin-like growth factor - R3-IGF-1, ascorbic acid, hydrocortisone and gentamicin and 
amphotericin anitbiotics) and passaged according to their “P-status” (P – parent generation) as shown 
in figure 3.1.   
All experiments were performed once the AECs reached confluency, which secured cell cycle arrest 
which basically entails that any further cell proliferation is terminated at the G0 phase due to cell to 
cell contact. This essentially minimizes possible cell cycle variability when evaluating experimental 
results. At this stage the cells were still morphologically and functionally viable as well as they 
yielded the required number of plates for statistically acceptable sample sizes. Petri dishes were 
randomly assigned to respective control and experimental groups.  
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Figure 3.1: Cell culture passaging procedure (Genis; PhD dissertation 2014). 
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3.2.2 HL2/3 cell cultures HIV- Conditioned in vitro model 
In order to simulate a HIV-infection micro-environment, AECs were incubated in conditioned growth 
medium that had previously been exposed to HL2/ 3 cells. HL2/3 cells are known to secrete HIV 
proteins into the growth medium and were kindly donated by Dr Carine Smith from the Department 
of Physiological Sciences, University of Stellenbosch. The HIV-protein conditioned medium protocol 
using HL2/3 cells has previously been demonstrated (Africa and Smith 2015). 
The HL2/3 cells were received at generation 9 (9th passage) and can be sustained up to generation 15. 
The cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) with 4.5g/L glucose and 
4.5g/L  L-Glutamine, and supplemented with 10% FBS and 1% penicillin streptomycin (“pen strep”). 
HL2/3 cells were cultured in 100x 20mm petri dishes and passaged up to generation 11, after which 
they were stored in liquid nitrogen for future use. Refer to figure 3.2 A for a complete schematic of 
the HL2/3 cells passaging procedure.  
 
3.3 HIV conditioned medium protocol 
Approximately two weeks before the intended use of the HIV conditioned medium, the stored HL2/3 
cells (generation 11) were taken from storage and cultured.  The cells were passaged until generation 
14, and upon 75% confluency, the medium was replaced with AEC growth medium. The HL2/3 cells 
were allowed to grow in this medium for 24 hours, after which the HIV protein-containing 
conditioned AEC growth medium was removed from the cells and stored at -80 ⁰C (refer to figure 
3.2 B).  
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Figure 3.2: Schematic representation of the conditioned medium protocol. 
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3.4 Protein precipitation and extraction for Proteomics analysis 
To identify and confirm that the conditioned growth medium contained HIV proteins, samples of the 
medium were sent for proteomics analysis at the Centre for Proteomic and Genomic Research 
(CPGR), Cape Town. For the purpose of proteomics analysis, the HL2/3 cells were incubated for 24 
hours in medium containing no FBS, as it might “mask” the presence of other proteins, such as the 
HIV proteins of interest (Nonnis, Maffioli et al. 2016). 
 
3.4.1 Precipitation process 
A fixed volume was taken from the conditioned medium. Cold (-20°C) acetone (four times the 
volume of the medium) was added.  The samples were vortexed thoroughly and left to incubate for 
60 minutes at -20°C.  Following this, the samples were centrifuged at 15000 rpm for 10 minutes.  The 
supernatant was carefully removed (not to dislodge the precipitated protein pellet). 
 
3.4.2 Protein extraction: from pellet with Lysis Buffer 
To extract protein, 800 µl lysis buffer consisting of: 20mM Tris-HCl; 1mM EGTA; 1mM EDTA; 
150mM NaCl; 1mM β-glycerophosphate; 1mM sodium orthovanadate; 2.5mM tetra-sodium 
diphosphate; 50µg/ml PMSF; 10μg/ml aprotinin; 10μg/ml leupeptinin and 1 % triton-X100 were 
added to each pellet.  Samples were homogenized by use of a Heidolph Silent Crusher Homogenizer 
and left at 4 ⁰C for 20 minutes.  After homogenization, the tubes were centrifuged at 15 000 rpm for 
20 minutes, the supernatant was collected and the protein content was determined by the Bradford 
protein assay (Bradford, 1976). 
The standard curve was set up by calculating the mean of the duplicate standard values (mean OD 
values) using Excel. The protein (μg) values were plotted on the X-axis against the mean OD values 
on the Y-axis. Using the standard curve, the amount of protein, lysis buffer and Laemmli sample 
buffer (Laemmli, 1970), that must be added to each sample, to ensure that an equal amount of protein 
per volume unit used was calculated. 
850 μl Laemmli sample buffer (4% SDS, 20% glycerol, 10% 2-mercaptothanol (2-ME), 0.0004% 
bromophenol blue and 0.125 M Tris-HCl) was diluted with 150μl 2-ME before it was added to the 
lysates. After the lysates were prepared using the calculated values, the samples were boiled for 5 
minutes and the aliquots were stored at -80°C. 
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The lysates were then loaded onto a gel and sent to the centre of proteomics and genomics research 
(CPGR) for the identification of the HIV related proteins. The methods used by CPGR included ‘in 
gel digestion’ and liquid chromatography–mass spectrometry (LCMS) refer to appendix C, 
analytical report by CPGR proteomics manager, Dr Zac Macdonald). 
 
3.5 Flow cytometric analysis (for assessment of NO, ROS and cell 
viability) 
Flow cytometry was originally developed in the late 1960s. Today it is a popular technique that 
utilises light to count and profile cells in a heterogeneous fluid mixture. It is a technology that is used 
to analyse the physical and chemical characteristics of particles in a fluid as it passes through a 
minimum of one laser. Cell components are fluorescently labelled and then excited by the laser to 
emit light at varying wavelengths. The fluorescence can be measured to determine various properties 
of single cells. Up to thousands of particles per second can be analysed as they pass through the liquid 
stream. A flow cytometer has five components: 
1. A flow cell - liquid stream (sheath fluid), which is responsible for the carrying and the 
alignment of cells ensuring that single file passes through the light beam for sensing.  
2. A measuring system - typically used to measure conductivity (measurement of impedance) 
and optical systems - lamps (mercury, xenon); high-power water-cooled lasers 
(argon, krypton, dye laser); low-power air-cooled lasers (argon (488 nm), red-HeNe 
(633 nm), green-HeNe, HeCd (UV)); diode lasers (blue, green, red, violet) resulting in light 
signals 
3. A detector and Analog-to-Digital Conversion (ADC) system - which converts analog 
measurements of forward-scattered light (FSC) and side-scattered light (SSC) as well as dye-
specific fluorescence signals into digital signals that can be processed by a binary computer 
4. An amplification system - linear or logarithmic 
5. A computer for analysis of the signals. 
The process of collecting data from samples using the flow cytometer is termed 'acquisition'. 
Acquisition is mediated by a computer physically connected to the flow cytometer, and the software 
which handles the digital interface with the cytometer. 
Flow cytometric analyses formed a cornerstone of the cell culture experiments and were conducted 
on a Becton-Dickinson FACSCalibur flow cytometer (Franklin Lakes, NJ) (figure 3.3). located in 
the Stellenbosch University-BD Flow Cytometry Unit, Department of Biomedical Sciences, Faculty 
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of Medicine and Health Sciences. Data were analysed by means of the FlowJo version 10.1 software 
package. For each experimental sample, a total of 5000 - 10 000 “events” (cells) were acquired and 
visualised on a scatterplot (figure 3.4 A). The cell population of a given sample was subsequently 
gated (figure 3.4 B) in order to exclude any debris and non-cellular particles. From the gated 
populations, the mean fluorescent intensity emitted by the fluorescent probe was determined and 
depicted on histogram graphs (figure 3.4 C). All fluorescence data are expressed relative to control 
which was adjusted to 100%. 
The flow cytometer has different channels under which the various probe experiments can be 
conducted. 
 FL-1H: Excitation: 488 nm / emission: 530 nm (argon laser); 
 FL-2H: Excitation: 488 nm / emission: 585 nm (argon laser); 
 FL-3H: Excitation: 488 nm / emission: 670 nm (argon laser); 
 FL-4H: Excitation: 635 nm / emission: 661 nm (red diode laser). 
Each flow cytometry experiment included probe containing control samples and an absolute control 
(AC) sample without the probe which represented the auto-fluorescence of cells. The experiments 
also contained a few positive control samples which validated the specificity of the probe and the 
entire experiment in general. The positive control should demonstrate a significantly higher 
fluorescence compared to control samples for the experiment and probe to be considered valid. 
 
 
Figure 3.3: FACS Calibur flow cytometer. 
Stellenbosch University  https://scholar.sun.ac.za
63 
 
A 
 
B 
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Figure 3.4: A representative scatterplot of an AEC sample indicating the forward scatter (FSCH; X 
axis), which measures cell size, and side scatter (SSC-H; Y axis) which measures cell granularity. B. 
The population of interest is gated and only events acquired within the gate will be taken into account 
in the histogram. C. A representative histogram plot showing the flow channel 1 (FL1-H; X axis) 
which measures fluorescence intensity and number of events/ counts (Events; Y axis). 
 
3.5.1  NO measurements 
3.5.1.1  Diaminofluorescein diacetate (DAF-2 DA) 
DAF has been widely used for the measurement of nitric oxide (NO) in living cells and tissues (Zhou, 
He 2011). DAF-2 DA is a non-fluorescent cell permeable reagent that upon entry in the cell is 
hydrolysed by cystolic esterases, releasing DAF-2 and sequestering the reagent intracellularly. Upon 
reacting with NO, DAF- 2/DA is oxidized and emits a green fluorescent colour which can be analysed 
in flow channel 1 (FL1-H) of the flow cytometer. This 2-hour protocol of NO measurement has been 
previously established in our laboratory (Strijdom et al., 2004; Strijdom et al., 2006).  Please refer to 
figure 3.5 for a schematic representation of the protocol used for DAF-2/DA treatment.   
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Figure 3.5: Schematic representation of the DAF-2/DA and positive control (DEA/NO) protocol. 
 
3.5.1.1.1 Positive control: Diethylamine NONOate (DEA/NO) 
It has been previously shown that DEA/NO, an NO donor is a consistent and reliable positive control 
for intracellular NO measured by DAF-2/DA (refer to figure 3.6 for schematic DEA/NO protocol).  
It is able to significantly increase DAF-2/ DA fluorescence (refer to figure 3.7).  
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Figure 3.6: DEA/ NO significantly increased mean DAF-2/ DA fluorescence intensity and was 
included as a positive control in all DAF experiments, n = 11 / group. 
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3.5.2  ROS measurements 
3.5.2.1.       2′,7′-Dichlorofluorescin diacetate (DCF) 
DCF is a cell-permeable non-fluorescent probe, widely used to evaluate cellular ROS levels. DCF is 
chemically reduced and once it passes through the plasma membrane, it is de-esterified intracellularly 
to a hydrophilic alcohol and may turn into highly fluorescent 2′,7′-dichlorofluorescein due to 
oxidation that can be considered to involve ROS (Karlsson, Kurz et al. 2010). The oxidation can be 
as a result of acetate groups removing intracellular esterases within the cell, i.e. oxidation is by ROS. 
This results in a yellow fluorescent colour being emitted which can be analysed in flow channel 3 
(FL3-H) of the flow cytometer.  Therefore, cells that show high fluorescence are deemed to have 
higher ROS intracellularly.  Please refer to figure 3.8 for a schematic representation of the DCF 
protocol used. 
 
 
Figure 3.7: Schematic presentation of the DCF and positive control H2O2 protocol. 
 
3.5.2.1.1  Positive control: Hydrogen peroxide (H2O2) 
H2O2 was used as a positive control for DCF (refer to figure 3.8 for a schematic H2O2 protocol). 
H2O2 induces oxidation and causes a redox reaction. Reaction with reactive oxygen species (ROS) 
results in the conversion of the non-fluorescent molecule DCF into fluorescent DCF which 
significantly increases DCF fluorescence intensity, making it an ideal control to validate effects of 
the DCF probe (refer to figure 3.9).  
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Figure 3.8: H2 O2 significantly increased mean DCF fluorescence intensity and was included as a 
positive control in all DCF experiments, n = 8 / group. 
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3.5.3  Cell viability measurements 
3.5.3.1 Propidium Iodide  
Propidium iodide is an intercalating agent and a fluorescent molecule that can be used to stain cells. 
This fluorescent stain is specific for nucleic acids. When cell membrane integrity is lost due to 
necrosis, it permits propidium iodide to enter the cell due to large holes forming in the membrane. 
These large enough holes permit the entry of large propidium iodide molecules which subsequently 
stain the nucleus (Riccardi, Nicoletti 2006, Genis 2014, Westcott 2015). A red fluorescent colour is 
emitted and analysed in flow channel 2 (FL2-H) of the flow cytometer (FACS caliber).  Thus cells 
that display a high propidium iodide uptake and show an increased propidium iodide fluorescence are 
considered necrotic (refer to figure 3.10) (Wilkins, Kutzner et al. 2002).  Please refer to figure 3.11 
for a schematic representation of the propidium iodide protocol used. 
 
 
 
 
 
Figure 3.9: A representative scatterplot in which the sub-populations of viable and necrotic cells have 
been gated. Propidium iodide fluorescence is measured on the x-axis (FL2-H). 
17 % necrotic cells 
83 % viable cells 
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Figure 3.10: Schematic overview of the propidium iodide experimental protocol. 
3.5.3.1.1.  Positive control: distilled H2O 
Distilled H2O was used as positive control for the propidium iodide experiments as it increases 
propidium iodide staining in cells (Refer to figure 3.12). H2O diffuses across a semi-permeable 
membrane from an area with low osmolarity to an area of high osmolarity due to osmosis. Therefore, 
the net result of treating the ECs with distilled H2O is the movement of H2O molecules over the cell 
membrane and into the cell. Cells swell and eventually burst (Westcott 2015). Rupturing of the cell 
membrane due to necrosis allows the propidium iodide fluorescent probe to enter and stain the nucleus 
by intercalating with the DNA.  
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Figure 3.11: Distilled 𝐻2O significantly increased propidium iodide fluorescence and was included 
in all propidium experiments, n = 7 / group. 
 
3.6  First line and second line ART drug treatment protocol for 
AECs 
As mentioned in the first chapter, the second aim of the in vitro study was to investigate the effects 
of first line and second line ART drugs in AECs in culture on cell viability, NO production and 
oxidative stress status. The South African first line ART regime comprises of a combination of 
efavirenz (EFV), emtricitabine (FTC), and tenofovir (TDF), and the second line ART regime 
comprises of a combination of lopinavir (LPV) and ritonavir (RTV). Therefore, the AECs were 
treated with a combination of the first line ART drugs and the second line ART drugs for 24hours. 
The concentrations of first line drugs were based on previous studies by Feng et al (2009) and Grigsby 
et al (2010), whereas the second line drug’s concentration were based on a previous study by Noor et 
al. Drugs were purchased commercially from SantaCruz Biotechnology (WhiteHead Scientific). They 
were received in 10mg powder form. For experimental purposes, each of these drugs was prepared in 
its respective solvents (vehicles) (refer to table 3.1 for first and second line ART drug concentration 
and vehicles). 
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Table 3.1: First and second line ART drug concentration and vehicles. 
Drugs Concentration Solvents/ vehicles 
Efavirenz 5.6nM The 10mg powder was dissolved in 1ml Methanol, after 
which from this stock, it was further dissolved in phosphate 
buffer saline (PBS) buffer to achieve the required 
concentration 
Emtricitabine 1.3uM The 10mg powder was dissolved in 1ml 𝐇𝟐𝐎, after which 
from this stock, it was further dissolved in phosphate buffer 
saline (PBS) buffer to achieve the required concentration. 
Tenofovir 500nM The 10mg powder was dissolved in 1ml dimethyl sulfoxide 
(DMSO), after which from this stock, it was further 
dissolved in phosphate buffer saline (PBS) buffer to 
achieve the required concentration. 
Lopinavir 10uM The 10mg powder was dissolved in 1ml dimethyl sulfoxide 
(DMSO), after which from this stock, it was further 
dissolved in phosphate buffer saline (PBS) buffer to 
achieve the required concentration. 
Ritonavir 2uM The 10mg powder was dissolved in 1ml dimethyl sulfoxide 
(DMSO), after which from this stock, it was further 
dissolved in phosphate buffer saline (PBS) buffer to 
achieve the required concentration. 
 
 
Since the drugs were dissolved in their respective vehicles, to eliminate the effects of the vehicles in 
the experiments, the first line and second line ART drugs were compared to a control group consisting 
of a combination the vehicles of the drugs. Therefore, the first line combination of ART drugs 
(efavirenz with emtricitabine and tenofovir) was compared with a control group consisting of 
combination of vehicles (methanol, H2O and DMSO in PBS). In the same way, the second line 
combination of ART drugs (lopinavir and ritonavir) was compared with a combination of vehicles 
(DMSO in PBS). Refer to Appendix D, for detailed ART drug and vehicle protocols and 
calculations. 
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Chapter 4 : Results (clinical study) 
This chapter describes the results obtained from the clinical (main) study.  
4.1 Descriptive and demographic profile of the total study population. 
The total population consisted of 152 participants. 83 % (n= 124) of the total population was of the 
mixed race origin (refer to figure 4.1 A). In addition, 67% (n=102) of the total population was female 
(refer to figure 4.1 B). Furthermore, the total population consisted of 24% (n= 36) HIV negative, 22 
% (n= 33) HIV positive- ART naïve, 32% (n= 50) HIV positive-  first line ART, and 22% (n= 33) 
HIV positive- second line ART (refer to figure 4.1 C).  
 
 
Figure 4.1: Distribution of the study participants, A, ethnicity distribution; B, gender distribution; 
C, HIV status distribution. 
Female
67%
Male
33%
B: Gender
HIV -
24%
HIV +, ART 
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22%
C: Groups
Mixed race
83%
African 
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A: Ethnicity
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4.2 Descriptive profile of the HIV positive and negative groups 
4.2.1 Demographic, life style and anthropometric characteristics  
The median BMI of participants in the HIV negative group was significantly higher than that of the 
HIV positive, ART naïve group (p = 0.01) and the first line ART group (p = 0.01) (Refer to Table 
4.1). Furthermore, the median waist circumference was significantly higher in the HIV negative group 
when compared to the HIV positive- ART naïve, HIV positive- first line ART as well as HIV positive-  
second line ART (p <0.01, p < 0.01, p= 0.040 respectively). There were no significant differences in 
terms of age, gender, ethnicity and the use of cardiovascular medication amongst the four study 
population groups. 
 
Table 4.1: Demographic, lifestyle and anthropometric characteristics of the HIV negative, HIV 
positive ART naive, HIV positive first line ART, and HIV positive second line ART participants. 
 HIV-Negative 
(n=36) 
HIV-Positive 
ART Naïve 
(n=33) 
HIV-Positive on 
first line ART 
(n=50) 
HIV- positive 
on second line 
ART (33) 
Age (years) 40.722 ± 8.74 36.212 ± 10.08 37.740 ± 8.22 41.394 ± 9.38 
Gender: F, n 
(%) 
29 (80.6%) 20 (60.6%) 28 (56.6%) 25 (75.8%) 
Ethnicity, 
Mixed Race, 
 n (%) 
30 (83.3%) 29 (87.9%) 43 (86.0%) 22 (66.7%) 
Smoking, n 
(%) 
5 (13.9%) 13 (40.6%) 18 (36.7%) 8 (24.2%) 
CVS 
Medication, n 
(%) 
5 (13.9%) 5 (15.2%) 10 (20 %) 4 (12.1%) 
BMI (kg/m2) 29.2 (23.8- 35.2)a; b 20.7 (19.0- 24.1)a 21.6 (19.8- 25.4)b 24.7 (19.3- 29.9) 
WC (cm) 101 (92.0- 112)a, c, d 84 (77- 90)a 87 (82-92) b, c 92 (83- 99)b, d  
n indicates number of participants; ART, antiretroviral therapy; BMI, body mass index; WC, waist 
circumference; CVS, cardiovascular. Normally distributed data are expressed as mean ± standard error of 
mean, and non-parametric data is expressed as median with 25th and 75th percentiles. N, % of n and p values 
were obtained with ANOVA for parametric data or Kruskal Wallis for non-parametric data.. Means with same 
superscript letter: differ significantly (p <0.05). 
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4.2.2 Cardiovascular and biochemical characteristics 
Cardiovascular characteristics such as the SBP and DBP were found to not be significantly different 
amongst the four groups (refer to table 4.2). Analysis of specific biochemical blood parameters 
revealed a significantly higher median total cholesterol level in the HIV negative group in comparison 
to the HIV positive- first line and second line ART groups (p = 0.046, p = 0.023 respectively). 
Interestingly, HIV positive first line group displayed a modest, but significantly higher median total 
cholesterol level than the HIV positive ART naïve group (p = 0.041). In addition, a significantly 
higher mean LDL-cholesterol level was observed in the HIV negative group in comparison to all 
three HIV positive groups, ART naïve, first line ART as well as second line ART (p = 0.010; p = 
0.001, p < 0.01 respectively). The median HBA1C percentage was observed to be significantly lower 
in the HIV positive- second line group compared to the HIV positive ART-naïve group (p = 0.031). 
All the other biochemical parameters measured were found to not be significantly different amongst 
the groups.  
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Table 4.2: Cardiovascular and biochemical characteristics of the HIV negative, HIV positive ART 
naive, HIV positive first line ART, and HIV positive second line ART participants. 
 HIV-Negative 
(n=36) 
HIV-Positive 
ART Naïve 
(n=33) 
HIV-Positive on 
first line ART 
(n=50) 
HIV- positive 
on second line 
ART (33) 
SBP (mm Hg) 128.86 ± 18.38 123.12 ± 18.12 128.64 ± 28.67 122.76 ± 15.38 
DBP (mm Hg) 88 (78.5- 94.5) 83 (75.0- 93.0) 87 (77.0-97.0) 84 (78.0- 88.0) 
Total Cholesterol 
(mmol/L) 
5.2 (4.1- 5.5)a, c 4.2 (3.6- 4.8)b 4.3 (3.8- 4.7)b, c 4.2 (3.4- 4.8)a 
HDL-C (mmol/L) 1.3 (1.0- 1.4) 1.2 (1.0-1.5) 1.4 (1.4- 1.0) 1.3 (1.2- 1.5) 
LDL-C (mmol/L) 3.09 ± 0.84a, b, c 2.50 ± 0.75a 2.45 ± 0.65b 2.23 ± 0.72c 
Triglycerides 
(mmol/L) 
1.1 (0.8- 1.5) 0.9 (0.8- 1.1) 0.9 (0.6- 1.4) 1.2 (0.9- 1.6) 
Fasting Glucose 
(mmol/L) 
5.0 (4.7- 5.5) 4.7 (4.5- 4.9) 4.8 (4.5- 5.2) 4.7 (4.3- 5.2) 
HbA1C (%) 5.6 (5.5- 5.8) 5.6 (4.3- 5.9)a 5.4 (5.2-5.8) 5.3 (5.2- 5.5)a 
CRP (mg/L) 6.0 (3.0-10.0)  3.0 (1.0- 10.0) 5.0 (2.0- 10.6) 3.2 (2.0- 8.0) 
CD4 count (cells / 
uL) 
NA 551.0 (424- 764) 358.0 (236.5- 
589.5) 
348.0 (177.0- 
551.0) 
n indicates number of participants; ART, antiretroviral therapy; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density 
lipoprotein cholesterol; TG, triglycerides; HbA1c, glycated haemoglobin; CRP, C-reactive protein. Normally 
distributed data are expressed as mean with ± standard error of mean, non-parametric data is expressed as 
median with 25th and 75th percentiles. N, % of n and p values were obtained with ANOVA for parametric data 
or Kruskal Wallis for non-parametric data. Means with same superscript letter: differ significantly (p < 
0.05). 
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4.2.3 Vascular function 
No significant differences were observed in terms of baseline brachial artery diameter, maximum 
brachial artery diameter and FMD% amongst the four groups (refer to table 4.3). 
Table 4.3: FMD and related characteristics of the HIV negative, HIV positive ART naive, HIV 
positive first line ART, and HIV positive second line ART participants. 
 HIV-Negative 
(n=36) 
HIV-Positive 
ART Naïve 
(n=33) 
HIV-Positive on 
first line ART 
(n=50) 
HIV- 
positive on 
second line 
ART (33) 
Baseline Brachial 
artery diameter 
(mm) 
3.65 ± 0.68 3.54 ± 0.65  3.54 ± 0.65 3.41 ± 0.73 
Maximum Brachial 
artery diameter 
(mm) 
3.80 ± 0.81 3.77 ± 0.62 3.83 ± 0.75 3.66 ± 0.75 
FMD (%) 5.86 ± 4.91 6.71 ± 4.43 7.65 ± 5.38 7.74 ± 4.39 
n indicates number of participants; ART, antiretroviral therapy; FMD, Flow mediated dilatation. Normally 
distributed data are expressed as mean with ± standard error of mean.  
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4.3 Associations of vascular variables with various demographic and 
cardiovascular risk variables in the total population, HIV negative 
population, and HIV positive population 
Multiple regression analysis with baseline artery diameter, maximum artery diameter and FMD% as 
dependent variables (refer to table 4.4) showed that the female gender was inversely associated with 
baseline and maximum artery diameter in the total population (p < 0.01), HIV negative population (p 
= 0.005) as well as the total HIV positive population (p < 0.01). Whereas, interestingly, smoking 
history was borderline positively associated with baseline artery diameter in the total population (p = 
0.053). CRP was inversely associated with the baseline artery diameter in the total population (p = 
0.042). Fasting glucose levels were inversely associated with baseline artery diameter in the total as 
well the HIV positive population (p = 0.018, p = 0.038 respectively). In addition, fasting glucose 
levels were inversely associated with maximum artery diameter in the HIV positive population (p = 
0.038). Furthermore, the use of cardiovascular medication was inversely associated with baseline and 
maximum artery diameter in the HIV positive population (p = 0.035, p = 0.062 respectively).  
Notably, baseline artery diameter was inversely associated with FMD% in the total population as well 
as the HIV positive population (p = 0.007, p = 0.029 respectively). Interestingly, no associations were 
observed between HIV positive status and the dependent variables. Furthermore, no significant 
associations were found between any of the other independent variables and the three dependent 
variables (refer to table 4.4).
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Table 4.4: Independent associations of baseline artery diameter, maximum artery diameter, and FMD, with various cardiovascular risk factors in the 
total study population, HIV negative population and HIV positive population. 
Baseline Artery Diameter 
𝑅2; Adjusted 𝑅2 
Total Group 
0.4074; 0.353 
HIV negative Group 
0.6409; 0.4613 
HIV positive Group 
0.3996; 0.3281 
Regression coefficient 
(95% CI) 
p Regression coefficient 
(95% CI) 
p Regression coefficient 
(95% CI) 
p 
HIV-infection -0,153 (-0,42; 0,11) 0.255      - - - - 
Female Gender -0,940 (-1,18; -0,70) < 0.01   -1,156 (-1.92; -0.40) 0.005     -0,865 (-1,14; -0,59) < 0.01 
Age (years) 0,001 (-0,01; 0,01) 0.800     0,018 (-0,57; 0,83) 0.142     -0,001 (-0,01; 0,01) 0.932     
CVS Medication, yes  -0,202 (-0,53; 0,13) 0.230     0,337 (-0,01; 0,03) 0.342     -0,453 (-0,87; -0,03) 0.035     
Smoking history, yes 0,236 (0,00; 0,47) 0.053 0,128 (-0,01; 0,01) 0.708     0,215 (-0,05; 0,48) 0.113     
Waist circumference (cm) 0,008 (0,00; 0,02) 0.061     0,010 (-0,38; 0,30) 0.183     0,006 (-0,01; 0,02) 0.292     
Mean SBP (mmHg)  0,001 (-0,01; 0,01) 0.868     0,001 (-0,87; 0,93) 0.946     -0,004 (-0,01; 0,00) 0.380     
LDL cholesterol (mmol/L) 0,097 (-0,04; 0,24) 0.178     -0,041 (-0,04; 0,01) 0.803     0,133 (-0,04; 0,31) 0.131     
HDL cholesterol (mmol/L) 0,051 (-0,21; 0,31) 0.703     0,033 (-0,17; 0,03) 0.940     0,091 (-0,20; 0,38) 0.537     
CRP (mg/L)  -0,008 (-0,01; 0,00) 0.042      -0,012 (-0,38; 1,06) 0.318     -0,007 (-0,01; 0,00) 0.103     
Fasting Glucose (mmol/L) -0,094 (-0,17; -0,02) 0.018     -0,069 (-0,57; 0,83) 0.165 -0,140 (-0,27; -0,01) 0.038     
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Table 4.4: continued 
 
Maximum Artery Diameter 
𝑅2; Adjusted 𝑅2 
Total Group 
0.3457; 0.2826 
HIV negative Group 
0.4660; 0.1990 
HIV positive Group 
0.3790; 0.3050 
Regression coefficient 
(95% CI) 
p Regression coefficient 
(95% CI) 
p Regression coefficient 
(95% CI) 
p 
HIV-infection -0,045 (-0,35; 0,27) 0.775     - - - - 
Female Gender -0,944 (-1,22; -0,67) < 0.01     -1,709 (-2,85; -0,57) 0.005 -0,883 (-1,18; -0,58) < 0.01 
Age (years) 0,003 (-0,01; 0,02) 0.702     0,021 (-0,02; 0,06) 0.271     -0,001 (-0,02; 0,01) 0.879     
CVS Medication, yes  -0,276 (-0,66; 0,11) 0.161     0,142 (-0,95; 1,23) 0.789     -0,434 (-0,89; 0,02) 0.062     
Smoking history, yes 0,185 (-0,09; 0,46) 0.191     0,104 (-0,95; 1,16) 0.839     0,154 (-0,14; 0,44) 0.295     
Waist circumference (cm) 0,006 (0,00; 0,02) 0.223      0,009 (-0,01; 0,32) 0.455     0,006 (-0,01; 0,02) 0.293     
Mean SBP (mmHg)  -0,001 (-0,01; 0,01) 0.859     -0,011 (-0,03; 0,01) 0.251     -0,001 (-0,01; 0,01) 0.889     
LDL cholesterol (mmol/L) 0,119 (-0,05; 0,28) 0.160     0,172 (-0,34; 0,69) 0.495     0,134 (-0,05; 0,32) 0.162     
HDL cholesterol (mmol/L) 0,068 (-0,24; 0,38) 0.664      0,575 (-0,78; 1,93) 0.387     0,072 (-0,25; 0,39) 0.653      
CRP (mg/L)  -0,007 (-0,02; 0,00) 0.125     -0,003 (-0,04; 0,03) 0.854     -0,006 (-0,01; 0,00) 0.170     
Fasting Glucose (mmol/L) -0,069 (-0,16; 0,02) 0.132     -0,037 (-0,19; 0,11) 0.612     -0,152 (-0,30; -0,01) 0.038     
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
80 
 
Table 4.4: continued 
FMD % 
𝑅2; Adjusted 𝑅2 
Total Group 
0.1488; 0.0550 
HIV negative Group 
0.3268; -0.1089 
HIV positive Group 
0.1367; 0.0194 
Regression coefficient 
(95% CI) 
p Regression coefficient 
(95% CI) 
p Regression coefficient 
(95% CI) 
p 
HIV-infection 0,721 (-1,79; 3,23) 0.571     - -   
Female Gender -0,140 (-2,89; 2,61) 0.920     0,491 (-12,22; 13.20) 0.936      0,022 (-3,01; 3,06) 0.989     
Age (years) -0,038 (-0,14; 0,07) 0.484      -0,072 (-0,38; 0,23) 0.627 -0,060 (-0,19; 0,06) 0.340     
CVS Medication, yes  -0,444 (-3,50; 2,61) 0.774     -1,410 (-9,71; 6,89) 0.724     0,868 (-3,01; 4,75) 0.657     
Smoking history, yes -1,052 (-3,27; 1,17) 0.349     2,140 (-5,85; 10,13) 0.580     -1,659 (-4,10; 0,79) 0.181     
Waist circumference (cm) 0,016 (-0,06; 0,09) 0.679     -0,035 (-0,22; 0,15) 0.698     0,062 (-0,04; 0,16) 0.229     
Mean SBP (mmHg)  -0,010 (-0,07; 0,05) 0.739     -0,042 (-0,19; 0,10) 0.544     0,017 (-0,06; 0,09) 0.667     
LDL cholesterol (mmol/L) 0,239 (-1,08; 1,56) 0.720     -0,199 (-4,16; 3,76) 0.917     0,389 (-1,20; 1,98) 0.626     
HDL cholesterol (mmol/L) 0,194 (-2,22; 2,61) 0.873      2,337 (-8,26; 12,93) 0.648      0,294 (-2,36; 2,95) 0.826     
CRP (mg/L)  0,001 (-0,07; 0,07) 0.966     -0,034 (-0,32; 0,25) 0.804     0,016 (-0,06; 0,09) 0.671     
Fasting Glucose (mmol/L) -0,528 (-1,26; 0,20) 0.155     -0,644 (-1,89; 0,61) 0.292     -0,056 (-1,28; 1,17) 0.927     
Baseline artery diameter (mm) -2.439 (-4.19; -0.68) 0.007 -1,884 (-7,69; 3,93) 0.503 -2,266 (-4,29; -0,24) 0.029  
 
FMD%, flow mediated dilatation; CI, confidence interval; CVS, cardiovascular; SBP, brachial systolic blood pressure; HDL-C, high-density lipoprotein cholesterol; 
LDL-C, low-density lipoprotein cholesterol; CRP, C-reactive protein. Associations were determined by forward stepwise multiple regression analyses. P < 0.05 is 
regarded as statistically significant. Independent variables in the model: age; gender; HIV status (for total group); waist circumference; CVs medication; smoking 
history; SBP; LDL-cholesterol; HDL- cholesterol; CRP; fasting glucose and baseline artery diameter (for FMD% variable). 
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4.4 Associations of vascular variables with various demographic 
and cardiovascular risk variables in the HIV positive ART 
naïve, first line ART and second line ART populations 
respectively. 
Multiple regression analysis with baseline artery diameter, maximum artery diameter and FMD% as 
dependent variables (refer to table 4.5) showed that the female gender was inversely associated with 
baseline and maximum artery diameter in the HIV positive- ART naïve group (p = 0.002, p = 0.006 
respectively), first line ART group (p= 0.001, p = 0.005 respectively), and second line ART group (p 
= 0.027, p = 0.019 respectively). Fasting glucose levels were inversely associated with baseline artery 
diameter in the ART naïve group (p = 0.047). Interestingly, waist circumference (p = 0.044) was 
positively associated, and CRP (p = 0.065) borderline negatively associated with baseline artery 
diameter in the first line ART group. HDL-cholesterol was found to be positively associated with 
baseline and maximum artery diameter in the second line ART group (p = 0.044, p = 0.023 
respectively). 
Smoking history was observed to be borderline negatively associated with FMD% in the first line 
ART group (p = 0.052). Furthermore, CRP and baseline artery diameter were negatively associated 
with FMD% in the second line ART group (p = 0.031, p= 0.014 respectively). No associations were 
observed with FMD% in the ART naïve group. Furthermore, no significant associations were found 
between any of the other independent variables and the three dependent variables. 
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Table 4.5: Independent associations of baseline artery diameter, maximum artery diameter, and FMD% with various cardiovascular risk factors in the 
HIV positive ART naive population, HIV positive first line ART population and HIV positive second line ART population.  
Baseline Artery Diameter 
𝑅2; Adjusted 𝑅2 
ART naive 
0.5976; 0.3293 
First Line ART 
0.5437; 0.3915 
Second Line ART 
0.5134; 0.2271 
Regression coefficient 
(95% CI) 
p Regression coefficient 
(95% CI) 
p Regression coefficient 
(95% CI) 
p 
Female Gender -0,992 (-1,56; -0,42) 0.002     -0,823 (-1,26; -0,39) 0.001      -0,960 (-1,80; -0,12) 0.027     
Age (years) 0,008 (-0,02; 0,04) 0.605     0,004 (-0,02; 0,03) 0.691     -0,023 (-0,07; 0,02) 0.286     
CVS Medication, yes  -0,266 (-1,61; 1,08) 0.680     -0,517 (-1,23; 0,19) 0.148     -0,521 (-1,40; 0,36) 0.229     
Smoking history, yes 0,222 (-0,32; 0,76) 0.397     0,279 (-0,18; 0,74) 0.227     -0,061 (-0,70; 0,58) 0.843     
Waist circumference (cm) 0,007 (-0,02; 0,04) 0.578     0,021 (0,00; 0,04) 0.044      0,010 (-0,02; 0,04) 0.407     
Mean SBP (mmHg)  -0,006 (-0,03; 0,02) 0.621     -0,002 (-0,01; 0,01) 0.725     -0,008 (-0,03; 0,02) 0.498      
LDL cholesterol (mmol/L) 0,242 (-0,15; 0,63) 0.207     0,185 (-0,11; 0,48) 0.218     -0,046 (-0,46; 0,37) 0.817     
HDL cholesterol (mmol/L) -0,163 (-0,67; 0,35) 0.506     0,253 (-0,29; 0,84) 0.381     1,133 (0,04; 2,23) 0.044      
CRP (mg/L)  -0,010 (-0,05; 0,03) 0.584     -0,009 (-0,02; 0,00) 0.065     0,004 (-0,03; 0,03) 0.769     
Fasting Glucose (mmol/L) -0,213 (-0,42; 0,00) 0.047     -0,166 (-0,42; 0,09) 0.198     -0,107 (-0,58; 0,36) 0.639     
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Table 4.5: continued 
Maximum Artery Diameter 
𝑅2; Adjusted 𝑅2 
ART naive 
0.5128; 0.1880 
First Line ART 
0.5169; 0.3558 
Second Line ART 
0.5739; 0.3232 
Regression coefficient 
(95% CI) 
p Regression coefficient 
(95% CI) 
p Regression coefficient 
(95% CI) 
p 
Female Gender -0,900 (-1,51; -0,29) 0.006 -0,787 (-1,31; -0,26) 0.005 -0,989 (-1,79; -0,19) 0.019     
Age (years) 0,004 (-0,03; 0,04) 0.806     0,007 (-0,02; 0,03) 0.610     -0,021 (-0,06; 0,02) 0.322     
CVS Medication, yes  -0,127 (-1,55; 1,30) 0.853     -0,634 (-1,49; 0,22) 0.142     -0,502 (-1,35; 0,34) 0.227     
Smoking history, yes 0,268 (-0,31; 0,84) 0.337     0,045 (-0,51; 0,60) 0.872     -0,158 (-0,77; 0,46) 0.595     
Waist circumference (cm) 0,006 (-0,02; 0,04) 0.645     0,021 (0,00; 0,05) 0.087     0,011 (-0,01; 0,04) 0.361     
Mean SBP (mmHg)  -0,007 (-0,03; 0,02) 0.613     0,004 (-0,01; 0,02) 0.605     -0,010 (-0,03; 0,01) 0.371      
LDL cholesterol (mmol/L) 0,207 (-0,21; 0,62) 0.303     0,180 (-0,18; 0,54) 0.317     0,008 (-0,39; 0,41) 0.968     
HDL cholesterol (mmol/L) -0,134 (-0,68; 0,41) 0.605     0,225 (-0,48; 0,93) 0.517     1,242 (0,19; 2,29) 0.023      
CRP (mg/L)  -0,012 (-0,05; 0,03) 0.550     -0,006 (-0,02; 0,01) 0.276     -0,003 (-0,03; 0,03) 0.828     
Fasting Glucose (mmol/L) -0,203 (-0,43; 0,02) 0.071     -0,240 (-0,55; 0,07) 0.126     -0,117 (-0,57; 0,34) 0.593     
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Table 4.5: continued 
FMD % 
𝑅2; Adjusted 𝑅2 
ART naive 
0.5027; 0.1119 
First Line ART 
0.2505; -0.0549 
Second Line ART 
0.6275; 0.3714 
Regression coefficient 
(95% CI) 
p Regression coefficient 
(95% CI) 
p Regression coefficient 
(95% CI) 
p 
Female Gender 3,647 (-2,58; 9,87) 0.230     1,450 (-4,93; 7,83) 0.645     -2,764 (-8,17; 2,64) 0.294     
Age (years) -0,098 (-0,34; 0,15) 0.410     -0,123 (-0,39; 0,14) 0.348     -0,007 (-0,26; 0,25) 0.956     
CVS Medication, yes  5,038 (-5,62; 15,70) 0.328     -0,916 (-9,48; 7,65) 0.828     -0,897 (-6,02; 4,23) 0.715     
Smoking history, yes 0,967 (-3,42; 5,35) 0.643     -5,683 (-11,41; 0.04) 0.052     -3,331 (-6,89; 0,23) 0.065  
Waist circumference (cm) -0,029 (-0,25; 0,19) 0.784     0,156 (-0,11; 0,42) 0.240      0,040 (-0,11; 0,19) 0.571     
Mean SBP (mmHg)  0,007 (-0,20; 0,21) 0.940     0,074 (-0,07; 0,22) 0.303     -0,039 (-0,18; 0,10) 0.555     
LDL cholesterol (mmol/L) -0,815 (-4,06; 2,43) 0.599     0,366 (-3,29; 4,02) 0.839     1,917 (-0,39; 4,23) 0.098     
HDL cholesterol (mmol/L) 0,590 (-3,49; 4,67) 0.761     0,194 (-6,69; 7,08) 0.954     5,452 (-1,45; 12,35) 0.113     
CRP (mg/L)  -0,021 (-0,33; 0,29) 0.886     0,077 (-0,04; 0,19) 0.179     -0,190 (-0,36; -0,02) 0.031     
Fasting Glucose (mmol/L) 0,338 (-1,55; 2,23) 0.707     -1,357 (-4,57; 1,85) 0.393     -0,198 (-2,84; 2,44) 0.876     
Baseline artery diameter (mm) -0,886 (-5,22; 3,45) 0.668     -2,268 (-7,14; 2,60) 0.348     -3,717 (-6,56; -0,87) 0.014     
 
FMD%, flow mediated dilatation; CI, confidence interval; CVS, cardiovascular; SBP, brachial systolic blood pressure; HDL-C, high-density lipoprotein cholesterol; 
LDL-C, low-density lipoprotein cholesterol; CRP, C-reactive protein. Associations were determined by forward stepwise multiple regression analyses. P < 0.05 is 
regarded as statistically significant. Independent variables in the model: age; gender; waist circumference; CVs medication; smoking history; SBP; LDL-cholesterol; 
HDL- cholesterol; CRP; fasting glucose and baseline artery diameter (for FMD% dependent variable). 
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4.5  Associations of vascular variables with CD4 count in the total 
HIV positive population and ART groups 
CD4 count (p = 0.027) was negatively associated with FMD% in the second line ART group. There 
were no other associations observed with CD4 count in any of the other HIV positive groups (refer 
to table 4.6).  
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Table 4.6: Independent associations of baseline artery diameter, maximum artery diameter, and FMD% with CD4 count in the total HIV positive 
population, HIV positive ART naive population, HIV positive first line ART population and HIV positive second line ART population. 
 
 
 
 
 
Baseline Artery 
Diameter 
𝑅2; Adjusted 𝑅2 
Total HIV population 
0.3517; 0.2983 
ART naive 
0.3832; 0.2430 
First Line ART 
0.4709; 0.3882 
Second Line ART 
0.3115; 0.1475 
Regression 
coefficient  
(95% CI) 
p Regression 
coefficient  
(95% CI) 
p Regression 
coefficient  
(95% CI) 
p Regression 
coefficient  
(95% CI) 
p 
First line ART, yes -0,038 (-0,33; 0,25) 0.792     - - - - - - 
Second line ART, yes -0,035 (-0,37; 0,30) 0.833     - - - - - - 
CD4 0,001 (-0,01; 0,03) 0.719     0,000 (-0,001; 0,001) 0.754     0,000 (0,000; 0,001) 0.458     0,000 (-0,001; 0,001) 0.639     
Female Gender -0,758 (-1,02; -0,50) < 0.01     -0,871 (-1,41; -0,34) 0.003     -0,629 (-1,00; -0,25) 0.002     -0,992 (-1,75; -0,24) 0.012     
Age (years) 0,001 (-0,01; 0,01) 0.919     0,002 (-0,02; 0,03) 0.901     0,012 (-0,01; 0,03) 0.242     -0,016 (-0,05; 0,02) 0.397     
CVS Medication, yes  -0,395 (-0,73; -0,06) 0.020     -0,184 (-0,96; 0,59) 0.628     -0,571 (-1,00; -0,14) 0.011     -0,490 (-1,39; 0,41) 0.269     
Smoking history, yes 0,086 (-0,17; 0,34) 0.508     0,116 (-0,39; 0,62) 0.637     0,131 (-0,24; 0,51) 0.482     -0,140 (-0,80; 0,52) 0.663      
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Table 4.6: continued 
 
Maximum Artery 
Diameter 
𝑅2; Adjusted 𝑅2 
Total HIV population 
0.3505; 0.2970 
ART naive 
0.3125; 0.1562 
First Line ART 
0.4551; 0.3700 
Second Line ART 
0.3850; 0.2386 
Regression 
coefficient  
(95% CI) 
p Regression 
coefficient  
(95% CI) 
p Regression 
coefficient  
(95% CI) 
p Regression 
coefficient  
 (95% CI) 
p 
First line ART, yes 0,055 (-0,26; 0,37) 0.724 - - - - - - 
Second line ART, yes 0,006 (-0,35; 0,36) 0.975     - - - - - - 
CD4 0,000 (0,00; 0,001) 0.739     0,000 (-0,001; 0,001) 0.918      0,000 (0,000; 0,001) 0.464     0,000 (-0,001; 0,002) 0.399     
Female Gender -0,806 (-1,09; -0,52) <0.01   -0,762 (-1,31; -0,21) 0.009       -0,733 (-1,19; -0,28) 0.003     -1,109 (-1,85; -0,37) 0.005      
Age (years) 0,001 (-0,01; 0,02) 0.932     -0,003 (-0,03; 0,02) 0.828     0,015 (-0,01; 0,04) 0.227     -0,015 (-0,05; 0,02) 0.405     
CVS Medication, yes  -0,408 (-0,77; -0,05) 0.026      -0,063 (-0,86; 0,73) 0.872     -0,654 (-1,18; -0,13) 0.016     -0,469 (-1,35; 0,41) 0.280     
Smoking history, yes 0,038 (-0,24; 0,31) 0.788     0,145 (-0,37; 0,66) 0.566     0,053 (-0,40; 0,51) 0.813     -0,242 (-0,89; 0,40) 0.444     
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Table 4.6: continued 
 
FMD%, flow mediated dilatation; CI, confidence interval; CVS, cardiovascular; SBP, brachial systolic blood pressure; HDL-C, high-density lipoprotein cholesterol; 
LDL-C, low-density lipoprotein cholesterol; CRP, C-reactive protein. Associations were determined by forward stepwise multiple regression analyses. P< 0.05 is 
regarded as statistically significant. Independent variables in the model: age; gender; first line ART (for total HIV population); second line ART (for total HIV 
population); CD4; CVs medication; smoking history; and baseline artery diameter (for FMD% dependent variable).
FMD% 
𝑅2; Adjusted 𝑅2 
Total HIV population 
0.1767; 0.0964 
ART naive 
0.4095; 0.2408 
First Line ART 
0.2375; 0.0797 
Second Line ART 
0.4265; 0.2545 
Regression 
coefficient  
(95% CI) 
p Regression 
coefficient  
(95% CI) 
p Regression 
coefficient  
(95% CI) 
p Regression 
coefficient  
(95% CI) 
p 
First line ART, yes 1,924 (-0,43; 4,28) 0.107     - - - - - - 
Second line ART, yes 1,747 (-0,95; 4,44) 0.201     - - - - - - 
CD4 0,002 (0,00; 0,01) 0.131     0,002 (0,00; 0,01) 0.456     0,004 (0,00; 0,01) 0.189     0,007 (0,00; 0,01) 0.027  
Female Gender -0,910 (-3,46; 1,64) 0.480     3,193 (-1,25; 7,64) 0.150     -2,343 (-7,32; 2,64) 0.344     -4,609 (-9,18; -0,04) 0.048     
Age (years) -0,045 (-0,16; 0,07) 0.426     -0,099 (-0,27; 0,07) 0.237     -0,107 (-0,34; 0,13) 0.360     0,001 (-0,20; 0,20) 0.995     
CVS Medication, yes  1,444 (-1,39; 4,27) 0.313     3,799 (-1,47; 9,07) 0.149      0,843 (-4,47; 6,16) 0.748     -0,311 (-5,13; 4,50) 0.894     
Smoking history, yes -1,663 (-3,78; 0,45) 0.121     0,456 (-2,96; 3,87) 0.784     -2,770 (-6,97; 1,43) 0.188     -2,762 (-6,21; 0,68) 0.110     
Baseline brachial 
artery diameter 
(mm) 
-2,479 (-4,33; -
0,63) 
0.009 -1,501 (-4,48; 1,48) 0.307     -3,179 (-7,74; 1,38) 0.165     -3,083 (-5,45; -0,72) 0.013     
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Chapter 5 : Results (in vitro sub-study) 
This section describes and reports data collected from the in vitro sub-study. 
5.1 Proteomic analysis of the HIV-conditioned model 
Proteomic analysis by the CPGR showed detectable expression levels of HIV-1 glycoprotein Gp160 
in the FBS-free HIV-conditioned medium, and no traces of any HIV-1 related proteins were detected 
in the control medium (refer to appendix C for the analytical report from CPGR, proteomics 
manager, Dr Zac Macdonald) 
 
5.2 The effects of the HIV-conditioned growth medium in an in 
vitro model on AECs 
As the initial aim of the in vitro study was to develop an HIV-conditioned in vitro model of AECs in 
which the ART drugs could be tested, it was deemed vital to investigate whether and / or how the 
HIV-conditioned growth medium would affect the AECs as a first step, especially since this protocol 
was not previously established in our laboratory. AECs treated with HIV-conditioned medium (CM) 
for 24 hours were compared with AECs treated with normal (non-conditioned) AEC medium (NM) 
for 24 hours and NO production, cell viability and ROS production was measured. The n value 
represents the number of individual experiments that were conducted for the endpoints. Each 
experiment used between 2 and 6 samples for which the mean value was calculated.  
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5.2.1  The effect of CM on NO production in AECs 
AECs exposed to CM (24 hours), showed no change (104.32± 14.58 % vs. 100± 20.35 %NM) in 
mean DAF-2/DA fluorescence (measuring NO) (refer to figure 5.1), compared to untreated controls 
(AECs in NM).   
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Figure 5.1: Effects of CM vs. NM on NO production as measured by DAF-2/DA fluorescence. NO 
expressed as % DAF-2/DA stained cells (calculated as a percentage of NM; NM fluorescence 
adjusted to 100 %), n= 7 / group.
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5.2.2  The effect of CM on cell viability in AECs 
AECs exposed to CM (24 hours), showed no change (101.59± 27.34 % vs. 100 ± 41.19% NM) in 
mean PI fluorescence (measuring necrosis) (refer to figure 5.2), compared to untreated controls 
(AECs in NM).   
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Figure 5.2: Effects of CM vs. NM on necrosis as measured by PI fluorescence. Necrosis expressed 
as % PI stained cells (calculated as a percentage of NM; NM adjusted to 100 %), n = 3 / group. 
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5.2.3 The effect of CM on ROS production in AECs 
AECs exposed to CM (24 hours), showed no change (93.81 ± 2.55% vs. 100 ± 2.55% NM) in 
mean DCF fluorescence (measuring ROS) (refer to figure 5.3), compared to untreated controls 
(AECs in NM).   
 
 
Figure 5.3: Effects of CM vs. NM on ROS production as measured by DCF fluorescence. ROS 
expressed as % DCF stained cells (calculated as a percentage of NM; NM adjusted to 100 %), 
n= 4 / group. 
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5.3 Effects of first line and second line ART on AECs in vitro 
In view of the fact that the CM had no effect on any of the measured parameters (see previous 
sections) and in view of time constraints, it was decided to test for the effects of ART drugs on 
AECs incubated in normal (non-conditioned growth medium) for the purposes of this thesis. 
The ART containing groups were compared with the vehicle control groups which comprised 
of a combination of the drug’s vehicles. Dose-response studies were designed to determine 
which dose of the ART combination elicits an effect on the AECs. Normal drug concentration 
(based on the literature; see in vitro Methods Chapter 3, section 3.6) vs. normal vehicle control, 
half of the normal drug concentration (half drug) vs. half vehicle control, and double the normal 
drug concentration (double drug) vs. double vehicle control. All of the experimental conditions 
were included in each separate experiment. The n value represents the number of individual 
experiments that were conducted for the endpoints, with each experimental group containing 
4- 12 samples. 
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5.3.1 First line ART- dosage response 
5.3.1.1 The effect of a first line ART combination drug cocktail (dose-
response) on NO production in AECs 
AECs exposed to half drug concentration (24 hours), showed no change (104.72 ± 14.03 % vs. 
100± 12.60 % half vehicle control) in mean DAF-2/DA fluorescence (measuring NO) (refer 
to figure 5.4).  AECs exposed to normal drug concentration (24 hours), showed a significant 
decrease (88.36 ± 6.66 % vs. 100± 6.75 % normal vehicle control: p < 0.02) in mean DAF-
2/DA fluorescence (measuring NO) (refer to figure 5.4).  AECs exposed to double drug 
concentration (24 hours), showed no change (101.33 ± 11.87 % vs. 100± 7.29 % double vehicle 
control) in mean DAF-2/DA fluorescence (measuring NO) (refer to figure 5.4).  
 
Figure 5.4: Effects of half drug concentration vs. half control, normal drug concentration vs. 
normal control and double drug concentration vs. double control on NO as measured by 
DAF-2/DA fluorescence. NO expressed as % DAF-2/DA stained cells (calculated as a 
percentage of control; control adjusted to 100 %), n= 8 / group.  [ ]: Concentration. 
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5.3.1.2 The effect of a first line ART combination drug cocktail (dose-
response) on the cell viability of AECs 
AECs exposed to half drug concentration (24 hours), showed no change (97.67 ± 17.07 % vs. 
100 ± 14.98 % half vehicle control) in mean PI fluorescence (measuring necrosis) (refer to 
figure 5.5). AECs exposed to normal drug concentration (24 hours), showed no change (95.50 
± 47.20 % vs. 100 ± 46.81 % normal vehicle control) in mean PI fluorescence (measuring 
necrosis) (refer to figure 5.5).  AECs exposed to double drug concentration (24 hours), showed 
no change (106.42 ± 15.35 % vs. 100 ± 35.42 % double vehicle vs. control) in mean PI 
fluorescence (measuring necrosis) (refer to figure 5.5).  
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Figure 5.5: Effects of half drug concentration vs. half control, normal drug concentration vs. 
normal control and double drug concentration vs. double control on necrosis as measured by 
PI fluorescence. Necrosis expressed as % PI stained cells (calculated as a percentage of 
control; control adjusted to 100 %), n= 4 / group. [ ]: Concentration. 
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5.3.1.3 The effect of first line ART combination drug cocktail (dose-
response) on ROS production in AECs 
AECs exposed to half drug concentration (24 hours), showed a significant increase (127.12 ± 
2.59 % vs. 100 ± 1.96 % half vehicle control: p < 0.01) in mean DCF fluorescence (measuring 
ROS) (refer to figure 5.6). AECs exposed to normal drug concentration (24 hours), showed 
no change (95.02 ± 2.50 % vs. 100 ± 5.79 % normal vehicle control: p = 0.01) in mean DCF 
fluorescence (measuring ROS) (refer to figure 5.6). AECs exposed to double drug 
concentration (24 hours), showed a significant decrease (86.23 ± 1.47 % vs. 100 ± 3.43% 
double vehicle control: p < 0.05) in mean DCF fluorescence (measuring ROS) (refer to figure 
5.6).  
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Figure 5.6: Effects of half drug concentration vs. half control, normal drug concentration vs. 
normal control and double drug concentration vs. double control on ROS production as 
measured by DCF fluorescence. ROS expressed as % DCF stained cells (calculated as a 
percentage of control; control adjusted to 100 %), n= 5 / group.  [ ]: Concentration.   
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5.3.2 Second line ART dose-response 
5.3.2.1 The effect of a second line ART combination drug cocktail (dose-
response) on NO production in AECs 
AECs exposed to half drug concentration (24 hours), showed no change (107.62± 7.77% vs. 
100 ± 7.25 % half vehicle control) in mean DAF-2/DA fluorescence (measuring NO) (refer to 
figure 5.7).  AECs exposed to normal drug concentration (24 hours), showed no change (98.55 
± 11.60 % vs. 100 ± 8.22 % normal vehicle control) in mean DAF-2/DA fluorescence 
(measuring NO) (refer to figure 5.7). AECs exposed to double drug concentration (24 hours), 
showed no change (96.32 ± 13.68 % vs. 100 ± 15.60 % double vehicle control) in mean DAF-
2/DA fluorescence (measuring NO) (refer to figure 5.7). 
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Figure 5.7: Effects of half drug concentration vs. half control, normal drug concentration vs. 
normal control and double drug concentration vs. double control on NO as measured by 
DAF-2/DA fluorescence. NO expressed as % DAF-2/DA stained cells (calculated as a 
percentage of control; control adjusted to 100 %), n= 5 / group. [ ]: Concentration. 
Stellenbosch University  https://scholar.sun.ac.za
98 
 
5.3.2.2 The effect of second line ART combination drug cocktail (dose-
response) on the cell viability of AECs 
AECs exposed to half drug concentration (24 hours), showed no change (133.34 ± 22.77 % vs. 
100 ± 39.96 % half vehicle control) in mean PI fluorescence (measuring necrosis) (refer to 
figure 5.8). AECs exposed to normal drug concentration (24 hours), showed no change (113.08 
± 22.14 % vs. 100 ± 48.85 % normal vehicle control) in mean PI fluorescence (measuring 
necrosis) (refer to figure 5.8).  AECs exposed to double drug concentration (24 hours), showed 
no change (97.58 ± 17.90 % vs. 100 ± 25.77 % double vehicle control) in mean PI fluorescence 
(measuring necrosis) (refer to figure 5.8).  
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Figure 5.8: Effects of half drug concentration vs. half control, normal drug concentration vs. 
normal control and double drug concentration vs. double control on necrosis as measured by 
PI fluorescence. Necrosis expressed as % PI stained cells (calculated as a percentage of 
control; control adjusted to 100 %), n= 5 / group. [ ]: Concentration. 
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5.3.2.3 The effect of second line ART combination drug cocktail (dose-
response) on ROS production in AECs 
AECs exposed to half drug concentration (24 hours), showed a significant increase (115.07 ± 
13.86 % vs. 100 ± 16 % half vehicle control) in mean DCF fluorescence (measuring ROS) 
(refer to figure 5.9).  AECs exposed to normal drug concentration (24 hours), showed no 
change (96.82± 2.56 % vs. 100 ± 8.08 % normal vehicle control: p = 0.0046) in mean DCF 
fluorescence (measuring ROS) (refer to figure 5.9).  AECs exposed to double drug 
concentration (24 hours), showed a significant increase (116.51 ± 7.71 % vs. 100 ± 4.92 % 
double vehicle control: p= 0.008) in mean DCF fluorescence (measuring ROS) (refer to figure 
5.9).  
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Figure 5.9: Effects of half drug concentration vs. half control, normal drug concentration vs. 
normal control and double drug concentration vs. double control on ROS production as 
measured by DCF fluorescence. ROS expressed as % DCF stained cells (calculated as a 
percentage of control; control adjusted to 100 %), n= 4 / group. [ ]: Concentration. 
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Chapter 6 : Discussion & Conclusion (clinical study) 
This chapter argues the findings from the main cross-sectional study and summarises key 
findings followed by a conclusion. 
 
6.1 Demographic, life style and anthropometric findings of the 
study population 
In the present study, mean age and the number of females present in each group was not 
significantly different, ensuring that the four groups were similar in terms of age- and gender. 
The median BMI and waist circumference levels in all the HIV positive groups were 
significantly lower than in the HIV negative group. Although recent reports have emerged 
demonstrating an increased incidence of cardiovascular risk factors (such as increased waist 
circumference and BMI) in HIV-infected individuals, HIV infection does profoundly impact 
the nutritional status of these individuals. HIV-infected individuals are riddled with poor 
appetite, impaired nutrient absorption, increased basal metabolic rate and opportunistic 
infections (Lemmer, Badri et al. 2011). Under-nutrition in HIV-infected individuals is 
manifested by weight loss, loss of lean body mass and micronutrient deficiencies (Macallan, 
Miller et al. 1999). Interestingly, one study has found a lower BMI in HIV positive individuals 
to be associated with cardiomyopathy (Lemmer, Badri et al. 2011).   
In light of arguing the current finding, the literature is somewhat inconclusive. A recently 
published study found that, particularly ART exposed HIV-infected individuals in a sub-
Saharan African setting showed significantly higher BMI and waist circumference values in 
comparison to the HIV ART naïve individuals (Nduka, Uthman et al. 2016). In contrast, in the 
current study, no significant difference is found between the different HIV positive groups. 
Furthermore, increased abdominal fat deposition is known to occur in more than half of HIV-
infected individuals, with ART naïve individuals demonstrating clear increases in their visceral 
adipose tissue and trunk fat once commencing with ART (Stanley & Grinspoon 2012, Shlay, 
Bartsch et al. 2007). Furthermore, a study by Shlay et al. specifically demonstrated an increased 
BMI in HIV individuals’ after commencement on PI, NNRTIs as well as PIs in combination 
with NNRTIs (Shlay, Bartsch et al. 2007). Moreover, many studies have also found no 
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significant difference in BMI and waist circumference between HIIV-infected and non HIV-
infected individuals.  
Ultimately our finding does correspond to some previous findings from Southern Africa where 
HIV infection is associated with a lower BMI and a lower prevalence of obesity and overweight 
(Malaza, Mossong et al. 2012, Bärnighausen, Welz et al. 2008). As discussed, the literature has 
observed HIV-infected individuals to be associated with higher BMI and waist circumference, 
our finding could be attributed to late presentation and initiation of ART. Thus ART 
participants could be in a more advanced stage of HIV disease which could have resulted in 
severe weight loss as HIV stage is largely attributed to weight loss in HIV-infected individuals 
(Brennan-Benson 2009, Malaza, Mossong et al. 2012). However, it is imperative to note that 
the current study did not record the duration of HIV infection and ART of the participants, this 
in fact is a limitation and thus the finding cannot be conclusively attributed to late presentation 
and initiation of ART. 
Furthermore, it is interesting to note that according to the WHO recommended BMI cut-off 
values, the median BMI in the HIV negative group would be considered ‘overweight’, whereas 
the median BMI in the HIV positive groups would be considered to fall within the normal 
range. This is in itself could be considered a finding which is in line with the current SA weight 
and obesity trends. The general adult population of South Africa is under an increased burden 
of obesity, in fact South Africa has the highest prevalence of obesity in sub-Saharan Africa 
(Tugendhaft, Manyema et al. 2015). 
 
6.2 Cardiovascular and biochemical findings of the study 
population 
HIV positive first line and second line ART groups demonstrated significantly lower median 
total cholesterol and LDL-C levels in comparison to the HIV negative group. Furthermore, 
LDL-C levels were additionally observed to be significantly lower in the ART naïve compared 
to the HIV negative group. Our findings seem to contradict the literature, as ART, particularly 
protease inhibitors (which the present study’s second line ART group were using) has shown 
to elevate the lipid profiles of HIV-infected individuals (refer to table 6.1 for the overall effects 
of ARTs on lipids and glucose levels). Furthermore, a recent study investigated the type of PIs 
and their impact on the lipid profile and it was clear that greater elevations in total cholesterol 
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was observed in the group that was on lopinavir and ritonavir (second line ARTs in SA) but no 
differences in the LDL and HDL levels. HIV-infected individuals treated with efavirenz (first 
line ART in SA) showed similar increases in total cholesterol compared with the individuals 
taking lopinavir and ritonavir. In addition, HIV infected individuals treated with 
abacavir/lamivudine, zidovudine/lamiuvudine, or stavudine/lamivudine showed significantly 
higher elevations in all lipid parameters, in comparison to individuals using 
tenofovir/emtricitabine. Thus it has been demonstrated in literature that there is definitely a 
wide range of lipid elevations, which depends on the ART drug class and type used (Hill, 
Sawyer et al. 2015). PIs such as ritonavir, indinavir, and amprenavir are known to upregulate 
CD36, a scavenger receptor, mediating cholesterol uptake in macrophages (Dressman, Kincer 
et al. 2003). 
Our finding of modest but significant higher median total cholesterol levels in the HIV positive 
first line ART group in comparison to ART naïve group is somewhat in line with literature. 
Although NNRTIs induce a less harmful effect on lipids than PIs, it has been found that 
efavirenz has a harmful effect on lipids when compared to other NNRTIs (Feeney, Mallon 
2011). Furthermore, ART naïve individuals have been observed to have a lower total, LDL-C 
and HDL-C levels, as well as elevated serum triglycerides (Grunfeld 2008, Feeney, Mallon 
2011). HIV-infection was associated with altered lipid metabolism, even before the advent of 
ART. In the early phase of acute HIV-infection, individuals demonstrate several diverse 
clinical signs of immunosuppression such as fever, intestinal infections, weight loss and 
depletion of protein reserves (da Cunha, Maselli et al. 2015). The possibility of HIV infection, 
by itself, causing changes in lipid metabolism has been postulated, because it is evident that 
plasma viremia may promote a decrease in the plasma concentrations of total cholesterol, HDL 
and LDL and, in later stages of infection, an elevation in the concentration of TG (Sellmeyer, 
Grunfeld 1996, Pedersen, Lindhardt et al. 1989, da Cunha, Maselli et al. 2015). Specifically, 
the reduction of HDL likely occurs as a result of an activation of the immune system in early 
HIV infection, which promotes an increase in lipid peroxidation, inflammatory cytokine 
production, and alterations in the reverse cholesterol transport. This process promotes an 
imbalance in their antioxidant system, a decrease in the production of anti-inflammatory 
cytokines and an elevation of proinflammatory cytokines, which increases the chance of 
developing atherosclerotic diseases (da Cunha, Maselli et al. 2015, Sellmeyer, Grunfeld 1996, 
Pedersen, Lindhardt et al. 1989).  
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The present study also observed that the median HBA1C% levels were significantly lower in 
the HIV positive second line group compared to the HIV positive ART-naïve group. Studies 
have demonstrated that individuals with HIV infection have lower baseline HbA1c values than 
the HIV-negative controls (Han, Crane et al. 2012). Furthermore, the type of ART has been 
related to changes in HbA1c levels (Refer to table 6.1). People receiving a PI-based regimen, 
but not those on a non-PI containing regimen, have shown to have significantly lower HbA1c 
levels compared to the controls (Han, Crane et al. 2012). In contrast, relatively new evidence 
is emerging in the literature showing that certain protease inhibitors, such as indinavir, 
lopinavir, and ritonavir, can reversibly induce insulin resistance, probably by inhibition of 
glucose translocation through glucose transporter type 4 (GLUT4) (Grunfeld 2008, Brown, 
Tassiopoulos et al. 2010). 
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Table 6.1: Overall effects of main ARTs on lipid profiles (da Cunha, Maselli et al. 2015) 
Antiretroviral 
class 
Drug Effects on lipids Effects on glucose 
NRTIs Emtricitabine (FTC)  ↑ Dyslipidaemia No effect 
Lamivudine (3TC) ↑ Dyslipidaemia  No effect 
Tenofovir (TDF) ↑ Dyslipidaemia  No effect 
Zidovudine (AZT) ↑↑ Dyslipidaemia  Insulin resistance 
NNRTIs Efavirenz (EFV)  ↑↑ HDL, ↑ 
Dyslipidaemia 
No effect 
Etravirine (ETR) Neutral effects  No effect 
Nevirapine (NVP)  ↑↑ HDL, ↑LDL No effect 
PIs Lopinavir/ritonavir  ↑↑↑ Dyslipidaemia  Insulin resistance 
Amprenavir/ritonavir  ↑↑↑ Dyslipidaemia  Insulin resistance 
Atazanavir/ritonavir  ↑ Dyslipidaemia Insulin resistance 
Darunavir/ritonavir ↑  ↑ Dyslipidemia  Insulin resistance 
↑: increase; ↑↑: 2 X increase; ↑↑↑: 3 X increase. 
 
6.3 Vascular function 
The present study did not find any significant differences in the measured vascular function 
variables amongst the four groups of the total cohort. Our findings correspond with a few 
studies where FMD% was not significantly different between the HIV-infected and non-
infected individuals (Blanco, Garcia et al. 2006, Nolan, Watts et al. 2003, Mondy, de las 
Fuentes et al. 2008). 
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Conversely, our findings contradict those of other studies using FMD to assess vascular 
function that HIV infected individuals present with endothelial dysfunction in comparison to 
individuals without HIV infection (Stein, Currier et al. 2014). A case-control study of 83 HIV 
infected-children, found that FMD% was significantly lower in the HIV positive group when 
compared to the HIV negative group. When comparing the different treatment exposure 
groups, it was found that FMD % was even worse in children using PIs (which the second line 
ART group of the present study are using) (Charakida, Donald et al. 2005). In fact, the present 
study demonstrated the highest mean FMD% for the group on second line ART, albeit not 
significant.  Furthermore, a study of adult HIV-infected individuals by Stein et al. reported on 
impaired (lower FMD% relative to study’s control group’s FMD%) endothelial function in 
HIV-infected individuals using PIs containing regimen while the HIV infected ART naïve 
individuals presented with normal FMD% (“normal FMD%” was considered more than or 
equal to the mean FMD% in the study’s control group). This study further concluded that PIs 
are associated with pro-atherogenic lipoprotein changes and with endothelial dysfunction 
(Stein, Currier et al. 2014, Stein, Klein et al. 2001). Another study evaluating endothelial 
function in an adult population, also found significantly impaired FMD in HIV-infected 
individuals in comparison to healthy controls (Solages, Vita et al. 2006). In addition, a most 
recent study of 2016, based in Ethiopia also found significant differences between their HIV-
infected populations. They observed that FMD was impaired in younger adults treated with 
efavirenz and lopinavir in combination with ritonavir in comparison to ART naïve younger 
adults. Furthermore, FMD was impaired in efavirenz-treated younger adults group compared 
to nevaripine-treated young and older adults, and in lopinavir with ritonavir treated group 
compared to nevaripine-treated older adults (Gleason Jr., Caulk et al. 2016). 
On the other hand, there are some studies that have demonstrated improved endothelial 
function upon commencement of ART (Torriani et al 2008.). This study observed an 
improvement in the HIV-infected individuals’ FMD% after commencement of a PI sparing 
regimen of NRTIs plus efavirenz, NNRTI-sparing regimen of NRTIs plus lopinavir/ritonavir, 
or a NRTI-sparing regimen of efavirenz plus lopinavir/ritonavir. The NRTIs were lamivudine, 
stavudine, zidovudine, or tenofovir. (Torriani, Komarow et al. 2008). In addition, a study by 
Stein et al 2014, demonstrated that FMD% was impaired in the ART naïve group prior to ART 
commencement. The participants were assigned to use one of three antiretroviral regimens: 
efavirenz + 2 NRTI (PI sparing regimen); lopinavir/ritonavir + 2 NRTI (NNRTI sparing 
regimen); and lopinavir/ritonavir + efavirenz (NRTI sparing regimen). Endothelial function 
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determined by flow-mediated vasodilatation was measured at baseline, week 4 and at week 24. 
After 4 weeks of treatment, FMD had significantly improved by 1.1% (p=0.003) and the 
improvement was of similar magnitude in each arm. After 24 weeks of treatment, FMD had 
increased significantly by 1.9% (p<0.001) and it was of similar magnitude for each arm. This 
suggests that the use of the three different antiretroviral regimens rapidly improved endothelial 
function in HIV positive ART naïve individuals and that the benefits were similar regardless 
of antiretroviral regimen. Furthermore, the benefits were noticeable as early as after 4 weeks 
and persisted at 24 weeks of treatment. This study concluded that antiretroviral treatment in 
HIV positive ART naïve individuals improved vascular reactivity and it may have decreased 
short term cardiovascular risks (Andrade, Cotter 2006). 
In light of contradicting findings in literature with regards to vascular function in HIV-infected 
populations, the present study’s findings could be attributed to the specific ART drugs that the 
participants are using as well as the difference in population characteristics and a small sample 
size. It is noteworthy that none of the studies in the literature have assessed endothelial function 
in groups taking SA approved first line and second line ART.  
 
 
6.4 Associations of vascular variables with various 
demographic and cardiovascular risk variables in the 
total population, HIV negative population, and HIV 
positive population 
One of the major findings of the present study is that HIV-infection was not associated with 
poorer vascular endothelial function measurements. This includes all the vascular variables, 
namely baseline artery diameter, maximum artery diameter, and FMD%. In adults, case-control 
studies investigating the effects of HIV infection on FMD% have had inconsistent results 
(Solages, Vita et al. 2006, Mondy, de las Fuentes et al. 2008, Blanco, Garcia et al. 2006, Nolan, 
Watts et al. 2003). Each of these studies have been relatively small with the largest including 
only 83 HIV-infected individuals and the population characteristics as well as imaging 
techniques have varied between studies. However, as mentioned earlier, the extent of infection 
and inflammation as well as the use and type of ART might play a role.  
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Our findings show that female gender was inversely associated with baseline brachial artery 
diameter in all the groups. This is in line with literature as it has been established that females 
generally have a smaller baseline brachial artery diameter than males (Pham, Kim et al. 2016, 
Kapuku, Treiber et al. 2004). The confounding impact of baseline artery diameter on the 
FMD% is the underlying reason for forcing it to remain in the regression model where FMD is 
the dependent variable, hence ensuring that it is adjusted for and that any associations with 
FMD% are observed independently of the baseline artery diameter. 
Since baseline artery diameter is used in the calculation of FMD%, it follows that it is an 
indirect predictor of endothelial function (FMD%). Therefore, associations with baseline artery 
diameter will also be briefly discussed. In our study, smoking was positively associated with 
baseline artery diameter in the total population. This is difficult to explain as the literature 
largely points to the opposite thus the finding can be attributed to being a statistical finding. 
Although baseline artery diameter is not a reflection of endothelial function, it has been 
established that cigarette smoking can induce vascular dysfunction.  
Furthermore, the present study did not find any significant associations with various 
cardiovascular risk factors and FMD in the total HIV-infected group. A large body of scientific 
evidence, does however point to a range of risk factors to be associated with impaired vascular 
function in HIV-infected individuals. These risk factors include lipoprotein levels, systolic 
blood pressure, markers of insulin-glucose metabolism, and presence of metabolic syndrome, 
among others (Stein, Currier et al. 2014). Our findings could be attributed to a small sample 
size, difference in population characteristics (this is the first study of its kind in a population of 
mainly mixed-race adults in the Western Cape with no previous data to which our findings can 
be compared and validated), and different distributions of traditional cardiovascular risk 
factors. Additionally, it is important to note that in the regression analysis models, the current 
study’s total HIV-infected group consisted of ART naïve individuals as well as those that are 
using first line and second line ART, which may have affected the observed associations.  
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6.5 Associations of vascular variables with various 
demographic and cardiovascular risk variables in the 
HIV positive ART naïve, first line ART and second line 
ART populations respectively. 
An important finding of the present study is that CRP-levels were negatively associated with 
FMD% in the second line ART group. CRP is an inflammatory marker synthesized in 
hepatocytes in response to stimulation from IL-6. It has been demonstrated that CRP levels 
increase during acute inflammatory conditions. C-reactive protein can be considered a 
biomarker of the process of endothelial dysfunction and, at supraphysiological concentrations, 
as a predictor of vascular disease. It also plays an important role in down regulation of eNOS 
and in protein transcription of endothelial cells, which causes destabilization of eNOS-RNA. 
This process results in reduced production of NO. 
In literature, the relationship between CRP and FMD% is inconclusive. A study by Mondy et 
al. found no significant correlation between high-sensitivity CRP and FMD% in HIV positive 
individuals on long term HAART (Mondy, de las Fuentes et al. 2008). Furthermore, a study 
investigating endothelial function in HIV-infected individuals on various regimes, including 
lopinavir and ritonavir (SA approved second line drugs), also could not find an association with 
CRP and endothelial function (Torriani, Komarow et al. 2008). Additionally, three other 
studies found no association between CRP and endothelial function (Nolan, Watts et al. 2003, 
van Wijk, de Koning et al. 2006, Charakida, Donald et al. 2005). It is noteworthy that each 
study had less than 100 HIV-infected subjects with varying demographic, CVD risk factors, 
and HIV treatment profiles. Additionally, some of the studies measured high-sensitivity CRP, 
whereas the current study measured normal CRP. 
In light of arguing the current finding, there is no concrete evidence from previous studies that 
PIs are associated with increased CRP levels in HIV individuals which could then be associated 
with a lower FMD. It is well known that in HIV-negative patients, inflammation plays an 
important role in endothelial dysfunction and atherosclerosis. Similarly, higher levels of CRP 
have been found in HIV-infected patients compared to controls and this has been shown to 
predict cardiovascular mortality and morbidity even after accounting for viral load and CD4 
count (Hsue et al., 2004). In fact, one study has shown that CRP levels did not normalize after 
96 weeks of treatment (Shikuma et al., 2011). Furthermore, CRP is not the only marker of 
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inflammation in HIV infection; HIV appears to be associated with a generalized inflammatory 
activation of the vascular wall. Proinflammatory markers and adhesion molecules that are 
implicated in the pathogenesis of cardiovascular disease in non-HIV individuals are similarly 
studied in the context of HIV. An example of this is, TNF-α, which is also expressed in large 
quantities by macrophages in HIV-infected individuals (Subbarao, Lowe et al. 2011). 
The present study demonstrates the potential of CRP as a biomarker of reduced endothelial 
function in the second line group. This is a highly interesting finding which has not been 
demonstrated in the past and warrants further investigation. 
Smoking showed a borderline negative association (p= 0.052) with FMD% in the first line 
ART group. Endothelial dysfunction has been correlated with a wide range of cardiovascular 
risk factors, including smoking. Cigarette smoking does play a role in atherogenesis and 
endothelial dysfunction (Messner & Bernhard 2014). Therefore, HIV-infected individuals that 
smoke, may present with poor vascular endothelial function, possibly even to a greater extent 
compared to the general smoking population. Furthermore, since smoking is linked to 
endothelial dysfunction, it was included in the model to ‘adjust’ for it and find associations 
with other variables independent of smoking. 
 
6.6. Associations of vascular variables with CD4 count in the 
total HIV positive population and ART groups 
The present study found that CD4 count is positively associated with endothelial function in 
the second line ART group. CD4 cells play an important and central role in the immune system, 
coordinating the arms of the adaptive immune system to shape an effective response while 
simultaneously regulating non-essential or deleterious activities. Their importance is 
demonstrated most strikingly during AIDs, when there is significant depletion of CD4 cells by 
the HI virus. The depletion of CD4 cells ultimately results in a host of immune dysfunctions 
and susceptibility to opportunistic pathogens (Soghoian 2015). In HIV, protease inhibitors 
based combination therapy has shown to increase CD4 count in children and adolescents (Soh, 
Oleske et al. 2003).  
With regards to CD4 count being positively associated with endothelial function, the present 
study’s finding is somewhat in line with literature. It has been found that ‘nadir’ CD4 count of 
less than 350 cells/μl is associated with lower FMD%. In fact, even after adjusting for various 
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cardiovascular risk factors, the association remained in that study (Ho, Scherzer et al. 2012). 
Furthermore, another study has found a negative correlation between CD4 count and FMD% 
(Nolan, Watts et al. 2003). The CD4 count in a way represents the HIV disease stage of the 
individuals. A lower CD4 count points to a worse stage of HIV disease progression. HIV 
infection and the stage of it has been linked with endothelial dysfunction (Subbarao, Lowe et 
al. 2011). Therefore, an increased CD4 count represents healthier HIV individuals and thus can 
be correlated to a better endothelial function.  
Interestingly, this association is only found in the study’s second line ART group. HIV-infected 
individuals that are on second line treatment in South Africa, generally are in a more progressed 
phase of the infection. In view of that, these participants may be particularly sensitive to any 
changes in their CD4 counts, which could significantly impact on their vascular and endothelial 
health. This further could suggest that the immunological status of these individuals impacts 
their vascular function. Furthermore, previous studies have not investigated the association of 
CD4 count with vascular endothelial function in HIV positive individuals using the particular 
SA approved drugs. The particular PI drugs that the participants were using may also play a 
role in this association. 
 
6.7  Concluding remarks 
In the present study, the groups were similar in terms of age, gender and ethnic composition. 
In this cohort, the mean values of markers of cardiovascular risk were generally lower in HIV 
positive groups in comparison to the HIV negative group, which suggests a generally more 
favourable cardiovascular risk profile. This includes BMI, waist circumference and lipid 
parameters such as total cholesterol and LDL cholesterol. In the present study, endothelial 
function was not found to be significantly different amongst the four groups. When evaluating 
independent associations, CD4 count, CRP levels, as well as female gender were found to be 
independent predictors of endothelial function in HIV positive, second line ART group. 
Furthermore, cigarette smoking history was found to be a negative independent predictor of 
endothelial function in the first line ART group. 
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6.8  Advantages, Limitations and Future Directions 
This study has several advantages. It is the first of its kind to assess endothelial function in HIV 
infected adult individuals in the Western Cape Province of South Africa. Furthermore, it is the 
first study to assess endothelial function and its association with cardiovascular risk factors in 
HIV-infected populations receiving the South African approved first line and second line ART.  
The clinical study has some limitations. The study was of a cross sectional nature and the 
number of participants were relatively low, however still higher than several other studies such 
as of Nolan & Watts (2003), Blanco et al. (2006), Lebech et al. (2007), Torriani et al. (2008), 
and Mondy et al. (2008), assessing endothelial function in HIV-infected populations. Although 
the current study found a few independent predictors of endothelial function, some researchers 
may argue that the findings could be attributed to the statistical regression model having too 
many independent variables and thus making the model less stable. This could be corrected by 
running a forward stepwise multiple regression model with a full list of dependent variables. 
This would allow the model to consider all confounding variables in earlier steps, but at a final 
stage only the most important variables are considered. Furthermore, the duration of HIV-
infection and ART were not measured. Thus more studies are warranted, especially those of 
longitudinal nature in South Africa. With regards to regression analysis, ART status was not 
included as an independent variable in the model for the total HIV positive group. This could 
have impacted the study’s finding. Although intra-group regression analyses were conducted 
in the ART treatment groups, future studies are recommended to include ART in their 
regression models when measuring independent associations in the HIV population. 
Additionally, this study did not perform serum analysis for biomarkers of endothelial 
dysfunction due to funding restrictions. These biomarkers could include VCAM-1, ICAM-1, 
E-selectin, P-selectin, VEGF, TNF-α. These have previously been demonstrated to be 
predictors of ED in HIV populations by Graham et al. (2013). Furthermore, with current trends 
in clinical and health related research, male participant recruitment was not easy and even after 
planning for equal number of participants in each gender group, although not significant, the 
present study did have more females than males. In light with our finding of female gender 
being associated with a smaller baseline artery diameter and FMD%, it would be interesting to 
compare and assess endothelial function in HIV participants based on their gender. Therefore, 
future studies are warranted keeping these limitations in mind. 
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Chapter 7 : Discussion and Conclusion (in vitro sub-study) 
This chapter argues the findings of the in vitro sub-study. 
 
7.1 Findings from Proteomic analysis of the HIV-conditioned 
model 
The present sub study identified detectable expression levels of HIV-1 glycoprotein gp160 in 
the FBS-free HIV-conditioned medium. This is somewhat in line with current literature. The 
HL2/3 hela cells are transfected with a clone of the HXB2 strain that lack the reverse 
transcriptase coding sequence. This results in a high level production of the HIV-1 Gag, Env 
(particularly gp120), Tat, Rev and Nef proteins without shedding of infectious viral particles 
(Ciminale & Felber et al. 1990, Klug, Ashkenazi et al. 2014, Africa 2014). 
Although, only gp160 protein was identified in the present study, its role in HIV virus 
replication is crucial. In the HIV replication cycle, Env is translated to a heavily glycosylated 
160 kD precursor (gp160) that initially self-assembles as a membrane-bound homotrimer in 
the lipid bilayer of the trans Golgi network. Host proteases (known as furin) cleave the protein 
into a 41 kDa transmembrane subunit (gp41) that remains non-covalently associated with a120 
kDa surface subunit (gp120) (Moulard & Decroly 2000). This leads to production of the mature 
trimeric viral spike protein that is ultimately incorporated into the viral envelope during 
budding from the cell (refer to figure 7.1) The viral spike protein has two main parts: the 
surface protein (SU) and the transmembrane protein (TM). The tropism of the virus is 
determined by the SU protein domain because it is responsible for the receptor-binding function 
of the virus. The SU domain therefore determines the specificity of the virus for a single 
receptor molecule. Env spikes surround the viral surface and mediate events required for cell 
entry, including CD4/co-receptor binding and membrane fusion steps (Melikyan 2014, Wilen, 
Tilton et al. 2012). While proteolytic maturation of gp160 is not strictly required for CD4 
binding, the immature gp160 trimer spike does not support fusion (Nakatani-Webster, Hu et 
al. 2015) (Refer to figure 7.2). 
Interestingly, another study demonstrated a role for HIV-1 glycoproteins, gp160 and gp120 in 
endothelial cell injury (Ullrich, Groopman et al. 2000). It has been previously established that 
gp120 can damage the endothelium by its interaction with CXCR4, a receptor for the α-
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chemokine stromal cell–derived factor-1 (SDF-1). In addition, this particular study observed 
that gp160 also was able to induce endothelial apoptosis, especially by activating caspases and 
mildly enhancing bax (a pro- apoptotic molecule). This novel finding points to a role for these 
viral envelope proteins in the transition of HIV infected cells from circulation to tissues 
(Ullrich, Groopman et al. 2000). Ultimately, the authors concluded that gp160 and gp120 are 
able to disrupt endothelial integrity via their interaction with CXCR4, enabling virus transition 
from the circulation and further playing a role in endothelial injury syndromes linked with HIV 
and AIDs (Ullrich, Groopman et al. 2000). This role of gp160 in cultured endothelial cells, 
largely adds value to the current study’s identification of this protein in the conditioned 
medium. The identification of this protein further validates the current HIV-conditioned in vitro 
model.  
 
 
 
Figure 7.1: HIV viral spike protein. 
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Figure 7.2: The structure of gp160. 
A. The linear domain structure of gp160. Gp160 is cleaved into gp120 (the surface protein) and 
gp41 (the transmembrane fusion protein). B. A trimer of gp120/gp41 is associated with the 
viral membrane.  C. Gp120 has a number of hypervariable domains (V1-V5). The red bars 
show disulphide bridges (Nakatani-Webster, Hu et al. 2015). 
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7.2 The effects of a HIV-conditioned in vitro model on NO 
production, cell viability and ROS production of AECs 
No significant results were observed with regards to the HIV-conditioned in vitro model on NO 
production, cell viability and ROS production in the AECs. According to the literature, in vitro studies 
correlate endothelial dysfunction to decreased NO production, increase in NO -quenching reactive 
oxygen species (ROS), endothelial chemokine/adhesion protein expression, and endothelial cell death 
(apoptosis or necrosis) due to local inflammation in the cells (Wang, Yi et al. 2015). As discussed in 
previous chapters, untreated HIV-infection has been associated with impaired endothelial function 
(Torriani, Komarow et al. 2008). This state has been best experimentally shown in literature using 
whole virus or HIV gp120 in in vitro studies. Studies with HIV envelope as recombinant gp120 
protein from CXCR4 binding strains have shown that it induces endothelial apoptosis by CXCR4-
dependent caspase activation (Fiala, Murphy et al. 2004, Fiala, Polik et al. 2004). Furthermore, a 
study found that NO production, was reduced by HIV gp120 in tumour necrosis factor α (TNF-α) 
activated endothelial cells (Jiang, Fu et al. 2010, Wang, Yi et al. 2015b). Gp120 is known to stimulate 
macrophages to nitric oxide production which can lead to direct endothelial damage (Chi, Henry et 
al. 2000). Most importantly, in contrast to our findings, another study reported that gp160 (identified 
protein in the study’s HIV-conditioned in vitro model) and gp120 are able to induce apoptosis in a 
time and concentration manner in HUVECs. Furthermore, this study pointed to a role of gp160 in 
endothelial injury (Ullrich, Groopman et al. 2000). However, it is vital to note that all the mentioned 
studies used different HIV-infection in vitro models and the experiments were done on various 
endothelial cells (mostly human derived endothelial cells), while the current study utilized adult rat 
aortic endothelial cells.  
In light of arguing the current finding, it is imperative to note that the study’s HIV conditioned model 
did not express detectable levels of gp120 as per proteomics analysis, whereas others have found a 
role of gp120 in in vitro studies. Although Ullrich et al. (2000) did find a harmful role for gp160 by 
inducing apoptosis, our study did not measure cell apoptosis. Therefore, it is possible that our 
conditioned medium may well have resulted in adverse effects that were not detected by our chosen 
end-points of NO production, necrosis and ROS production. Furthermore, it is important to note that 
the HIV-1 related protein was not quantified; thus the lack of cellular effects could be attributed to 
insufficient concentrations of the gp160 present in the medium. Finally, the current study incubated 
the AECs in the HIV-1 conditioned medium for one-time period only, namely 24 hours; a longer 
incubation period could possibly have been more effective in eliciting injury.   
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7.3 The effect of first line ART (dose-response) on NO production, 
cell viability and ROS production in AECs 
The current South African approved first line fixed dose combination (FDC) tablet (trade name: 
Atripla®, or Odimune®) comprises of Tenofovir (NRTI), Emtricitbine (NRTI) and, Efavirenz 
(NNRTI). Therefore, in order to simulate the FDC tablet, the three drugs were used in combination 
in the cell culture experiments. The first line ART drug’s normal concentration was based on previous 
studies that demonstrated anti HIV activity with synergistic effects of the three drugs in combination 
in cell culture (Feng, Ly et al. 2009, Grigsby, Pham et al. 2010). The present study found that, at the 
normal concentration, the first line ART drugs in combination, significantly reduced NO production 
in AECs (albeit modestly) in comparison to the control. One study showed that ART agents generally 
reduce NO serum levels and increase ROS which can accelerate foam cell formation (Skowyra, 
Zdziechowicz et al. 2012). Endothelial cells are known to be highly sensitive to ROS, and it is 
believed that the interaction of ROS with endothelial cell-generated nitric oxide (NO) may be one of 
the reasons for the sensitivity and increased cardiovascular dysfunction observed in patients receiving 
HIV treatment-related drugs (Skowyra, Zdziechowicz et al. 2012).  
The present study did not find any significant difference in cell viability of AECs treated with first 
line ART agents, as measured by propidium iodide staining. One particular agent in the first line 
regime, efavirenz has been shown to increase cell necrosis and ROS production in human umbilical 
vein endothelial cells (HUVECs) at concentrations 10ug/ml and 15ug/ml (Weiß, Kost et al. 2016). 
This study demonstrated that relevant concentrations of efavirenz led to the generation of ROS in 
human endothelial cells, associated with the induction of heat-shock proteins, ER stress, and 
autophagy. The current study’s normal concentration for Efavirenz was 5.6nM (0.0018ug/ml), far 
smaller concentration in comparison to study by Weib et al. Moreover, the stress inducing effects of 
efavirenz on HUVEC were demonstrated to be aggravated by a drug combination with nelfinavir. 
Furthermore, efavirenz was also reported to cause oxidative stress in human hepatic cells 
(Apostolova, Gomez‐Sucerquia et al. 2010). The current study contradicted the literature in groups 
that received normal and double drug concentrations in terms of ROS production, as the present study 
found significant decreases in ROS levels in first line ART treated AECs. However, the present study 
did find a significant increase in ROS production with half drug combination. In the literature it is 
fairly unclear as to how first line ART agents increase ROS levels. Furthermore, the mechanism by 
which efavirenz, the drug which is largely associated with increase ROS, is also unknown (Weiß, 
Kost et al. 2016). 
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The current study’s contradicting results with literature could be attributed to the drug concentrations. 
As mentioned, many previous studies have used a different drug concentration in comparison to the 
current study. Furthermore, it is imperative to note that most of the previous studies have used human 
derived endothelial cells, meanwhile the current study has used adult rat aortic endothelial cells. 
Furthermore, many previous studies showed drug effects using different incubation periods (4- 36 
hours), whereas our study only made use of a single incubation period of 24 hours.  
 
7.4 The effect of second line ART (dose-response) on NO 
production, cell viability and ROS production in AECs 
The second line ART normal drug concentration was based on previous in vitro studies (Noor, Flint 
et al. 2006). The present study did not demonstrate any significant difference in AECs NO production 
in any of the three drug groups. In literature, ritonavir (at 15.5umol/L) has been found to decrease 
eNOS mRNA and protein levels in cultured human coronary endothelial cells (Fu, Chai et al. 2005, 
Subbarao, Lowe et al. 2011). Furthermore, ritonavir is found to downregulate eNOS in human 
pulmonary artery endothelial cells (Wang, Chai et al. 2009). The present study did find a significant 
increase in cell necrosis in the AECs treated with half drug concentration. Ritonavir at concentrations 
near clinical plasma levels was shown to cause endothelial mitochondrial DNA damage and cell death 
mainly through necrosis pathways (Zhong, Lu et al. 2002). However, the said study used 
concentrations of 7.5, 15 and 30umol/L, whereas our study observed a significant increase in cell 
necrosis, in AECs treated in 1 uM, (1umol/L) (half of normal drug concentration) (Zhong, Lu et al. 
2002). 
The present study observed a significant increase in ROS production in the double drug group and a 
significant decrease in ROS production in the normal drug group, although the latter was by a small 
margin. In literature, the drugs from the protease inhibitor class are implicated to increase production 
of ROS in experiments (Kline & Sutliff 2008). They have been found to also increase endothelial cell 
permeability and leukocyte adhesion in cell culture models (Mondal, Pradhan et al. 2004, Kline & 
Sutliff 2008, Lowe et al. 2011). However, most of these experiments have investigated the effects of 
the drug zidovudine on cell ROS production (Kline & Sutliff 2008). Furthermore, it is important to 
note that all the second line ART studies in literature vary in terms of their ART drug, concentration 
as well as the type of cells used. Thus making it difficult to make accurate deduction on the effects 
of ART on endothelial function in vitro. 
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7.5 Concluding Remarks 
The present sub-study attempted to establish a HIV-conditioned in vitro model and was successful in 
identifying the HIV-1 envelope protein, gp160, in the conditioned growth medium. However, the 
effect of this HIV-conditioned in vitro model did not elicit any significant effects on the AECs NO 
production, cell viability and ROS production. With regards to the effect of the first line and second 
line ART on AECs, mixed results were obtained (refer to table 7.1 for summary of results). It is 
imperative to note that the current study combined the first line drugs in a one ‘cocktail’ and the 
second line drugs in one ‘cocktail’, in order to stimulate the SA approved FDC and second line 
combination regime. Most studies in the literature investigated the effects of these drugs separately, 
therefore there is a possibility that these drugs may elicit a different effect when investigated 
separately. However, it is evident from the present study’s experiments with first line ART regime, 
that the double drug concentration did not induce any endothelial damage as it decreased ROS levels, 
while the half drug concentration increased ROS, and normal drug concentration reduced cellular NO 
production. For the experiments with the second line ART regime, it appears that the normal drug 
concentration did not induce endothelial damage as it had no effect on cellular ROS levels, meanwhile 
the double drug concentration increased ROS levels. Therefore, double drug concentration for first 
line ART and normal drug concentration for second line ART, could be considered a relevant dose 
for future investigations into the effects of ART drugs in an HIV-1 infected model. 
 
Table 7.1: Summary of results from First and Second line ART dose response 
ART 
regime 
Drug concentration NO 
production 
Necrosis ROS 
production 
 
First line 
ART 
Half drug concentration No effect No effect  Increase 
Normal drug concentration Decrease  No effect  No effect 
Double drug concentration No effect No effect  Decrease 
 
Second line 
ART 
Half drug concentration No effect No effect Increase 
Normal drug concentration No effect No effect No effect 
Double drug concentration No effect No effect Increase 
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7.5 Advantages, Limitations and Future Directions 
To the best of our knowledge, there are no previously published studies that investigated the effects 
of the South African approved ART regimes on endothelial cells with NO production, cellular 
necrosis and ROS production as end-points.  
A limitation in the present study, was that HIV-conditioned in vitro model elicited no effect on the 
measured parameters of NO production, cell viability and ROS production. More than a year was 
spent establishing the protocol to develop this model. Several stumbling blocks were faced and 
unsuccessful experiments performed. The development of this model would be ideal to ‘mimic’ HIV-
infection in in vitro for the investigations of ARTs. Furthermore, it would be a cost-effective and safe 
to work with as it doesn’t consist of a live HI virus. Finally, due to time constrains and in view of the 
unsuccessful HIV-conditioned in vitro model, the effects of the first line and second line ART agents 
were not investigated on ‘HIV exposed’ endothelial cells. Instead the effects of these ART regimes 
was investigated on AECs in their normal AEC medium. Although, the effects of various ART doses 
were demonstrated on AECs, the results were mixed. Another major limitation of the sub study is 
that the sample size for each parameter was relatively small and the concentration of the drugs used 
relatively low compared to other studies in the literature. More studies are warranted with bigger 
sample size and an established HIV-infected in vitro model.  
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Chapter 8: Overall conclusion 
The current study aimed to investigate the effects of the South African Government approved first 
line and second line ART drugs on HIV-exposed endothelial function. The clinical study highlighted 
CRP, CD4 as well as female gender to be independent predictors of vascular endothelial function in 
HIV positive, second line ART individuals. Furthermore, a modest association with vascular 
endothelial function was noted with smoking history in HIV positive, first line ART individuals. 
Overall, a more favourable cardiovascular risk profile was noted in the HIV-positive individuals of 
the present cohort. Additionally, the successful identification of a HIV envelope protein gp160 in the 
HIV-conditioned medium, to an extent validated the sub-study’s HIV-conditioned in vitro model. 
The identification of a safe combination dose of the specific first line and second line ART drug 
combinations used in South Africa appear to be findings that have never been demonstrated in the 
past in an in vitro model of endothelial cells.  
Furthermore, the study’s interdisciplinary nature of both clinical and in vitro aspects, enabled a 
broader (macro view) on the topic. It permitted a cellular as well as clinical overview of endothelial 
function in HIV infection treated with ART. Although it was not possible to fully align the findings 
of the two models, the two aspects further exposed the study to new exciting challenges. However, 
future studies are warranted to shed a clearer light on the effect of HIV-infection and SA approved 
ART regimes on endothelial function, both from a clinical as well as from a basic scientific point of 
view. 
 
8.1 Research outputs associated with the study 
Published Abstracts: 
 Mashele, N, Charania, S, Essop, F, Webster, I, Westcott, C, Goswami, N, De Boever, P, 
Nawrot, T. and Strijdom, H, 2016. The effects of HIV-infection and anti-retroviral treatment on 
endothelial function in a South African cohort. Atherosclerosis, 252, pp.e162-e163. 
 Strijdom H, De Boever P, Nawrot T, Walzl G, Webster I, Westcott C, Mashele N, Charania S, 
Stelzl E, Kessler HH, Goswami N. HIV and cardiovascular risk in a study population of mixed 
ancestry living in Cape Town, South Africa: preliminary data from the EndoAfrica study. 11th 
International Symposium on Molecular Diagnostics, Graz, Austria, May 2016. Clin Chem Lab 
Med 2016; 54(5): eA10. 
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International conference output: 
 Mashele N, Charania S, Essop F, Webster I, Westcott C, Goswami N, De Boever P, Nawrot T, 
Strijdom H. The effects of HIV-infection and ART treatment on endothelial function in a South 
African cohort. 84th European Atherosclerosis Society Congress, Innsbruck, Austria, 29 May – 
1 June 2016. 
 
Other outputs:  
 Charania S, Mashele N, Genis A, Essop F.M, Webster I, Westcott C, Strijdom H. The effects of 
HIV and antiretroviral therapy on cardiovascular risk and vascular endothelial function- A cross 
sectional study of a population in Worcester. 44th conference of the Physiology Society of 
Southern Africa, hosted by university of Cape Town, 28- 31 August 2016. 
 Charania S, Mashele N, Genis A, Essop F.M, Westcott C, Webster I, Strijdom H. Cardiovascular 
risk and vascular endothelial function in a Worcester study population of people living with HIV. 
Biomedical day, Faculty of Medicine and Health Sciences, Stellenbosch University, 23 November 
2016. 
 Westcott C, Mashele N, Charania S, Essop F, Webster I, Goswami N, De Boever P, Nawrot T, 
Strijdom H. Cardiovascular risk and vascular endothelial function in people living with and 
without HIV: A cross-sectional study in Worcester. SASCAR conference, Cape Town, September 
2016. 
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Appendix A: Informed consent document 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
TITLE OF THE RESEARCH PROJECT: 
WINELANDS HAART to HEART STUDY  
 
REFERENCE NUMBER: N12/12/086 
PRINCIPAL INVESTIGATOR: Prof MF Essop 
ADDRESS: 
Department of Physiological Sciences 
Mike de Vries Building 
Room 2005a  
Stellenbosch University 
 
CONTACT NUMBER: 021 8083146 
 
You are being invited to take part in a research project.  Please take some time to read the 
information presented here, which will explain the details of this project.  Please ask the study staff 
or doctor any questions about any part of this project that you do not fully understand.  It is very 
important that you are fully satisfied that you clearly understand what this research entails and how 
you could be involved. Also, your participation is entirely voluntary and you are free to decline to 
participate. If you say no, this will not affect you negatively in any way whatsoever. You are also 
free to withdraw from the study at any point, even if you do agree to take part. 
 
This study has been approved by the Health Research Ethics Committee at Stellenbosch University 
and will be conducted according to the ethical guidelines and principles of the international 
Declaration of Helsinki, South African Guidelines for Good Clinical Practice and the Medical 
Research Council (MRC) Ethical Guidelines for Research. 
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What is this research study all about? 
This study will only be done in the Stellenbosch district and surrounding areas.  We are hoping to 
include 3300 people. We are trying to get more information on the amount of fat, muscle and fluid 
in the body, as well as how the heart and metabolism of the body functions when people with HIV 
are on anti-retroviral (ARV) medication.  By getting this information we would be able to see how 
the body uses and stores sugar and fat and that the ARV treatment does not cause any problems 
with the heart.  
Additionally, we will also do a sonar imaging of your arm. The sonar test imaging and testing will 
involve inflating a blood pressure cuff around your arm for a few minutes – this may cause mild 
discomfort, but will not cause any damage.  
If you agree to volunteer to take part in the study, a blood sample will be taken by a nurse.  It will 
then be taken to a laboratory, called Pathcare in Stellenbosch, where the blood sample will be 
analysed for glucose and the different types of proteins that carry fat in the blood.  Other tests that 
will be done by the laboratory will tell us more about the infection.  The remainder of your blood 
can be used to obtain genetic material (RNA), however, this will be explained to you in a separate 
consent form, which you will need to sign if you agree that we can use your blood sample for 
genetic testing. 
We will also take a blood pressure measurement, look and listen to your heart with a special 
machine and we will determine the amount of fat, muscle and fluid you have in your body with a 
special machine. We will also ask you to complete a questionnaire regarding your lifestyle, 
including diet and physical activity. 
There is also a machine (SONOST 3000) in which you will be asked to take off your shoes so that 
your foot can be placed in this machine that will not hurt or harm you in anyway.  This machine 
will tell us how your bone health looks like. 
 
Why have you been invited to participate? 
You have been invited to voluntary participate because you are HIV positive and you are receiving 
ARV therapy or not.  
By agreeing to participate in this study, you will be helping us to determine if the current ARV 
treatment (those on treatment only) affects your metabolism, body composition, the function of your 
heart and your blood vessels.  
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What will your responsibilities be? 
We will ask if we can do a physical examination on you as one of the selected patients.  A blood 
sample will then be taken from your arm for laboratory tests. We will ask you to complete the Health 
and lifestyle questionnaire that contains questions regarding your family history of heart disease, 
diet, physical activity and what medication you are taking. One of the researchers will help you to 
complete this questionnaire. A registered scientist, Dr Theo Nell, will also perform body 
measurements on you. These measurements include your waist circumference, hip circumference, 
and arm circumference, the back of your arm’s skin fold, height and weight. You will be asked to 
wear light or minimal clothing when these measurements are taken. However, the research team will 
ensure that these measurements are taken in a completely private area. You will also be asked to lie 
on the examination bed where Dr. Nell will use a special machine that will tell us how much fat, fluid 
and muscle is in your body.  This machine will not harm you in anyway. The machine works by placing 
stickers on your hands and feet which will tell us how much fat, muscle and fluid is in your body.   
You will then be asked to sit in front of the bone machine that will be used to see how healthy your 
bones are.  A small amount of gel will be placed on your ankles and then the machine will test your 
bone health by using two rubbers that are touching your ankles. 
Before you come for the test you must not eat as well as drink any fluids such as alcohol or caffeine, 
exercise or take medication that make you want to urinate.  You would need to empty your bladder 
and remove all metallic objects from your body. 
We will additionally ask to perform a sonar test on you. This test involves inflating a blood pressure 
cuff around your arm for a few minutes – this may cause mild discomfort, but will not cause any 
damage. This test will involve sonar imaging of your arm and may require you to wear clothing that 
is not too tight around the arms. You will be asked not to eat or drink anything the morning prior to 
your clinic visit.  
 
Will you benefit from taking part in this research? 
There are no direct benefits to you as the participant of this research project. By voluntarily taking 
part in this research, you will be helping the researchers to find out more about HIV positive patients 
on ARV treatment and how this can affect your body.   
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If you choose to know the results of your blood tests we will make these available to you.  However, 
you would have to discuss this information with your personal doctor, in order to assess your medical 
status with ARV treatment (metabolic and cardiac status).   
If we find any problems, we will inform your physician and also refer you for medical assessment. 
 
Are there any risks involved in your taking part in this research? 
There are no more than minimal medical or physiological risks associated with this study.  All the 
researchers that are part of this study have been properly trained. 
 
You may feel some pain associated with having blood drawn from a vein in my arm, and may 
experience some discomfort, bruising and/or slight bleeding at the site where the needle will go in 
the vein.   
The body shape test will require you to take some of your clothes (not naked) and shoes off, but there 
is no pain involved during this procedure.  All measurements will be done in private and 
confidentiality is very important. 
The machine that will be used to determine the fat in the body uses a very small electrical current 
that you will not feel and is not dangerous to your health. 
The bone machine will also not hurt you in any way.  It feels like two soft rubber balls touching the 
ankles. 
You may feel discomfort during the inflation stage of the sonar test; however, this will not harm you 
in anyway.  
 
If you do not agree to take part, what alternatives do you have? 
It is your decision to voluntary participate or not, and nothing will be done from the researchers’ 
part or medical staff at the clinic/hospital to in any way to persuade you to take part. If you decide 
not to participate, this decision will not influence your current medical treatment. 
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Who will have access to your medical records? 
Only the principal researcher (Prof Faadiel Essop and the following masters students: Dr. Faten 
Abaid, Sana Charania, and Post-doctoral fellow: Dr. Nyiko Mashele) will have access to your data 
and records.  All information will be treated with respect and utmost confidentiality.  Under no 
circumstances will your name or any form of identification be used in any publication, poster, lecture 
or thesis that results from this study.  Professor Faadiel Essop, Dr. Faten Abaid, Sana Charania and 
Dr. Nyiko Mashele will be the only authorised personnel who will have access to your results from 
this study as well as the lifestyle questionnaire and anthropometric measurements. No personal 
contact information will be collected in the study. If you agree to participate, you will receive a 
subject number and we will use that subject number to link all your data. The subject number will not 
be linked to your name / contact details (which will not be collected). This ensures that all your 
information is anonymous. 
 
What will happen in the unlikely event of some form injury occurring as a direct result of 
your taking part in this research study? 
There are no risks involved that could lead to injury. In the event of a test that shows abnormal the 
researcher will write a referral to the attending doctor at the clinic/hospital.  
 
Will you be paid to take part in this study and are there any costs involved? 
No, you will not be paid to take part in the study.  There will be no costs involved for you, if you do 
take part.  Travelling costs in order to get to the Department of Physiological Sciences will be covered 
by this study, and you will not need to pay for taxi fare if so needed. 
 
Would you like to know the results of your blood tests? 
Please indicate by marking the correct box with an X 
         YES 
          NO 
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Is there anything else that you should know or do? 
You can contact Professor MF Essop on 021 808 3146 if you have any further queries or encounter 
any problems. 
You can contact the Health Research Ethics Committee at 021-938 9207 if you have any concerns 
or complaints that have not been adequately addressed by your study doctor. You will receive a 
copy of this information and consent form for your own records. 
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Declaration by participant 
 
By signing below, I (name) …………………………………..…………. agree to take part in a 
research study entitled (WINELANDS HAART to HEART STUDY). 
 
I declare that: 
 
I have read or had read to me this information and consent form and it is written in a language with 
which I am fluent and comfortable. 
I have had a chance to ask questions and all my questions have been adequately answered. 
I understand that taking part in this study is voluntary and I have not been pressurised to take part. 
I may choose to leave the study at any time and will not be penalised or prejudiced in any way. 
I may be asked to leave the study before it has finished, if the study doctor or researcher feels it is in 
my best interests, or if I do not follow the study plan, as agreed to. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2016. 
 
 
 
    
Signature of participant Signature of witness 
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Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
I explained the information in this document to (participant name): 
………………………………….. 
I encouraged him/her to ask questions and took adequate time to answer them. 
I am satisfied that he/she adequately understands all aspects of the research, as discussed above 
I did/did not use an interpreter.  (If an interpreter is used then the interpreter must sign the 
declaration below. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2016. 
 
 
 
    
Signature of investigator Signature of witness 
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Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 
I assisted the investigator (participant name) ………………………………………. to explain the 
information in this document to (name of participant) ……………..…………………………….. 
using the language medium of Afrikaans/Xhosa/Zulu/English. 
We encouraged him/her to ask questions and took adequate time to answer them. 
I conveyed a factually correct version of what was related to me. 
I am satisfied that the participant fully understands the content of this informed consent document 
and has had all his/her question satisfactorily answered. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……………….. 
 
 
 
    
Signature of interpreter Signature of witness 
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Appendix B: Questionnaire example 
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Appendix C: Proteomics Analytical report 
By Dr Zac Mcdonald (Proteomics Manager 
1. Background and samples submitted  
The aim of the project was to identify HIV derived proteins in conditioned cell culture media. 
Initially two in-solution samples were provided. No HIV proteins could be identified in the 
initial samples. To deal with the high concentrations of foetal bovine serum (FBS) following 
samples (14 in-gel samples) were gel fractionated and FBS was excluded in half of the samples. 
24 bands were excised and digested.  
 
2. Analysis synopsis  
HIV gp160 was identified in conditioned media without FBS added. HIV gp160 was found not 
to be present in the corresponding normal media sample.  
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3. Experimental procedures  
3.1. In gel digestion  
All reagents are analytical grade or equivalent. Bands were excised from the provided gel and 
were destained in a 96-well perforated plate (Glygen PER.HOL.10) with 100mM ammo-nium 
bicarbonate (Ambic, Sigma 40867F) , 50% acetonitrile (ACN, Anatech BJ015CS) until clear. 
Samples were dehydrated and desiccated before reduction with 2mM triscarboxyeth-yl 
phosphine (TCEP; Fluka 646547) in 25mM Ambic for 15 minutes at room temperature with 
agitation. Excess TCEP was removed and the gel pieces again dehydrated. Cysteine res-idues 
were carbamidomethylated with 20mM iodoacetamide (Sigma I6125) in 25mM Ambic for 30 
minutes at room temperature in the dark. After carbamidomethylation the gel pieces were 
dehydrated and washed with 25mM Ambic followed by another dehydration step. Proteins 
were digested by rehydrating the gel pieces in trypsin (Promega PRV5111) solution (20ng/uL) 
and incubating at 37°C overnight. Peptides were extracted from the gel pieces once with 50μl 
0.1% trifluoroacetic acid (TFA, Sigma T6508). The samples were dried down and 200μl water 
added and concentrated to less than 20μl to remove residual Ambic.  
The samples were dried and re-dissolved in 0.1% formic acid (Sigma 56302), 2.5% ACN for 
LCMS analysis. 
 
3.2. LCMS  
LC−MS/MS analysis was conducted with a Q-Exactive quadrupole-Orbitrap mass spectrome-
ter (Thermo Fisher Scientific, USA) coupled with a Dionex Ultimate 3000 nano-HPLC system. 
The extracted peptides were dissolved in sample loading buffer (97.5% water, 2.5% Acetoni-
trile, 0.1% FA) and loaded on a C18 trap column (300 μm×5mm×5 μm). Chromatographic 
separation was performed with a C18 column (75 μm×250 mm×3.5 μm). The solvent system 
employed was solvent A, Water; 0.1% Formic Acid and solvent B, Acetonitrile; 0.1% FA. The 
linear gradient for peptide separation was generated at 250nL/min as follows- Time change: 
50min, gradient change: 6-25 % Solvent B. The mass spectrometer was operated in positive 
ion mode with a capillary temperature of 320°C. The applied electrospray voltage was 1.95 
kV. Details of data acquisition are in following table. An inclusion list was created to target 
possible gp160 derived peptides for MS/MS analysis (based on preliminary analysis). In the 
absence of these peptide targets other precursors were chosen for fragmentation. 
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3.3. Data analysis  
Database interrogation was performed with the Byonic algorithm (Proteinmetrics, San Car-
los,CA; version PMI-Byonic-Com:v2.5.6) using a combination of all Bos Taurus and HIV (or-
ganism) reviewed and unreviewed sequences in a uniprotKB sourced database 
(http://www.uniprot.org/). Search parameters are detailed in appendices. Proteins with at least 
two unique peptides and with a log probability score above 5 were considered high confidence 
hits.
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Appendix D: ART drug calculations 
First line ART drugs: Efavirenz (EFV), Emtricitabine (FTC) and, Tenofovir (TDF). 
Calculation of dosage - EFV: 5.6nM 
For a final concentration of 5.6nM EFV: 
Molecular weight (MW) of EFV: 315.67g/mol 
1M  = 315.67g/L 
1mM  = 315.67mg/L 
1µM  = 315.67µg/L 
1nM  = 0.31567µg/L 
5.6nM  = 1.767752µg/L 
  = 0.0017677µg/ml 
Prepare a stock x1000 times concentrated: 
5.6µM  = 1.767752µg/ml 
  = 176.7752µg/100ml 
* The powder is received in 10mg that will be dissolved in 1ml methanol (0.1767752mg / 10mg 
x 1ml = 0.01767752ml = 17.67752µl) 
Thus 17.67752µl (18µl) of the above solution (*) should be added to 100ml PBS to get the 
x1000 concentrated stock of 5.6µM. 
C1 x V1 = C2 x V2 
5.6µM x X (volume that should be added to 1ml of medium) = 5.6nM x 1ml 
5.6µM x X = 0.0056µM x 1000µl 
X = 5.6 / 5.6 = 1µl 
Thus 1µl from the x1000 concentrated stock should be added to 1ml of medium to get a final 
concentration of 5.6nM. 
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Calculation of dosage - FTC: 1.3µM 
For a final concentration of 1.3µM FTC: 
Molecular weight (MW) of FTC: 247.25g/mol 
1M  = 247.25g/L 
1mM  = 247.25mg/L 
1µM  = 247.25µg/L 
1.3µM  = 321.425µg/L 
  = 0.321425µg/ml 
Prepare a stock x1000 times concentrated: 
1.3mM = 321.425µg/ml 
* The powder is received in 10mg that will be dissolved in 1ml distilled water (0.321425mg / 
10mg x 1ml = 0.032143ml = 32.143µl) in 1mL 
Thus 32.143µl (32ul) of the above solution (*) should be added to 968ul of PBS to get x1000 
concentrated stock of 1.3mM. 
C1 x V1 = C2 x V2 
1.3mM x X (volume that should be added to 1ml of medium) = 1.3µM x 1ml 
1300µM x X = 1.3µM x 1000µl 
X = 1300 / 1300 = 1µl 
Thus 1µl from the x1000 concentrated stock should be added to 1ml of medium to get a final 
concentration of 1.3µM. 
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Calculation of dosage TDF:  500nM 
For a final concentration of 500nM TDF: 
Molecular weight (MW) of TDF  =  635.51g/mol 
1M  = 635.51g/L 
1mM  = 635.51mg/L 
1µM  = 635.51µg/L 
1nM  = 0.63551µg/L 
500nM  = 317.755µg/L 
  = 0.317755µg/ml 
Prepare a stock x1000 times concentrated: 
500µM = 317.755µg/ml 
   
* The powder is received in 10mg that will be dissolved in 1ml DMSO (0.317755mg / 10mg x 
1ml = 0.0317755ml = 31.776µl) 
Thus 31.776µl (32ul) of the above solution (*) should be added to 968ul of PBS to get the x1000 
concentrated stock of 500µM. 
C1 x V1 = C2 x V2 
500µM x X (volume that should be added to 1ml of medium) = 500nM x 1ml 
500µM x X = 0.5µM x 1000µl 
X = 500 / 500 = 1µl 
Thus 1µl from the x1000 concentrated stock should be added to 1ml of medium to get a 
final concentration of 500nM. 
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Protocol of first line ART drugs in AECs. 
All three drugs were added simultaneously to the AEC medium. In other words, 1ml of Medium 
contained 1ul of each of the drugs (1ul EFV + 1ul FTC+ 1ul TDF). 
 
First line Vehicle control protocol and calculations: 
Final concentration of methanol in 1 ml of medium: 
17.67752µl of methanol in 100ml PBS 
0.1767752µl in 1ml 
Diluted x1000 when 1ul of this is added to 1ml of medium = 0.0001767752ul/ml 
 
Final concentration of water in 1ml of medium: 
32.143ul of water in 1ml PBS 
Diluted x1000 when 1ul of this is added to 1ml of medium = 0.032143ul/ml 
 
Final concentration of DMSO in 1 ml of medium: 
31.776ul of DMSO in 1ml 
Diluted x1000 when 1ul of this is added to 1 ml of medium = 0.031776ul/ml 
 
 Therefore, a vehicle cocktail was made up of: 18ul of methanol + 32ul of water + 32ul of 
DMSO + 918ul of PBS. 
 From this cocktail, 3ul was added in 1ml AEC medium in the control groups to ensure that 
the concentration of vehicle per ml is the same in the controls groups as in the experimental 
groups. 
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Second line ART drugs: Lopinavir (LPV) and Ritonavir (RTV). 
Calculation of dosage - LPV: 10µM 
Molecular weight (MW) of LPV  =  628.80g/mol 
For a concentration of 10µM LPV: 
1M  = 628.80g/L 
1mM  = 628.80mg/L 
1µM  = 628.80µg/L 
  = 0.62880µg/mL 
10µM  = 6.2880µg/mL 
Prepare Stock x1000 times concentrated: 
10mM  = 6288.0µg/ml 
* The powder is received in 10mg that will be dissolved in 1ml DMSO (6.2880mg / 10mg x 1ml 
= 0.62880ml = 628.80µl) 
Thus 628.80µl (629ul) of the above solution (*) should be added to 371ul of PBS to get the 
x1000 concentrated stock of 10mM. 
C1 x V1 = C2 x V2 
10mM x X (volume that should be added to 1ml of medium) = 10µM x 1ml 
10mM x X = 0.01mM x 1ml 
X = 0.01 / 10 = 0.001ml = 1µl 
Thus 1µl from the x1000 concentrated stock should be added to 1ml of medium to get a 
final concentration of 10µM.   
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Calculation of dosage - RTV: 2µM 
Molecular weight (MW) of RTV = 720.94g/mol 
For a concentration of 2µM RTV: 
Molecular weight (MW) of RTV  =  720.94g/mol 
1M  = 720.94g/L 
1mM  = 720.94mg/L 
1µM  = 720.94µg/L 
  = 0.72094µg/mL 
2µM  = 1.4419µg/mL 
Prepare Stock x1000 times concentrated: 
2mM  = 1441.88µg/ml 
* The powder is received in 10mg that will be dissolved in 1ml DMSO (1.44188mg / 10mg x 
1ml = 0.144188ml = 144.188µl) 
Thus 144.188µl (144ul) of the above solution (*) should be added to 856ul of PBS to get the 
x1000 concentrated stock of 2mM. 
C1 x V1 = C2 x V2 
2mM x X (volume that should be added to 1ml of medium) = 2µM x 1ml 
2mM x X = 0.002mM x 1ml 
X = 0.002 / 2 = 0.001ml = 1µl 
Thus 1µl from the x1000 concentrated stock should be added to 1ml of medium to get a 
final concentration of 2µM.   
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Protocol of second line ART drugs in AECs. 
Both the drugs were added simultaneously to the AEC medium. In other words, 1ml of Medium 
contained 1ul of each of the drugs (1ul LPV + 1µl RTV). 
 
Final concentration of DMSO in 1ml of medium: 
 For LPV: 
628.8ul of DMSO in 1ml 
Diluted x1000 when 1ul of this is added to 1ml of medium = 0.6288ul/ml 
 
 For RTV: 
144.19µl of DMSO in 1ml 
Diluted x1000 when 1ul of this added to 1ml of medium = 0.144188ul/ml 
 
• Therefore, a vehicle cocktail was made up of: containing 0.6288ul of DMSO (from LPV) 
+ 0.14188ul of DMSO (from RTV) = 0.773ul of DMSO in 1 ml of PBS. 
• From this cocktail, 2ul was added in 1ml AEC medium in the control groups to ensure 
that the concentration of vehicle per ml is the same in the controls groups as in the experimental 
groups. 
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